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Summary
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder 
caused by mutation in either the TSC1 or TSC2 genes and characterised by 
the development of benign hamartomatous growths in multiple organ 
systems.
We have inactivated Tsc1 in the mouse germ line by gene targeting in ES 
cells and confirmed that the mutant allele (Tsc1~) has a recessive embryonic 
lethal phenotype. Tsc1+,~ mice developed macroscopically visible renal 
lesions as early as 3-6 months. Renal lesions progressed from cysts through 
cystadenomas to solid carcinomas. Eighty percent of Tsc1+/~ mice on a 
Balb/c background exhibited solid renal cell carcinomas (RCC) by 15-18 
months and in 41%, RCCs were £5mm, resulting in grossly deformed 
kidneys. Some RCCs had a sarcomatoid morphology of spindle cells in 
whorled patterns and metastasised to the lungs. This new murine model of 
hamartin deficiency exhibits a more severe phenotype than existing models.
A Bloom’s deficient mouse model (Blrrfn3/m3) has been shown to induce 
colorectal tumourigenesis when crossed with Apc+/M,n mice. Here, we 
investigate whether the B!rrfn3/m3 genotype could induce tumourigenesis in 
extra-colonic tissues in Tsc1+/~ mice that are predisposed to renal 
cystadenomas and carcinomas. Tsc1+I~ Blmfn3/m3 mice had significantly more 
macroscopic and microscopic renal lesions at 3-6 months compared to 
Tsc1+I~ Blm+/m3 mice. Tsc1+I~ Blmfn3/m3 mice tumours showed significantly 
increased levels of somatic LOH of the wild type Tsc1 (Tsc1"*) allele, as 
compared to those from Tsc1+,‘ Blm+/+ mice. This work demonstrates the 
utility of the Blrrfn3/m3 mice for inducing renal tumourigenesis and the high 
levels (~87%) of LOH in the resultant tumours will help facilitate mapping of 
loci involved in tumour progression.
TSC1 and TSC2 are generally considered to act as tumour suppressors that 
fulfil Knudson’s ‘2-hit hypothesis’. Here, we identified somatic Tsc1 mutations 
(2nd hits) in ~80% of CAs and RCCs, but only 31.6% of cysts from Tsc1+/~ 
mice, raising the possibility that haploinsufficiency for Tsc1 plays a role in 
cyst formation. Consistent with this proposal, many cysts showed little or no 
staining for phosphorylated mTOR and phosphorylated S6 ribosomal protein, 
whereas >90% of CAs and RCCs showed strong staining for both markers. 
We also sought somatic mutations in renal lesions from Tsc1+/~ Blm'A mice 
that have a high frequency of somatic LOH, thereby facilitating the detection 
of 2nd hits. We also found significantly less somatic mutations in cysts, as 
compared to CAs and RCCs from these mice. Our data indicate that 
although activation of the mTOR pathway is an important step in Tsc- 
associated renal tumourigenesis, it may not be the key initiating event in this 
process.
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Chapter 1: Introduction
1.1 Cancer genetics
Cancer is a common genetic disease. Each year in the UK more than
275.000 people are diagnosed with cancer (Cancer research UK). 
Tumourigenesis in cancers is caused by alterations in three types of genes: 
Oncogenes, tumour-suppressor genes (TSGs) and stability genes 
(Vogelstein and Kinzler 2004). Oncogene and TSG mutations operate at a 
similar physiologic level; they drive the neoplastic process by increasing 
tumour cell number through the stimulation of cell division or through the 
inhibition of cell death or cell-cycle arrest (Vogelstein and Kinzler 2004). 
Stability genes are involved in DNA repair and when mutated, increase 
genetic instability. They keep genetic alterations to a minimum and, when 
they are inactivated, somatic mutations in other genes occur at a higher rate 
(Fodde and Smits 2002). Mutations in these three classes of genes can 
occur in the germline, resulting in hereditary predispositions to cancer, or in 
single somatic cells, resulting in sporadic tumours.
1.1.1 Oncogenes
Oncogenes are genes whose normal activity promotes cell 
proliferation (Strachan and Read 1996). They can be mutated in ways that 
render the gene constitutively active, or active under conditions in which the 
wild-type gene is not. Oncogene activation can result from chromosomal 
translocations, from gene amplifications or from subtle intragenic mutations
1
affecting crucial residues that regulate the activity of the gene product 
(Vogelstein and Kinzler 2004).
1.1.2 Tumour suppressor genes
TSGs are genes whose normal activity restricts cell proliferation. 
Mutations in TSGs generally reduce the activity of the gene product. Thus 
far, about thirty TSGs have been identified and definitively implicated in 
cancer development (Fearon and Vogelstein 2000). Inactivation of TSGs 
may arise from missense mutations at residues that are essential for product 
activity, from mutations that result in a truncated protein, from deletions or 
insertions of various sizes, or from epigenetic silencing (Vogelstein and 
Kinzler 2004). Tumourigenesis generally requires mutations in both the 
maternal and paternal alleles of TSGs as described by Knudson’s 2-hit 
hypothesis (Fig. 1.1). Knudson’s 2-hit hypothesis states that: Biallelic 
inactivation of a tumour suppressor gene is required for tumour formation 
and that both inherited and sporadic cancers can result from mutations of the 
same gene. Individuals carrying a germline mutation are predisposed to the 
disease because a single somatic event is sufficient to initiate tumour 
formation. In sporadic cases, the number of tumours is lower and cancer 
occurs at a later age because both alleles must be somatically inactivated 
(Knudson, 1971).
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Figure 1.1: Knudson’s 2-hit hypothesis of tumourigenesis in sporadic (A) and inherited (B) forms of cancer.
1.1.3 Stability genes
Stability genes promote tumourigenesis in a completely different way 
when compared to oncogenes and TSGs. Stability genes keep genetic 
alterations to a minimum and, when inactivated, mutations in other genes 
occur at a higher rate. This class includes the mismatch repair (MMR), 
nucleotide-excision repair (NER) and base-excision repair (BER) genes that 
are responsible for repairing subtle mistakes made during normal DNA 
replication or that are induced by exposure to mutagens. Other stability 
genes control processes involving large portions of chromosomes, such as 
those responsible for mitotic recombination and chromosomal segregation. 
All genes are potentially affected by the resultant increased rate of mutation, 
but only mutations in oncogenes and TSGs affect net cell growth and can 
thereby confer a selective growth advantage to the mutant cell. As with 
TSGs, generally both alleles of stability genes must be inactivated for a 
physiologic effect (Vogelstein and Kinzler 2004).
1.1.4 Mutational events
Somatic mutational events or 'hits' can arise through several 
mechanisms (Cavenee etal. 1983). Genetic mechanisms include 
chromosomal loss with or without re-duplication, deletion, mitotic 
recombination, gene conversion and point mutation. Epigenetic mutational 
events cause a change in gene expression but are not associated with the 
changes in the coding sequence.
In the original formation of Knudson's hypothesis, the two hits leading 
to tumour formation represent independent mutation events, the end result of
4
which is loss of tumour suppressor function (Knudson 1996). However, 
evidence from the adenomatosis polyposis coli (APC) gene suggests that the 
two hits may not always be independent and that the first hit may determine 
the nature of the second (Lamlum et al. 1999, Albuquerque et al. 2002).
1.1.5 Multistage evolution of cancer
Cancers represent one of the few disease types in which somatic 
mutations occurring after birth are pathogenic. Most of these alterations 
would be expected to be neutral but some produce a growth or survival 
advantage for the mutated cell. A somatic mutation in an oncogene or TSG, 
for example, can cause a clonal expansion and initiate the neoplastic 
process. Subsequent somatic mutations result in additional rounds of clonal 
expansion and thus in tumour progression. Consequently, during the course 
of cancer development, a normal cell progresses towards malignancy by 
acquiring a specific series of mutations. The theory that human cancers are 
the end result of several successive cellular changes was first suggested by 
Armitage and Doll (1954). Based on epidemiological data (Renan 1993) and 
in vitro data (Hahn et al. 1999), it is estimated that between four and eight 
rate-limiting mutations occur during the development of most human cancers 
(Quon and Berns 2001). In 1990, Fearon and Vogelstein presented a model 
for the genetic basis of colorectal neoplasia (Fig. 1.2). The colorectal 
tumours appear to arise first as a result of the mutational activation of 
oncogenes coupled with inactivation of TSGs. Mutations in at least 4 or 5 
different genes are then required for the formation of a malignant tumour. 
Fewer changes are required for benign tumourigenesis. The total number of
5
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Figure 1.2: Multistage evolution of cancer for colorectal tumourigenesis: Tumourigenesis proceeds through a series of genetic changes involving oncogenes and 
TSGs (modified from Fearon and Vogelstein 1990).
accumulated changes rather than the order (though there is a preferred 
sequence) is responsible for the biological properties of the tumour (Fearon 
and Vogelstein 1990).
1.1.6 Haploinsufficiency
There have been recent indications that Knudson’s two hit mechanism 
of tumour growth may not be entirely universal. There is now considerable 
evidence suggesting that loss of only one allele of a TSGs, i.e. 
haploinsufficiency, might contribute to tumour development (Quon and Berns 
2001, Fodde and Smits 2002, Santarosa and Ashworth 2004). Heterozygous 
effect or haploinsufficiency means that a reduction in gene dosage leaves 
the cell with insufficient protein to accomplish normal activity, thus bringing 
about a phenotypic change that contributes to tumourigenesis. Even a small 
proliferative advantage could produce, over time, a relatively large sensitised 
population of target cells ripe for further mutagenesis (Quon and Berns 
2001). However, haploinsufficiency can comply with Knudson’s theory where 
the tumourigenic advantage conferred by a heterozygous mutation in a TSG 
is too low to be selected. In this case, a second mutation in another TSG can 
synergise with the first resulting in a proliferative increase (Santarosa and 
Ashworth 2004).
Tumours generated in a haploinsufficient way are frequently of later 
onset, less severe and associated with earlier stages of disease 
development than corresponding tumours carrying homozygously mutated 
genes (Cristofano etal. 1998, Fero etal. 1998, Venkatachalam etal. 1998, 
Xu et al. 2000, Santarosa and Ashworth 2004, Alberici et al. 2005). These
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observations have lead to a model of strong or partial haploinsufficiency (Fig. 
1.3). In partial haploinsufficiency, after a proliferative phase, the wild-type 
allele needs to be lost for tumour formation whereas in strong 
haploinsufficiency, a tumour can form in the absence of loss of the wild-type 
allele (Quon and Berns 2001).
1.2 Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a genetically determined multi 
system disorder in which many organs are affected by unusual growths 
termed hamartomas.
1.2.1 Identification
The first report of TSC was in 1835 by Pierre Francois Olive Rayer 
who published an atlas illustrating skin disease with a plate closely 
resembling facial angiofibroma (Rayer 1835). Subsequently, TSC was 
named in 1880 by Desire-Magloire Bourneville. Bourneville used the term 
tuberous sclerosis of the cerebral convolutions for the unique cerebral 
nodular tumour pathology seen in the brain of a 15 year-old mentally 
handicapped female (Gomez etal. 1999). The umbrella term, tuberous 
sclerosis complex, was assigned to the syndrome by Moolten (1942).
1.2.2 Characterisation and early diagnosis
In 1908, Vogt described the association between the cerebral sclerosis 
reported by Bourneville and the facial adenoma sebaceum. Vogt established 
a classic clinical triad of features for the diagnosis of TSC consisting of
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Figure 1.3: The effects of strong and partial haploinsufficiency with or without loss of heterozygosity (LOH). (A) Partial haploinsufficiency: after a 
proliferative phase, the wild type allele needs to be lost for tumour formation; (B) Strong haploinsufficiency: results in tumour formation in the absence of 
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seizures, learning disability and adenoma sebaceum. He also noted that 
cardiac and renal lesions formed part of the disease. Moolten and colleagues 
(1942) proposed that lesions of TSC belong to one of 3 types:
1. Hamartias: well circumscribed, misaligned or misarranged groups of 
dysplastic undifferentiated cells that are intrinsic for the organ or 
tissue involved. The cells do not grow or proliferate more rapidly than 
the normal surrounding tissue.
2. Hamartomas: well circumscribed groups of dysplastic cells that have a 
propensity to multiply excessively, thus growing into benign tumours 
that may or may not cause symptoms.
3. Hamartoblastomas: rare malignant tumours derived from 
hamartomas.
Phenotypic similarities between TSC, neurofibromatosis (NF1) and von 
Hippel-Lindau disease (VHL) were noted by Van der Hoeve (1920). He 
classified the three as phakomatoses; disorders characterised by the 
presence of circumscribed lesions or phakomas with the potential of getting 
larger and forming a tumour by cellular proliferation.
1.2.3 Prevalence
Original prevalence studies for TSC were inaccurate because the 
diagnosis of TSC was based on Vogt’s criteria of seizures, mental handicap 
and adenoma sebaceum (Vogt 1908). Consequently, at the time, the majority 
of known cases were institutionalised. By extrapolating the proportion of TSC 
sufferers from the total number of all mentally subnormal individuals in an 
entire population of a geographic region, the prevalence of TSC was
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estimated between 1:20,000 to1:150,000 (Gunther and Penrose 1935, Ross 
and Dickerson 1943, Dawson 1954, Paulson and Lyle 1966, Zaremba 1968). 
In the early 20th century, abundant reports of small groups of patients with 
TSC indicated that TSC was not as rare as earlier believed. More recently, 
appreciation of the differing phenotypes and advancement of technologies 
has meant the prevalence estimates of TSC have increased. Population 
based studies in Olmsted County have estimated prevalence as 1:9704 to 
1:14,492 (Wiederholt et al. 1985, Shepherd etal. 1991)
1.2.4 Manifestations
Pathologically, tuberous sclerosis is a disorder of cellular migration, 
proliferation and differentiation. Manifestations may be systemic and 
variable. The skin, brain, kidney and heart are most commonly involved. 
However the eyes, lungs, bones and many other organs may also be 
affected (Gomez 1988). Approximately 96% of patients with TSC have one 
or more type of skin lesion, 90% have symptoms or signs of cerebral 
pathology, 84% have or had seizures, an estimated 60% have renal 
pathology, and nearly 50% have retinal harmartomas (Gomez etal. 1999). 
The phenotype of TSC patients varies according to organ or organs involved, 
number and size of lesion, and sometimes the exact location of lesion. The 
age of the patient is another factor to be considered. Rhabdomyomas appear 
in foetal life and may disappear in infancy, while angiomyolipomas do not 
appear untill later in life. Phenotypic severity, both inter- and intra-familial is 
also highly variable making the assignment of disease status difficult.
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1.2.4.1 Manifestations of the central nervous system
1.2.4.1.1 CNS lesions
Central nervous system lesions in patients with TSC include cortical 
tubers, focal cortical dysplasia, subependymal nodules (SENs) and 
subependymal giant cell astrocytomas (SEGAs). Spinal cord involvement is 
rare (Lee-Jones et al. 2004).
Cortical tubers (Fig. 1.4a) constitute the hallmark of TSC. Cortical and 
subcortical tubers are hypomyelinated hamartias involving mainly the 
cerebral cortex and underlying white matter. Tubers are often multiple, vary 
in size and in cortical location (Gomez et al. 1999). Cortical tuber count is a 
biomarker of cerebral dysfuntion (Roach etal. 1987, Curatolo etal. 1991, 
Shepherd etal. 1995, Goodman etal. 1996), and there is some correlation 
with neurological outcome. Histologically, cortical tubers are characterised by 
architectural disarray. They vary considerably in cellularity and feature both 
neurons and large cells (Gomez etal. 1999).
SENs (Fig. 1.4a) are found in 80% of TSC patients. They are 
hamartomatous growths that are typically located along the outer walls of the 
lateral ventricles. They are often multiple and small in size, ranging from 2 to 
10mm, and are often partially or completely calcified (Hosoya etal. 1999). 
SENs develop during foetal life and are usually asymptomatic. Histologically, 
SENs are smooth surfaced, consisting of spindle and epithelioid, astrocyte­
like cells (Gomez et al. 1999).
SEGAs are histologically identical to SENs but are classified on the 
basis of their larger size. It is generally accepted that SEGAs evolve from 
SENs (Scheithauer 1992).
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Figure 1.4: TSC manifestations. (A) Magnetic Resononance Imaging study of the brain of a patient with Tuberous Sclerosis. With cortical and subcortical 
tubers (the peripheral, bright spots, large arrows) and subependymal nodules (the darker lumps along the outer walls of the lateral ventricles, small arrows). (B) 
Appearance of severe renal angiomyolipomas by contrast enhanced computed tomography (CT) examination of the abdomen; both kidneys are enlarged and 
essentially replaced by large masses of fat, blood vessels and soft tissue. (C) High-resolution CT imaging of the chest shows multiple cysts within the lung 
parenchyma which is the typical appearance of lymphangioleiomyomatosis (LAM). Images from http://commons.wikimedia.org/
1.2.4.1.2 Neurological manifestations
Abnormalities in neuronal migration, cellular proliferation and the 
formation of various brain lesions lead to neurological manifestations. These 
include seizures, learning disability and autism. Seizures are the most 
common neurological symptom of TSC and occurred in 92% of patients 
referred to the Mayo clinic (Gomez 1988). Patients with TSC range from 
intellectually normal to severely impaired. Children with infantile spasms and 
hypsarrhythmia are reported to be more severely impaired than those with 
any other form of epilepsy (Gomez 1988). In addition to learning disability, 
multiple behavioural problems including sleep disorders, hyperactivity, 
attention deficit, aggressiveness and autism have been found in children with 
TSC (Curatolo etal. 1991, Gillberg etal. 1994). Overall, the degree of 
intellectual deficit and behavioural disturbance varies greatly.
1.2.4.1.3 Ophthalmic manifestations
Approximately 50% of patients with TSC demonstrate ocular 
pathology. Retinal hamartomas, retinal pigmentation, retinal vascular 
changes, optic nerve atrophy, glaucoma, and coloboma of the iris, lens, 
choroids and retina are among the most frequent ophthalmologic 
manifestations (Curatolo 2003).
1.2.4.2 Renal manifestations
Eventually, more than 80% of patients with TSC develop morphologic 
abnormalities in their kidneys. These lesions include angiomyolipomas 
(AMLs), renal cysts and, rarely, renal cell carcinomas (RCCs).
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AMLs (Fig. 1.4b) are nonencapsulated localised proliferations of blood 
vessels, smooth muscle and fat, and are the most common renal lesions in 
patients with TSC. Because of their histological characteristics, they have 
been regarded histologically as tumourous malformations rather than true 
neoplasms (Bjornsson etal. 1999). AMLs are usually multiple and bilateral, 
with prevalence related to patient age (Stillwell et al. 1987, Cook et al. 1996). 
There is a slight preponderance to higher occurance in females than in 
males (1.2:1) (Ewalt etal. 1998).
The incidence of renal cysts in TSC patients varies between sexes 
being 9% in females to 20% in males (Torres et al. 1995). The true 
prevalence of renal cysts may be higher as, in autopsy studies, 53% of TSC 
patients had renal cysts (Stillwell et al. 1987). The cysts have a unique 
epithelial lining of hypertrophic, hyperplastic eosinophilic cells (Stapleton et 
al. 1980, Bernstein 1993). Renal cysts can cause impairment to renal 
function and hypertension (Gomez etal. 1999). Severe renal cystic disease, 
similar to advanced autosomal dominant Polycystic kidney disease (PKD), is 
seen in patients where deletions disrupt both TSC2 and the neighbouring 
PKD1 gene (Sampson etal. 1997).
An association appears to exist between TSC and RCC. The 
carcinomas are usually found at a younger age than would be expected 
typically in the general population and are thought to evolve from the lining of 
hyperplastic cysts (Bjornsson etal. 1996). RCCs in TSC patients include 
clear cell, papillary and chromophobe types, and have been shown to be 
metastatic (Bjornsson etal. 1996, Al-Saleem etal. 1998). The incidence of 
RCC in TSC has been estimated at 4.4% in the Mayo Clinic cohort (Stillwell
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et al. 1987) and 2.2% in the UK (Cook et al. 1996). These could be under 
estimates reflecting the younger patients who are typically followed by TSC 
clinics and the under recognition that TSC is a genetic syndrome 
predisposing to RCCs that are heterogeneous (Henske 2004). TSC 
associated RCCs may be rare, but they have clinical, pathologic and genetic 
features distinguishing them from sporadic RCCs (Weiner et al. 1998).
1.2.4.3 Dermatological manifestations
Dermatological manifestations are common in TSC. According to 
Gomez (1988), 96% of patients with TSC have one or more skin lesions 
(facial angiofibromas, ungula fibromas, shagreen patch and/or 
hypomelanotic macules).
Facial angiofibromas are pink to red nodules with a smooth glistening 
surface that are distributed bilaterally over the centrofacial areas. They 
usually present between the 2nd and 5th year of age (Curatolo 2003) and are 
composed of vascular fibrous and dermal tissue elements (Kwiatkowski and 
Short 1994). Ungual fibromas are fleshy lesions arising from beneath the 
nails, which histologically resemble facial angiofibromas. Shagreen patches 
are firm yellow-brown or pink hamartomatous lesions of the connective 
tissue. They occur mainly on the lower back and are generally multiple and 
small, but can become large lesions more than 10cm in diameter (Curatolo
2003). Hypomelanotic macules are patches of abnormal whiteness, which 
can be seen from the time of birth, and so are regarded as the first visible 
sign of TSC. Miscellaneous nevoid lesions also associated with TSC include
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forehead fibrous plaque, confetti like macules, cafg-au-lait macules and soft 
fibromas such as molluscum fibrosum pendulum.
1.2.4.4 Cardiac manifestations
Cardiac rhabdomyomas are very common and often multiple in 
neonates with TSC. Approximately 50% of infants with TSC have been 
reported to have rhabdomyomas (Bass etal. 1985, Smith etal. 1989), 
although, in most patients, these cardiac tumours have little or no clinical 
significance (Smith etal. 1989). Cardiac rhabdomyomas represent the 
earliest detectable hamartoma in TSC and, interestingly, appear to be the 
only lesions in TSC that may regress with age (Curatolo 2003). The lesions 
may be detected in any of the cardiac chambers but occur more commonly in 
the ventricles than in the atria (Fenoglio et al. 1976, Jozwiak et al. 1994). On 
gross examination, cardiac rhabdomyomas have a grey or yellowish-white 
appearance and vary in size. The tumour cells are typically characterised by 
a chicken wire appearance and by so called spider cells (Mair et al. 1999).
1.2.4.5 Pulmonary manifestations
Symptomatic pulmonary involvement in TSC is rare. It is estimated to 
occur in 1% to 6% of cases (Uzzo et al. 1994, Kwiatkowski and Short 1994). 
It develops predominantly in women between 20 and 40 years of age (Taylor 
et al. 1990, Uzzo et al. 1994) and thus has led to the hypothesis that 
estrogen regulates TSC signalling (Astrinidis and Henske 2005). The TSC 
lung lesions are morphologically undistinguishable from sporadic 
lymphangiomyomatosis (LAM) (Fig. 1.4c). Histologically, LAM is
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characterized by the diffuse, bilateral proliferation of abnormal smooth 
muscle cells and cystic degeneration of the lung parenchyma (Henske 2003). 
Patients with both sporadic LAM and TSC-LAM often have benign renal 
AMLs. The smooth muscle cells within the angiomyolipomas can be 
morphologically very similar to the smooth muscle cells in pulmonary LAM. 
Recent studies suggest that pulmonary LAM may be the result of a highly 
unusual disease mechanism: the metastasis of 'benign cells' (Karbowniczek 
et al. 2003, Henske 2003). The prognosis of LAM is often poor (Shepherd et 
al. 1991), though lung transplantation can be useful (Boehler etal. 1996).
1.2.4.6 Additional manifestations of TSC
An association of arterial aneurysms and TSC has been reported in a 
number of patients (Curatolo 2003). Hepatic hamartomas or hepatic AMLs 
have been reported in patients with TSC (Jozwiak et al. 1992). Dental 
enamel pitting is seen in 90% of patients with TSC (Flannagan et al. 1995). 
Other rare manifestations of TSC can been seen in the endocrine system 
(thyroid, pancreas, gonads, hypothalamus and pituitary) as well as the 
digestive tract, and spleen (Gomez et al. 1999).
1.2.5 Clinical diagnosis of TSC
After Vogt (1908) pointed out the early diagnostic triad of TSC, it was 
not until 1979 that Gomez succeeded in greatly improving the diagnostic 
method. Gomez observed that only 29% of patients presented all three of 
Vogt's triad characteristics (Gomez 1979, Gomez 1988). Gomez believed 
there were two different criteria for the primary and secondary diagnosis of
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TSC. For primary diagnosis, patients must have one of the following three 
groups of clinical signs; (1) a characteristic skin lesion; (2) cortical tubers or 
subependymal hamartomas; (3) multiple retinal hamartomas. If a primary 
characteristic was not present, two secondary features were acceptable for 
diagnosis. Secondary features included; infantile spasms, hypomelanotic 
macules, shagreen patch, single retinal hamartoma, subependymal or 
cortical calcifications, multiple renal tumours, cardiac rhabdomyoma or an 
immediate relative with TSC. In 1998 at the Tuberous Sclerosis Complex 
Consensus Conference, the diagnostic criteria were reassessed. The new 
criteria were divided into two groups, major and minor (Table 1.1); the 
diagnosis of TSC is established when two major features or one major plus 
two minor features can be demonstrated.
1.2.6 Identification of the TSC genes
TSC was first recognised as a genetic condition by Kirpicznik in 1910. 
He described the condition in fraternal twins and in a family with affected 
individuals in 3 generations. The hereditary nature of TSC was first reported 
by Berg in 1913 and, in 1914, Schuster confirmed it. Since then, studies by 
Gunther and Penrose (1935) and Nevin and Pearce (1968) demonstrated the 
dominant inheritance of TSC and its high mutation rate. Linkage between the 
ABO blood group on chromosome 9q34 and TSC was reported in 1987 
(Fryer et al. 1987). Analysis by Connor et al. (1987) supported this view but 
other early reports contradicted these findings (Northrup et al. 1987, Povey 
etal. 1988, Kandt etal. 1989). An international collaboration was established 
in an attempt to resolve the apparently contradicting data. Subsequent
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results confirmed linkage at 9q34 in approximately half the families studied 
(Sampson et al. 1992). This locus was denoted TSC1. Evidence for locus 
heterogeneity was presented (Northrup etal. 1987, Sampson etal. 1989, 
Janssen et al 1990, Northrup etal. 1992, Sampson etal. 1992) and further 
studies of five large families not linked to 9q34 led to the identification of a 
second locus at chromosome 16p13.3, denoted TSC2 (Kandt et al. 1992). 
Among families large enough to permit linkage analysis, half show linkage to 
9q34 and half to 16p13. There is no linkage evidence for a third TSC locus 
(Janssen etal. 1994, Povey etal. 1994).
Table 1.1: Clinical diagnostic criteria for TSC (modified from Roach et 
al. 1998)
Major features Minor features
Facial angiofibromas or forehead plaques Multiple pits in dental enamel
Non-traumatic ungual or periungual fibroma Hamartomatous rectal polyps
Hypomelanotic macules (3 or more) Bone cysts
Shagreen patch (connective tissue nevus) Cerebral white matter
Multiple retinal nodular hamartomas radial migration lines
Cortical tuber Gingival fibromas
Subependymal nodule Non-renal hamartoma
Subependymal giant cell astrocytoma Retinal achromic patch
Cardiac rhabdomyoma 'Confetti' skin lesions
Lymphangiomyomatosis Multiple renal cysts
Renal angiomyolipoma
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1.2.6.1 TSC1
The identification of TSC1 was a lengthy process that proved difficult 
for a number of reasons. First, the 9q34 region is gene rich with numerous 
TSC1 potential candidates. Secondly, several parts of the region were 
unstable in multiple cloning vectors (Zhou etal. 1995, Hornigold etal. 1997). 
Thirdly, unlike the TSC2 locus where the characterisation of large deletions 
in several families significantly reduced the candidate region (The European 
Chromosome 16 Tuberous Sclerosis Consortium 1993), no large 
rearrangements were identified at the TSC1 locus. Finally, conflicting linkage 
and haplotype studies pointed to both the distal and proximal parts of the 
candidate region (Nellist etal. 1993, Pitiot etal. 1994, Janssen etal. 1994). 
Initial definition of the 1.5Mb TSC1 candidate region on chromosome 9q34 
was achieved by identification of key meiotic recombination events in large 
TSC1 linked families (Haines etal. 1991, Nellist etal. 1993). Microsatellite 
markers from this region were identified and a contig assembled (Povey et 
al. 1994, van Slegtenhorst etal. 1995, Au etal. 1996, Hornigold etal. 1997). 
The region was further narrowed to 900kb between the markers D9S2127 
and DBH by two additional recombination events in unaffected individuals. In 
all, 30 genes were identified or mapped to the 900kb critical region and 
several genes identified appeared to be good candidates based on probable 
roles in signal transduction pathways. However, no mutations in these genes 
were identified in patients with TSC (van Slegtenhorst et al. 1997). A strategy 
to sequence the 900kb region was implemented. Predicted and confirmed 
exons in the initial 208kb of sequence were screened for mutations using 
heteroduplex analysis in a cohort of twenty unrelated TSC families with
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linkage to 9q34 and in 40 sporadic TSC cases. Mobility shifts in ten samples 
were revealed in the 62nd exon screened and sequencing confirmed 
truncating mutations in eight samples (7 frameshift and 1 nonsense 
mutations). A combination of 5'RACE, RT-PCR and isolation of other cDNA 
clones defined the remainder of the open reading frame of TSC1. The 
complete genomic structure of TSC1 was determined by comparison of the 
genomic and cDNA sequences (van Slegtenhorst et al. 1997). TSC1 spans 
approximately 43kb of genomic DNA and consists of 23 exons encoding a 
1164 amino acid, 130kDa protein named hamartin (Fig. 1.5). The translation
t
initiation and termination codons are at nucleotides 222 in exon 3 and 3738 
in exon 23, respectively. Northern blot analysis revealed a widely expressed 
8.6kb transcript (van Slegtenhorst et al. 1997).
1.2.6.2 TSC2
The identification TSC2 was rapid compared to TSC1. Two factors in 
particular aided in its swift discovery. First, mapping at the 16p13.3 locus 
was already advanced and, secondly, chromosomal rearrangements were 
identified that defined a small region in which the gene could be sought. 
Initially, linkage studies identified TSC2 to be located in a 1.5Mb region of 
chromosome 16p (Kandt et al. 1992). At the same time, a family with both 
TSC and autosomal dominant PKD was found to have a translocation 
between chromosomes 16p and 22q. The mother and daughter each carried 
a balanced translocation involving 16p13.3 (46,XX,t(16;22)(p13.3;q11.21) 
and had typical signs of PKD but no TSC. The son, on the other hand, had 
inherited an unbalanced karyotype (45,XY,-16,-
22
22,+der(16)(16qter-*16p13.3::22q11.21 —>22qter) and had CNS and skin 
phenotypes typical of TSC as well as renal cysts (European Polycystic 
Kidney Disease Consortium 1994). It was reasoned that the son manifested 
TSC because of a deletion of one copy of the TSC2 gene, the implied 
location of which was telomeric to the translocation breakpoint on 16p13.3. 
The breakpoint of the translocation was mapped by a combination of 
fluorescence in situ hybridisation (FISH) and pulsed-field gel eletrophoresis 
(PFGE) and was defined as lying 150kb telomeric to 16AC2.5. A previously 
reported patient had a de novo truncation of 16p but had no clinical 
manifestations of TSC (Wilkie etal. 1990), thus excluding approximately 
1.1Mb of the1.4Mb TSC2 candidate region. A cosmid contig of the remaining 
300kb was generated and a cohort of 255 patients with TSC was screened 
for rearrangements in the region using PFGE and Southern blotting.
Deletions ranging from 30kb to 100kb were observed in five patients all 
involving the same 120kb region. Four genes were isolated from this region 
by screening cDNA libraries, and it was shown only one of these genes was 
disrupted by all five deletions. Further analysis of this gene revealed 4 
smaller intragenic deletions thus confirming the identity of the TSC2 gene. 
TSC2 spans approximately 44kb of genomic DNA and consists of 41 exons 
encoding a 1807 amino acid, 198kDa protein that was named tuberin (Fig.
1.6). The translation initiation and termination codons are at nucleotides 19 in 
exon 1 and 5440 in exon 41, respectively. A non-coding leader exon (exon 
1a) has been identified (Kobayashi etal. 1997) and exons 25, 31 and the first 
codon of exon 26 are alternately spliced (Xu et al. 1995). Northern blot 
analysis reveals a widely expressed 5.5kb transcript.
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1.2.7 Mutation analysis of TSC1 and TSC2
More that 300 germline mutations have been reported for TSC2, 
including missense, nonsense, frameshift deletions/insertions and splice site 
mutations (Jones etal. 1999, Dabora etal. 2001, Sancak etal. 2005). 
Interestingly, exons 35-39 which encode the essential GTPase activating 
protein domain contained 46% of missense mutations and 93% of all in­
frame deletions (Sancak et al. 2005). In contrast, nearly all (>90%) reported 
in TSC1 mutations are either nonsense or frameshift variants that cause 
premature protein truncation (Sancak et al. 2005). Both somatic and 
germline mosaicism for causative mutations in TSC1 and TSC2 has been 
documented in many patients (Cheadle et al. 2000a).
In agreement with Knudson’s two hit hypothesis, inactivation of both 
alleles of either TSC1 or TSC2 is necessary for some of the clinical 
manifestations, suggesting that TSC1 and TSC2 function as tumour 
suppressor genes. Loss of heterozygosity (LOH) at TSC1 and TSC2 has 
been observed in 56% of renal AMLs and rhabdomyomas, but in only 4% of 
TSC-associated brain lesions. This suggests that brain lesions can result 
from different pathogenic mechanisms as compared to kidney and heart 
lesions (Henske etal. 1996). A novel mechanism specific to TSC-associate 
brain lesions has been proposed whereby tuberin can be inactivated by 
physiologically inappropriate phosphorylation (Han et al. 2004).
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1.2.8 Genotype/phenotype correlations
TSC2 mutations are approximately five times more common than 
TSC1 mutations in sporadic patients with TSC. This may be attributed to the 
smaller size and less complex structure of hamartin. However, the two genes 
appear to account for an equal proportion of mutations in large TSC families 
(Povey etal. 1994, Jones etal. 1997). Therefore, the rate of germline TSC1 
mutation appear to be lower than for TSC2 but each new sporadic TSC1 
patient has a better chance of founding a family than a TSC2 patient. These 
observations suggest that, on average, patients with TSC1 mutations may be 
less severely affected than those with TSC2 mutations (Cheadle et al.
2000a, Kwiatkowski 2005). Studies of large cohorts indicate that patients 
with a TSC1 mutation are less likely to be mentally retarded (Jones et al. 
1999, Sancak etal. 2005), whilst patients with TSC2 mutations have a higher 
number or severity of clinical features including renal AMLs and renal cysts 
(Dabora et al 2001, Sancak et al. 2005). Sex differences have also been 
noted. Males with TSC have been reported to have a higher risk of learning 
disorders, autism (Smalley etal. 1992) renal cysts, retinal lesions and 
fibromas (Sancak et al. 2005) when compared to females.
1.2.9 Biochemistry of the TSC proteins
1.2.9.1 Hamartin
Hamartin and tuberin expression analysis has been difficult due to 
antibody limitations but generally it is considered that hamartin is expressed 
in most cell types including those of the nervous system (Gutmann et al. 
2000), endocrine tissues and in many organs such as the kidney, uterus,
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intestine and liver (Fukuda etal. 2000, Johnson etal. 2001). Most reports 
place hamartin in the cytoplasm, localised to cytoplasmic vesicles (Plank et 
al. 1998, Nellist et al. 1999).
Hamartin is hydrophilic and forms homomeric complexes. It has a 
weakly predicted transmembrane domain at amino acids 127-144 (Fig. 1.5) 
and a predicted coiled-coil region at residues 719-998 (Nellist etal. 1999). It 
has a tuberin interaction domain that spans residues 302-430 (Hodges et al. 
2001, Nellist et al. 2001) and forms a tumour suppressor complex with 
tuberin (discussed below). Hamartin also has an ezrin-radixin-moesin (ERM) 
interaction domain that spans residues 881-1084 and a Rho-activating 
domain at amino acids 127-144; it has been suggested that hamartin 
regulates actin dynamics and cellular adhesion through these interacting 
domains (Lamb et al. 2000). Hamartin has also been found to bind to 
neurofilament-light chain (NF-L) and possibly functions as a novel integrator 
of the neuronal cytoskeleton (Haddad etal. 2002). Taken together, these 
data suggest that hamartin may act as a scaffolding protein for proper 
localisation of tuberin (Astrinidis and Henske 2005).
Reversible protein phosphorylation is a key mechanism controlling the 
activity of numerous proteins within the cell. Phosphorylation of hamartin by 
cyclin-dependant kinase CDK1 has been reported, late in the cell cycle, at 
three residues T417, S584 and T1047 (Astrinidis etal. 2003). Hamartin with 
alanine mutations in the three CDK1 phosphorylation sites increased the 
inhibition of p70 ribosomal protein S6 kinase 1 (S6K1) by the hamartin- 
tuberin complex, suggesting phosphorylation of hamartin regulates the 
function of the hamartin-tuberin complex during cell cycle progression
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Figure 1.5: Two-dimensional representation of Hamartin. Harmartin is a 1164 amino acid protein with a molecular mass of 130kDa. It interacts with tuberin 
through amino acids 302-430. It has a potential transmembrane domain, Rho-activating domain and an ezrin-radixin-moesin (ERM) interaction domain as 
well as a coiled-coil region from amino acids 730- 996. It is phosphorylated by cyclin-dependant kinase (CDK1) (residues T417, S584, T1047) and by 
Glycogen synthase kinase-3fc (GSK3p) (S357, S390).
(Astrinidis et al. 2003). In addition to phosphorylation by CDK1, hamartin is 
phosphorylated by Glycogen synthase kinase-3& (GSK3&) at residues T357 
and T390 (Mak et al. 2005). This increases the stability of the TSC complex 
causing reduction of B-catenin signalling. Finally, hamartin is phosphorylated 
at residue S505 (Nellist et al. 2005) although the responsible kinase is as yet 
unknown.
1.2.9.2 Tuberin
Tuberin localisations show overlapping, but non identical organ and 
cellular distribution when compared to hamartin (Fukuda etal. 2000). Tuberin 
is expressed in most cell types, with the highest levels found in brain, heart 
and kidney. Tuberin appears to be diffusely cytoplasmic but localisation has 
also been reported to the Golgi apparatus (Wienecke et al. 1996) and the 
nucleus (Lou et al. 2001). It is not clear whether the differences in cell type 
expression and localisation between tuberin and hamartin reflect cell type- or 
cell cycle-specific differential localisation or antibody specificity.
Tuberin shows significant homology to the Rap1-GTPase activating 
(GAP) protein. The GAP domain in tuberin spans residues 1517-1674 (Fig.
1.6) GAPs inhibit the Ras-related family of small G proteins such as Rap1, 
Rab5 and Rheb (Ras-homolog enriched in brain) (Wienecke etal. 1995, Xiao 
etal. 1997, Inoki etal. 2003a). Increased activation of Rheb, when tuberin is 
dysfunctional, effectively leads to increased mammalian target of rapamycin 
(mTOR) and ribosomal protein S6 phosphorylation, which can be blocked by 
the immunosuppressant drug rapamycin (Tee etal. 2003).
28
CaM-binding
domain (1740-1755)
□
Hamartin binding domain (1-418) 
■ — i
Rheb GAP domain (1517-1674)
\
S664
ERK2
S939 S1086 S1088 S1210 T1227 S1345 T1462 
Akt Akt Akt MK2 AMPK AMPK Akt
S1798
RSK1
Figure 1.6: Two-dimensional representation of tuberin. Tuberin is 1807 amino acid protein with a molecular mass of 200kDa. It interacts with hamartin 
through amino acids 1-418. It has a GTPase activating protein (GAP) domain with specificity for Rheb. It has a calmodulin (CaM) binding domain at amino 
acids 1750-1755. It is phosphorylated by the serine/threonine kinase Akt (residues S939, S1086, S1088, T1462), MAPK-activated protein kinase 2 (S1210), 
ribosomal S6 kinase 1 (RSK1) (1798), AMP-dependant protein kinase (AMPK) (T1227, S1345) and extracellular signal-regulated kinase 2 (ERK2) (S664).
Tuberin has a sequence (amino acids 1740-1755) that is capable of 
forming a basic amphipathic helix indicative of a calmodulin (CaM) binding 
domain (Noonan et al. 2002). Deletion mutagenesis studies suggested that 
this CaM binding domain is required for tuberin modulation of steroid 
receptor function. Competition binding studies identified a competitive 
relationship for binding of tuberin by estrogen receptor (ER) a and CaM, that 
is modulated by the presence of hamartin, supporting the hypothesis that 
interactions between the TSC complex, ER alpha, and CaM may play a 
critical role in the pathology of TSC and LAM disease (York et al. 2005).
The serine/threonine kinase Akt phosphorylates tuberin at S939, 
S1086, S1088 and T1462, which negatively regulates the TSC complex (Dan 
et al. 2002). A similar negative effect is also produced by phosphorylation of 
tuberin at residue S1798 by p90 ribosomal S6 kinase 1 (RSK1) (Roux et al.
2004). RSK1 is activated in the Raf/MAPK pathway. The phosphorylation of 
tuberin at residue S1210 by p38 MAPK-activated protein kinase 2 (MK2) (Li 
etal. 2003b) promotes binding of tuberin with 14-3-3 proteins, which may 
sequester tuberin from its physiological substrates (Astrinidis and Henske
2005). extracellular signal-regulated kinase 2 (ERK2) inactivates tuberin by 
phosphorylation at residue S664 (Ma et al. 2005) that disrupts the 
hamartin/tuberin complex. These four kinases cause inactivating 
phosphorylation of tuberin and positively regulate the mTOR signalling 
pathway, thus allowing protein translation and cell proliferation in response to 
growth factors. In contrast, under energy deprivation, tuberin undergoes 
activating phosphorylation at T1227 and S1345 by AMP-dependant protein 
kinase (AMPK) leading to enhanced inhibition of S6 ribosomal protein (Inoki
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et al 2003b). Another positive effect on tuberin is triggered in response to 
hypoxia; the TSC complex is required for mTOR inhibition during hypoxic 
conditions. Disruption of the complex through loss of TSC1 or TSC2 blocks 
the effects of hypoxia on mTOR and results in abnormal accumulation of 
hypoxia-induciblefactor (HIF) (Brugarolas etal. 2004). Additional tuberin 
phosphorylation sites at S1395/1397 and S1775 have been identified (Nellist 
et al. 2005a) but the kinase(s) are as yet unknown.
1.2.9.3 Interaction of the TSC proteins
The similarities in phenotypes produced by mutations in TSC1 or 
TSC2 suggest shared functions. However, there is no homology between the 
primary amino acid sequence of tuberin and hamartin, suggesting that they 
do not belong to the same family of proteins. An alternative explanation is 
that tuberin and hamartin work together in the same biological pathway (Au 
et al. 2004). Direct interaction between tuberin and hamartin was 
demonstrated by van Slegtenhorst et al. (1998) using the yeast two-hybrid 
system and is further supported by co-immunoprecipitation experiments 
(Plank etal. 1998, van Slegtenhorst etal. 1998, Nellist etal. 1999, Hodges et 
al. 2001). Gel filtration studies indicate that tuberin (200kDa) and hamartin 
(130kDa) are found in a TSC complex of approximately 450kDa, though the 
other components of this complex, if any, are yet to be defined (Nellist et 
al. 1999). It has been proposed that tuberin acts as a chaperone in the TSC 
complex, preventing hamartin from self-aggregation (Nellist etal. 1999).
Thus, the stability of tuberin and hamartin appear to be interdependent 
(Benvenuto et al. 2000).
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Immunohistochemical studies have demonstrated absent or 
diminished amounts of both proteins in TSC-related tumour cells (Mizuguchi 
et al. 2000). Furthermore, patient-derived TSC2 mutations that disrupt the 
association of tuberin with hamartin have decreased GAP activity, indicating 
that the interaction with hamartin is important for tuberin’s function as a GAP 
(Nellist et at. 2005b). In addition, it has been shown that TSC1-TSC2 
interaction is regulated by tuberin phosphorylation, and defective 
phosphorylation of tuberin is associated with loss of tumour suppressor 
activity (Aicher et al. 2001). Taken together, these data explain why complete 
deficiency of either protein has the same biochemical consequence, and 
produces a similar disease phenotype.
1.2.9.4 The mTOR signalling network
The Tor genes were originally identified in yeast as the targets of the 
immunosuppressant drug rapamycin (Heitman etal. 1991). TOR is a 
member of the phosphoinositide kinases-related kinase (PIKK) family and is 
structurally and functionally conserved between yeast and mammals (mTOR) 
(Inoki et al. 2005). TOR has been shown to have a central role in controlling 
cell growth, proliferation and metabolism by regulating translation, 
transcription, mRNA turnover, protein stability, actin cytoskeletal organisation 
and autophagy (Inoki et al. 2005). mTOR functions in two separate pathways 
in two distinct protein complexes (Fig. 1.7). mTOR complex 1 (mTORCI) 
consists of mTOR, raptor and gephyrin and is inhibited by the action of 
rapamycin. mTOR complex 2 (mTORC2) requires binding of rictor, and 
gephyrin and is rapamycin insensitive (Jozwiak etal. 2005). mTORC2
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Figure 1.7: The mTOR signalling network. The mTOR pathway integrates the three inputs of nutrients (amino acids), growth factors (insulin) and cellular 
energy status to control cell growth (adapted from Martin and Hall 2005). See text for explanation of abbreviations.
phosphorylates Akt at serine 473 (Sarbassov et al. 2005) and has a role in 
regulation of the actin cytoskeleton but does not appear to be directly 
affected by signalling events through the TSC complex. mTORCI is 
activated upon an elevation of Rheb-GTP levels, growth factors and 
intracellular amino acid availability (Kwiatkowski and Manning 2005). The 
activation of mTORCI primarily affect ribosomal S6 kinases (S6K) and 
eukaryotic initiation factor 4E (elF4E)-binding protein (4e-BP1) which, in turn, 
stimulate growth, accelerate protein synthesis, accelerate cell proliferation 
and even increase cell survival (reviewed in Kwiatkowski and Manning 2005, 
Inoki et al. 2005, Martin and Hall 2005, Guertin and Sabatini 2005, Jozwiak 
etal. 2005).
The TSC complex plays its roles in tumour suppression upstream of 
mTOR. The first evidence that tuberin and hamartin functioned within the 
insulin signalling pathway came from studies in Drosophila (Gao and Pan 
2001, Potter et al. 2001) where effects on cell size indicated that they act 
downstream of insulin. Current understanding of these biochemical 
interactions are as follows (Fig. 1.7): Growth factors including insulin bind to 
tyrosine kinase receptors and cause, either directly or via adapter proteins 
(e.g. IRS), phosphorylation and thus recruitment of phosphatidylinositol 3- 
kinase (PI3K) to the membrane. PI3K phosphorylates phosphatidylinositol 
(4,5) bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5) 
bisphosphate (PIP3), a reaction which is reversed by the tumour suppressor 
gene phosphatase and tension homolog deleted on chromosome 10 (PTEN). 
PIP3 serves as a membrane docking site for the protein Akt where it is 
phosphorylated by PDK1 or mTORC2. Akt, also known as protein kinase B
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(PKB), is one of the most frequently activated protein kinases in human 
cancer. Akt hyperactivation is associated with resistance to apoptosis, 
increased cell growth, cell proliferation and cellular energy metabolism. Akt 
phosphorylates several proteins including Forkhead family (FOXO) isoforms, 
BCL-2 family member BAD, Glycogen synthase 3-kinase (GSK3) as well as 
tuberin. Tuberin is a key within the pathway responding to phosphorylation 
from ERK1/2, RSK1 and AMPK as well as Akt. The TSC1/2 complex acts as 
a GAP for Rheb-GTP enhancing conversion to Rheb-GDP. When the TSC 
tumour suppressor complex is phosphorylated and inhibited by Akt, Rheb- 
GTP is able to accumulate. Rheb-GTP strongly enhances the kinase activity 
of mTOR and thus enhances protein translation and cell growth (reviewed in 
Kwiatkowski and Manning 2005, Inoki et al 2005, Martin and Hall 2005, 
Guertin and Sabatini 2005, Jozwiak et al. 2005). When no growth stimulus is 
present, Rheb-GDP is in abundance and consequently there is no mTOR 
activation. When growth stimuli are available or TSC1/2 are not functioning 
(biallelic inactivation) Rheb-GTP formation from its inactive substrate cannot 
be inhibited, thus leading to activation of mTOR.
1.2.9.5 The role of hamartin/tuberin in energy sensing
In addition to its control by nutrients and growth factors, the TSC 
complex is also targeted by the energy sensitive AMP-activated protein 
kinases (AMPK) (Fig. 1.7). AMPK is activated upon energy deprivation, and 
phosphorylation of tuberin enhances the stability of the TSC complex. Herein 
lies a link between two signalling pathways responsible for the formation of 
hamartomatous syndromes. Loss of both TSC1/2 or the serine/threonine
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kinase LKB1 TSG responsible for Peutz-Jeghers syndrome (PJS) result in 
the formation of multiple benign hamartomas. Interestingly, the LKB1 tumour 
suppressor gene controls AMPK by direct phosphorylation upon ATP 
depletion, and loss of LKB1 results in down regulation of the TSC complex 
thus stimulating mTOR activity. These finding suggest that hamartomas 
develop as a consequence of constitutively high mTOR activity (reviewed in 
Martin and Hall 2005, Inoki et al. 2005, Kwiatkowski and Manning 2005, 
Hardie 2005).
1.2.9.6 mTOR associated hamartoma syndromes
In addition to TSC and PJS, other hamartoma syndromes have also 
been linked to the mTOR pathway (Fig. 1.8). These include Cowden's 
disease, Bannayan-Riley-Ruvalcaba syndrone (BRRS), Lhermitte-Duclos 
disease and Proteus syndrome that are grouped together as PTEN 
hamartoma syndromes (PTHs). All are caused by germline mutations in 
PTEN (Inoki etal. 2005). PTEN lies upstream of Akt. It reduces intracellular 
levels of PI3K lipid products thereby inhibiting Akt activation. Thus, in cells 
lacking PTEN, Akt is constitutively active, and there is a corresponding 
increase in TSC2 phosphorylation and mTOR signalling (Manning et al.
2005). In addition to these syndromes with a well established molecular link 
to dysregulation of mTOR, further neoplastic syndromes are associated with 
dysregulation of mTOR related pathways. Neurofibromatosis type 1 (NF1) is 
caused by a mutation in the NF1 gene that is a GTPase-activating protein 
that can activate PI3K (Inoki et al. 2005). Some cases of juvenile polyposis 
(JP) are caused by mutations in mothers against DPP homolog 4 (SMAD4)
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Figure 1. 8: The molecular link between several inherited hamartoma syndromes (adapted from Inoki etal. 2005). Dysregulation of the mTOR pathway 
has been implicated in PTEN hamartoma syndromes (PTHs), Neurofibromatosis type 1 (NF1), Juvenile polyposis (JP), von Hippel-Lindau syndrome 
(VHL) and TSC1/TSC2 have been linked to Familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome (PJS)
which interacts with mothers against DPP homolog 3 (SMAD3) which in turn 
has been shown to interact with Akt and TSC2 (Birchenall-Roberts et al. 
2004). Familial adenomatous polyposis (FAP) is caused by a mutation in 
APC. The TSC proteins have been shown to interact with components of the 
APC/(3-catenin degradation complex (Mak et al. 2003). von Hippel-Lindau 
syndrome (VHL) is caused by a mutation an the VHL locus which encodes a 
protein involved in degradation of HIF of which mTOR is a key regulator 
(Inoki et al. 2005).
1.2.9.7 Akt negative feedback
Consistent with the theory of mTOR being a key effector in the biology 
of TSC and PJS, Tsc2/_ and L k b 1 mouse embryo fibroblasts (MEFs) share 
a number of properties that are uncharacteristic of cells lacking tumour 
suppressor genes. Both cell types are hypersensitive to apoptosis induced 
by energy stress, they proliferate more slowly than their wild-type derived 
counterparts and they display reduced Akt activation. The latter is in stark 
contrast to loss of PTEN which causes hyperactivation of Akt (Shaw et al.
2004). This difference goes someway to explain why TSC patients rarely 
develop malignant cancers in contrast to patients with Cowden's disease, 
that harbour PTEN mutations, who are predisposed to cancer. Two 
experimental results shown in TSC null cells may account for this negative 
feedback. First, there is a down regulation of expression of Platelet derived 
growth factor receptor (PDGFR) (Zhang et al. 2003). Secondly, there is a 
reduction in the expression and function of the IRS proteins (Fig. 1.7) 
(Harrington et al. 2004). Consequently, Akt activation is reduced and its
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multiple targets that promote cell growth and survival do not become active. 
This model is supported by recent observations in Tsc2+/~Pten+/~ mice. In 
Tsc2+/~ mice, TSC related lesions are slow growing with no Akt activation but, 
in Tsc2+/~ Pten+/~ mice, lesions are more severe and display Akt activation 
(Manning et al. 2005, Ma et al. 2005).
1.2.10 Treatments
Since mTOR is directly activated upon loss of TSC1 or TSC2, 
rapamycin, the mTOR inhibitor, has been identified as a potential therapeutic 
agent for TSC. Rapamycin (or Sirolimus, Wyeth, Madison, NJ) is a peptide 
that was isolated in 1975 from the bacteria strain Streptomyces 
hygroscopicus found in a soil sample from Easter Island (Sehgal et al. 1975). 
It is an antibiotic, which demonstrates anti-fungal, anti-inflammatory, anti­
tumour and immunosuppressive properties. Rapamycin is used as an 
immunosuppressant during renal transplant. It possesses high specificity 
against mTOR through binding with the receptor protein FKBP12. Treatment 
of TSC1 or TSC2 null cells with rapamycin results in apoptosis and 
decreased proliferation. Furthermore, rapamycin induced a reduction of 
tumour size in both the Eker rat and Tsc2+/~ mice (Kenderson et al. 2005, Lee 
et al. 2005). However, small precursor lesions were unresponsive to 
rapamycin treatment suggesting mTOR activation may be critical to tumour 
progression but that it is not necessary for tumour initiation (Kenerson et al.
2005). Clinical trials of rapamycin are ongoing but results so far look 
encouraging with regression of astrocytomas (Franz et al. 2006) and renal 
AMLs (Julian Sampson, unpublished data). The identification of the Akt
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feedback loop (Manning 2004) has led to concerns about rapamycin 
treatment. Rapamycin treatment restores insulin signalling towards Akt, and 
may increase the risk of malignant tumours in patients with TSC by 
reactivating Akt and is plethora of downstream biochemical signalling 
pathways.
Both Tsc1+/~ and Tsc2+/~ mice develop liver hemangiomas consisting of 
proliferating smooth muscle cells, endothelial cells and vascular channels 
similar to LAM and renal AMLs. They occur at a higher frequency in female 
mice as compared to males (Onda et al. 1999, Kwiatkowski et al. 2002), 
suggesting that oestrogen may contribute to their development. El- 
Hashemite at al. (2005) treated Tsc1+/~ mice with both oestrogen and 
tamoxifen. Tamoxifen is an anti-oestrogen drug that was developed over 30 
years ago and is used widely to treat breast cancer. Oestrogen treatment 
increased the severity and frequency of live hemangiomas. In contrast, 
tamoxifen reduced symptoms, thus, suggesting a benefit in the treatment of 
renal AMLs and LAM.
1.2.11 TSC models
The ability to create specific gene modifications to produce animal 
models of inherited disease has allowed for in vivo analysis of gene function 
and greater understanding of pathogenic mechanisms of human disease. 
Interestingly, the first genetic model for TSC dates to the era before 
molecular biology. First described in 1954 by Reidar Eker, the Eker rat strain 
contains a germline inactivation of one allele of TSC2. Following the 
identification of the TSC1 and TSC2 genes, murine and Drosophila models
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were quickly established. Extensive homology searches have failed to 
identify TSC1 and TSC2 homologs in Caenorhabditis elegans or 
Saccharomyces Cerevisiae, however, Schizosaccharomyces pombe does 
contains these homologs.
1.2.11.1 Schizosaccharomyces pombe
Comparison of human and Drosophila TSC1 and TSC2 genes with 
the fission yeast genome lead to the identification of fission yeast homologs 
of the genes that encode Tsc1 and Tsc2 proteins with calculated molecular 
weights of 103kD and 156kD, respectively (Matsumoto et al. 2002). The GAP 
related domain of tuberin is particularly well conserved with 39% identity. The 
fission yeast TSC1 and TSC2 physically interact with each other and hence 
appear to be similar to their mammalian counterparts in structure but also in 
biochemical properties. However, introduced TSC1 does not rescue yeast 
lacking Tsc1, indicating the functions have diverged significantly (Matsumoto 
et al. 2002). Disruption of either Tsc1 or Tsc2 in S. pombe results in amino 
acid uptake defects and partial sterility (Matsumoto et al. 2002, van 
Slegtenhorst et al. 2004).
1.2.11.2 Drosophila
In 1999, Ito and Rubin identified the Drosophila homologs o f TSC1 
(dTsd) and TSC2 (dTsc2 or gigas). Loss of dTsc2 was reported to result in 
dramatic increase in cell size and cells appeared to repeat S phase without 
entering M phase (Ito and Rubin 1999). dTsd mutants were shown to have 
a similar increased cell-size phenotype (Goa and Pan 2001, Potter et al.
41
2001, Tapon et al. 2001) Over expression experiments indicate that the 
dTsd protein binds to the dTsc2 protein in vitro (Potter et al. 2001) in a 
similar way to their mammalian counterparts. Genetic analysis identified the 
Tsc genes as novel negative regulators of insulin signalling, placing the 
dTsc1-dTsc2 complex genetically downstream of Akt but upstream of S6K 
(Goa and Pan 2001, Potter etal. 2001). The dTsc1-dTsc2 complex has been 
shown to physically associate with TOR, and negatively regulate TOR 
activity during the control of cell growth in Drosophila (Gao et al. 2002). More 
recently, several groups have identified the small GTPase Rheb in 
Drosophila (Saucedo et al. 2003, Stocker et al. 2003, Patel et al. 2003) and 
placed Rheb downstream of the Tsc complex, suggesting that Rheb is the 
target of the GAP activity of dTsc2 (Saucedo et al. 2003, Stocker et al.
2003).
1.2.11.3 Eker Rat
Hereditary cancer was first described in the rat by Eker and Mossige 
in 1954. The Eker rat model of hereditary RCC was the first example of a 
Mendelian dominantly-inherited predisposition to a specific cancer in an 
experimental animal (Eker and Mossige 1961, Hino et al. 2001). The Eker 
renal carcinoma locus was mapped to rat chromosome 10q12 by linkage 
analysis (Yeung et al. 1993, Hino et al 1993a). After the human TSC2 gene 
was identified by positional cloning, the Eker phenotype was shown to be 
tightly linked to its rat homologue (Hino etal. 1994). In addition, TSC2 
expression was not seen in Eker rat RCCs compared to normal renal tissue 
that expressed TSC2 (Hino et al. 1994). Detailed analysis confirmed that the
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Eker rat phenotype is caused by a mutation in Tsc2 that results from the 
insertion of a 6.3kb intracisternal A particle (IPA) on one allele which 
produces aberrant RNA expression (Yeung et al. 1994, Kobayashi et al. 
1995). No stable protein product has been demonstrated from the mutant 
allele, indicating that the Eker mutation is functionally null (Kobayashi et al. 
1995).
Phenotypically homozygous mutants are embryonicly lethal at 13 days 
and appear to be two days behind in development with brains showing 
grossly abnormal development (Hino et al. 1993b). In heterozygotes, renal 
carcinomas develop mainly in the outer cortex from early phenotypically 
altered renal tubules that begin to appear at 2 months of age, and have 
~100% penetrance by 1 year (Hino et al. 2003). Kidney lesions vary in 
morphology and include pure cysts, cysts with papillary projections and solid 
adenomas (Eker et al. 1981). Histological studies suggest that cystic 
adenomas arise from the distal nephron, principally the collecting duct, 
whereas the solid atypical tubules, hyperplasias, and adenomas arise from 
the proximal nephron, principally the proximal tubule (Wolf et al. 1995). A 
small minority of these tumours become malignant with nuclear atypica. They 
expand to include the entire kidney and metastasize to the lungs, pancreas 
and liver (Eker at al. 1981). Investigations of extra renal lesions reveal 
hemangiomas/ hemangiosarcomas of the spleen, leiomyomas/ 
leiomyosarcomas of the uterus (Everitt et al. 1992), pituitary adenomas 
(Kubo etal. 1995) and brain lesions such as subependymal hamartomas, 
subcortical hamartomas, cortical tubers and anaplastic gangliogliomas 
(Yeung etal. 1997, Mizuguchi etal. 2000).
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1.2.11.4 Mouse models
Spontaneous mutations in rodent models like the Eker rat are 
relatively infrequent events and the occurrence of specific mutations of 
biomedical interest are extremely rare. However, mice are invaluable tools 
for studying disease due extensive chromosome homology between mouse 
and man (Yu and Bradley 2001), the availability of inbred strains and the 
ease of controlled breeding. Chromosomal deletions, duplications, inversions 
and translocations can be induced in mice by using radiation or chemical 
mutagens. However, the usefulness of the rearrangements is limited by the 
fact that they cannot be predetermined (Yu and Bradley 2001).
Consequently, chromosomal engineering and embryonic stem (ES) cell 
technology has been used to produce specific murine models of disease. 
Typically, murine models are produced in 2 ways. First, DNA can be 
integrated in a random fashion by microinjection into the pronucleus of a 
fertilized ovum. Secondly, site specific gene targeting can be performed by 
introducing DNA into ES cells and selecting for cells in which the DNA has 
undergone homologous recombination.
1.2.11.4.1 Microinjection
The first report describing transgenic mice that developed from 
microinjected eggs was published in 1980 (Gordon etal. 1980). It quickly 
became apparent that the foreign genes could be expresseds, incorporated 
into the germline, and these expressions and integrations could be passed 
onto offspring causing a physiological effect (Palmiter and Brinster 1986).
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Microinjection involves introducing genes in a random fashion into the 
germline by injection of purified, cloned DNA into the pronucleus of fertilised 
mouse eggs. The eggs are then transferred into the oviduct of 
pseudopregnant foster mothers for gestation. The DNA integrates randomly, 
and usually in multiple copies, causing a fraction of the mice born to be 
transgenic (Klysik 2002).
1.2.11.4.2 Embryonic stem cell technology and gene targeting
Embryonic stem cell technology was initiated at the beginning of the 
1980s when ES cells were derived from the inner mass of the blastocyst 
(Evans and Kaufman 1981). ES cells allow site-specific genetic alterations to 
be efficiently transmitted into the germline, thus enabling manipulation of any 
locus within the mouse genome (Klysik 2002).
Production of transgenic mice by embryonic stem cell technology and 
gene targeting involves first targeting the ES cells at defined loci via 
homologous recombination. Alterations may be a single nucleotide change, 
gene knockouts or chromosomal rearrangements. The genetically modified 
cells are then injected into blastocysts (from mice with a different coat colour) 
and the modified blastocyst introduced into a pseudopregnant foster mother 
(Fig. 1.9). ES cells are pluripotent and have the ability to contribute to several 
tissues of the foetus, including the germ cells. The resultant chimeras with 
the most transgenic cells, predicted by coat colour, are likely to transmit the 
modified allele to some of the F1 progeny. A further intercross of F1s will 
produce F2 homozygous animals (Klysik 2002).
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Figure 1.9: Generation of transgenic mice by embryonic stem cell technology and gene targeting. Targeted ES stem cells from a brown mouse are 
injected into a blastocyst from a black mouse and introduced into a pseudopregnant foster mother. The chimera that is produced will be partly transgenic 
(brown areas) and partly normal (black areas). Subsequent F1 and F2 generations will be heterozygous and homozygous mutants, respectively.
A problem with ES cell technology can occur when disruption of a 
specific locus leads to a lethal embryonic phenotype and, consequently, 
conditional knockouts have been developed. Cre is a 38kDa recombinase 
protein from bacteriophage P1. It is used to conditionally control gene 
expression by site-specific DNA recombination of the 34bp recognition site 
loxP. A loxP site consists of two 13bp-inverted repeats separated by an 8bp 
asymmetric core region (Lewandoski 2001). Cre dimers will excise the region 
of DNA between two loxP sites. Two mouse lines are required for conditional 
gene deletion. First, a conventional transgenic mouse line with Cre targeted 
to a specific tissue or cell type and, secondly, a mouse strain that has a 
target gene flanked by two loxP sites in a direct orientation ("floxed gene"). 
Recombination (excision and consequently inactivation of the target gene) 
occurs in only those cells expressing Cre recombinase. Hence, the target 
gene remains active in all cells and tissues that do not express Cre (Yu and 
Bradley 2001).
1.2.11.4.3 TSC1 knockout mice
Two groups have developed Tsc1 knockout mice (Kobayashi et al. 
2001, Kwiatkowski etal. 2002). To disrupt the Tsc1 gene, Kobayashi etal. 
(2001) used homologous recombination in mouse ES cells to delete mouse 
Tsc1 exons 6 to 8 and introduce a DNA construct. The construct contained 
an internal ribosomal entry site (IRES), an enhanced green fluorescent 
protein (EGFP) coding sequence, and a poly(A) tail followed by an 
expression cassette of a neomycin resistant gene (neo). The consequence of
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this targeting event was predicted to cause splicing from exon 5 to exon 9 
resulting in a frameshift (Kobayashi et al. 2001). Northern blot analysis of 
homozygous lethal (Tsc1v‘) embryos revealed that the 8kb mRNA transcript 
of Tsc1 had disappeared. Kwiatkowski et al. (2002) used a two-step process 
to disrupt the Tsc1 allele. First, homologous recombination in mouse ES cells 
was used to insert a DNA fragment containing 2 LoxP sites that flanked 
exons 17 and 18. Next, Cre recombinase expression was employed to yield 
a Tsc1 allele where exons 17 and 18 were deleted (Kwiatkowski et al. 2002). 
Deletion of exons 17 and 18 from Tsc1 was predicted to result in premature 
termination of translation as the message goes out of the reading frame. 
Immunoblot analysis indicated that no hamartin was produced from the 
mutant allele (Kwiatkowski et al. 2002). Both Tsc1 mouse models display a 
homozygous lethal embryonic phenotype between embryonic day E9.5 and 
E13.5 of gestation (Kobayashi etal. 2001, Kwiatkowski etal. 2002). Null 
embryos were smaller, approximately a day behind normal development, and 
some exhibited failed neural tube closure, abnormal morphology of 
myocardial cells, liver hypoplasia and poor development of other abdominal 
organs (Kobayashi etal. 2001, Kwiatkowski etal. 2002).
The phenotype of Tsc1+/' mice is similar to that of the Eker rat in that 
they develop macroscopically visible multiple bilateral renal cystadenomas 
by 15 to 18 months (Kwiatkowski etal. 2002). Microscopically, phenotypically 
altered tubules (cysts) were also seen at 9 to 12 months (Kobayashi et al.
2001). Histologically, the lesions varied from pure cysts, cysts with papillary 
projections and solid adenomas. There was no evidence of metastasis.
Strain dependant differences were observed whereby BALB/c-129/Sv hybrid
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mice had more cystadenomas than C57BL6-129/Sv hybrid or 129/Sv mice 
(Kwiatkowski etal. 2002). Molecular analysis of renal lesions demonstrated 
that 33% (2/6) of lesions show ed LOH of the wild type Tsc1 allele, 
suggesting that a second h it  may be a critical event for the development of 
renal tumours in Tscf+/‘ m ic e  (Kobayashi et al. 2001). Extra-renal lesions 
included hepatic hemangiomas, tail or paw hemangiomas and leiomyoma or 
leiomyosarcomas in the u te ru s  (Kobayashi et al. 2001, Kwiatkowski et al. 
2002). Hepatic hemangiomas caused early mortality and consisted of 
aberrant vascular channels o f highly variable size that often had cuboidal- 
columnar endothelial cells and  proliferation of smooth muscle cells. The 
lesions were more frequent, of larger size, and caused death more 
commonly in females as c o m p a re d  to male Tsc1/ mice (Kwiatkowski et al.
2002).
1.2.11.4.4 TSC2 kn o ckou t m ice
Two groups have dovo lopod Tsc2 knockout mice (Kobayashi et al. 
1999, Onda etal. 1999). T o  disrupt the Tsc2 gene, Kobayashi et al. (1999) 
used homologous recomt>ination to insert a targeting vector containing a 
LacZ reporter gene and a n e o m y c in  selection marker. This caused a deletion 
of codon 74 in exon 2 th ro u g h  to codon 164 in exon 5. Inactivation of the 
Tsc2 gene was confirmed t>y 3 lack of signal to an anti-tuberin antibody in 
Western blot analysis (Kol>3 yashi et al. 1999). Onda etal. (1999) used a 
similar approach to disrupt th e  Tsc2 gene. The targeting vector contained a 
neomycin selection marker th a t disrupted exon 2 of the Tsc2 gene. 
Inactivation of the Tsc2 g o rte  was confirmed by lack of expression of tuberin
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by immunoblot analysis (Onda etal. 1999). Both Tsc2 mouse models 
exhibited a lethal embryonic phenotype. Most TscZ/~ embryos died at E10.5 
and none were seen past E12.5 (Kobayashi et al. 1999, Onda et al. 1999). 
Lethality was thus seen at a similar stage to Tsc1v' embryos and they 
displayed a similar phenotype. However, survival of Tscl^' embryos was 
significantly improved over that of Tsc2 null embryos as TscV^ embryos are 
viable up to E13.5 (Onda etal. 1999).
Tsc2+/' mice develop multiple bilateral renal cystadenomas by 6 
months of age, with complete penetrance by 15 months of age. Renal 
lesions display a similar histology to that of Tsc1+/~ mice. Rarely, lesions 
progressed to RCC and metastasis to the lung was observed in one mouse 
(Kobayashi etal. 1999, Onda etal. 1999). Molecular analysis of renal lesions 
demonstrated that 24% (9/37) of lesions showed LOH of the wild type Tsc2 
allele (Onda etal. 1999). In addition to renal lesions, Tsc2+/~mice displayed 
liver hemangiomas, angiosarcomas on extremities, and alveolar adenomas 
(Kobayashi etal. 1999, Onda etal. 1999).
1.2.11.4.5 Cre-LoxP mouse models of TSC
In an attempt to model TSC associated central nervous system 
abnormalities in mice, Uhlmann et al. (2002) have produced astrocyte- 
specific Tsc1 conditional knockout mice using the Cre-LoxP system. Mice 
with two copies of the conditional Tsc1 allele (Tsoi*0) were generated by 
insertion of LoxP sites flanking exons 17 and 18 (Kwiatkowski etal. 2002). 
These were crossed with transgenic mice that express nuclear targeted Cre 
recombinase under the control of the human glial fibrillary acidic protein
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(GFAP) promotor. The T srf^G FAP-Cre conditional knockout mutants 
demonstrate increased astrocyte proliferation, abnormal neuronal 
organisation, seizures by two months of age and death by four months 
(Uhlmann et al. 2002). A second conditional knockout has been produced 
where the Cre recombinase allele was expressed in ventricular myocytes 
(Meikle etal. 2005). Tscf0/0mice with LoxP sites flanking exons 17 and 18 
(Kwiatkowski et al. 2002) were crossed with mice having a modified myosin 
light chain 2v allele expressing Cre recombinase (MLC2vcneKI). The Tscf0/0 
MLC2vcreKI mice developed dilated cardiomyopathy with scattered foci of 
enlarged ventricular myocytes containing excess glycogen. Mice survived 
only 8 months.
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1.3 Aims
The aims of the project were:
• To develop and characterise a Tsc1 deficient mouse model to 
help determine the mechanisms by which hamartin deficiency 
leads to TSC-associated disease.
• To attempt induction of tumourigenesis with increased somatic 
deletions in Tscf+/' mice by crossing onto a Bloom's-deficient 
background (Blm).
• Investigate the potential role of Tsc1 haploinsufficiency in Tsc- 
associated renal tumourigenesis by molecular and 
immunohistochemical examination of cysts, cystadenomas and 
renal cell carcinomas from Tscf+/‘ and Tsc1+/~ Blm'^ mice.
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Chapter 2: Materials and Methods
2.1 Suppliers
Names and locations of all suppliers whose products were used in this study 
are listed below:
Abeam Ltd (Cambridgeshire, UK)
ABGene (Surrey, UK)
GE Healthcare (Buckinghamshire, UK)
Applied Biosystems (Cheshire, UK)
Bethesda Research Laboratories (Frederick, MD, USA)
Bibby Sterling (Staffordshire, UK)
Bioquote (Yorkshire, UK)
Bio Rad Laboratories Ltd (Hertfordshire, UK)
Cell Signalling Technologies (Danvers, MA, USA)
Corning Inc. (Surrey, UK)
DAKO (Cambridgeshire, UK)
Eurogentec (Hampshire, UK)
Fisher Scientific (Leicestershire, UK)
Flowgen (Leicestershire, UK)
Genetic Research Instrumentation (GRI) (Essex, UK)
Genta Medical (West Yorkshire, UK)
Invitrogen Life Technologies (Strathclyde, UK)
Invivogen (Toulouse, France)
Millipore (Hertfordshire, UK)
Motic (Suffolk, UK)
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MWG-Biotech (Buckinghamshire, UK)
New England Biolabs (Hertfordshire, UK)
Nikon (Surrey, UK)
Olympus (London, UK)
PALM (Bernried, Germany)
QBiogene (Cambridgeshire, UK)
Qiagen (West Sussex, UK)
Raymond A Lamb Ltd (East Sussex, UK)
Roche Biochemicals (East Sussex, UK)
Santa Cruz Biotechnologies (Santa Cruz, CA, USA)
Sigma-Aldrich (Dorset, UK)
Starlabs (Buckinghamshire, UK)
Thermo Electron Corporation (Middlesex, UK)
Upstate cell signalling solutions (Buckinghamshire, UK)
Vector Laboratories (Peterborough, UK)
VWR International Ltd (Dorset, UK)
Carl Zeiss Limited (Hertfordshire, UK)
2.2 Materials
2.2.1 Chemicals
Chemicals of analytical grade were supplied by Sigma-Aldrich or 
Fisher Scientific unless otherwise stated.
2.2.2 Histology
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Microtome blades, processing casscfltes, paraffin wax and cork 
disks were purchased from Raymond A LamfcLtd. Slides, cover slips, dibutyl 
phthalate and xylene (DPX) mountant, xylene, formaldehyde, optimum 
cutting temperature (OCT) embedding compound, haematoxylin and eosin 
(H&E), toluidine blue, hydrogen peroxide andsopentane were purchased 
from VWR International. Poly-L-lysine and mineral oil were obtained from 
Sigma-Aldrich. LacZ Reporter Assay Kit waspurchased from Invivogen.
PEN (polyethylene napthalate) membrane sles were purchased from 
PALM. Industrial methylated spirits (IMS) waspurchased from Genta 
medical, and ethanol from VWR International
2.2.3 Nucleic acid extraction and purificrion
QIAamp DNA mini kits, QIAamp DNAiicro kits and proteinase K 
were supplied by Qiagen. Aquaphenol was purchased from QBiogene, 
chloroform from Sigma-Aldrich, and isopropanol from VWR international.
2.2.4 Oligonucleotides
Oligonucleotides were purchased fromeither MWG or Eurogentec 
and diluted to 100pM in sterile water fo r stodsolutions.
2.2.5 PCR
AmpliTaq Gold DNA polymerase andiGeneAmp PCR buffers were 
purchased from Applied Biosystems. Deoxyicleotidetriphosphates (dNTPs) 
were from GE Healthcare.
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2.2.6 PCR purification
Exonuclease I was purchased from New England Biolabs and shrimp 
alkaline phosphatase was from GE Healthcare
2.2.7 Electrophoresis
Multipurpose agarose was obtained from Roche, Nusieve agarose 
from Flowgen and acrylamide/bisacrylamide from Bio-Rad. 1kb DNA ladder 
and See Blue Plus2 Pre-stained protein ladder were supplied by Invitrogen.
2.2.8 Southern blotting
MegaPrime DNA labelling system was purchased from GE 
Healthcare. Zetaprobe GT membrane was purchased from BioRad.
2.2.9 Sequencing and fluorescent product sizing
Big Dye Terminator Cycle Sequencing kit version 3.1, POP6 polymer, 
HiDi formamide and Genescan 500-Rox size standard were purchased from 
Applied Biosystems. Montage SEQg6 sequencing reaction clean-up kits were 
purchased from Millipore.
2.2.10 Restriction enzymes
Restriction enzymes with appropriate buffer were supplied by New 
England Biolabs.
2.2.11 Radioisotopes and autoradiographic film
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[a-32P]dCTP and Kodak BioMax MR film was supplied by GE 
Healthcare.
2.2.12 Antibodies
Anti-murine Gelsolin was a kind gift from Prof. D. Kwiatkowski 
(Boston, MA). Cell Signalling Technologies supplied the anti-phospho-S6 
ribosomal protein (Ser240/244), anti-mTOR and anti-phospho-mTOR (Ser 
2448) antibodies. For Western blotting, donkey anti-rabbit-HRP secondary 
antibody was supplied by GE Healthcare. Anti-f3 actin loading control 
antibody was purchased from Abeam Ltd.
2.2.13 Immunohistochemistry
The rabbit VECTASTAIN ELITE ABC horseradish peroxidase kit and 
3,3-diaminobenzidine (DAB) peroxidase substrate kit were supplied by 
Vector Laboratories. Bovine albumin fraction V was purchased from VWR 
international. Cytomation wax pens were supplied by DAKO.
2.2.14 Protein analysis
RIPA lysis buffer was purchased from Santa Cruz Biotechnologies. 
Acrylamide gel cassette moulds (1.0mm) were purchased from Invitrogen. 
BioRad supplied 40% acrylamide/bisacrylamide 29:1 mixture. Immobilon-P 
transfer membrane was supplied by Millipore. Visualizer EC Western blot 
detection kits were purchased from Upstate cell signalling solutions. 
Ponceau S stain was purchased from VWR international. Bradford assay 
reagents were bought from Bio-Rad.
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2.3 Equipment
2.3.1 Plastics
Sterile tips for Gilson pipettes were purchased from Starlabs. Bioquote 
supplied 0.6ml, 1.5ml and 2.0ml plastic eppendorf tubes. ThermoLife 
Sciences supplied thermo fast 96 well PCR plates. ABGene provided 0.2ml 
thermo strip tubes, adhesive PCR film and thermo fast 96 well detection 
plates. Sterile universal tubes were purchased from Bibby Sterling. Corning 
Costar Inc. supplied 5ml, 10ml and 25ml strippettes.
2.3.2 Histology
Fixed tissue was processed using a Thermo Shandon Citadel 2000 
wax processor and embedded using a Thermo Shandon Histocentre 2. 
Paraffin sections were cut on a Thermo Shandon Finesse microtome and 
stained with H&E on a GLX Thermo Shandon automatic ministain. Frozen 
sections were cut on a Bright cryostat. Tissues were viewed using an 
Olympus BX51 BF light microscope or a Motic B3 professional series light 
microscope.
2.3.3 Laser microdissection
Laser capture microdissection was carried out using the PALM 
Microlaser system and visualised using the PALM Robo software.
2.3.4 Immunohistochemistry
Raymond A Lamb Ltd provided plastic slide racks and Coplin jars.
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2.3.5 Protein analysis
Protein extraction was performed on the fast prep system from 
Thermo Savant. DNA and protein quantification was carried out using the 
GeneQuant Pro spectrophotometer from GE Healthcare.
2.3.6 Determining the level of radioactivity
The radioactivity levels of Southern blotting probe were determined on 
the Bioscan QC-2000.
2.3.7 Thermocycling
Thermocycling of single tubes was carried out in a DNA thermal cycler 
480 from Applied Biosystems. Thermocycling of 96-well plates and strip 
tubes was carried out in a PTC-225 Peltier thermal cycler from GRI.
2.3.8 Electrophoresis
Agarose gel electrophoresis was carried out using Horizon 11.14 gel 
tanks from Invitrogen Life Technologies, a Model H4 large gel tank from 
Bethesda Research Laboratories or a 96-well gel apparatus from ABGene. 
Biorad supplied the power packs. Capillary gel electrophoresis of fluorescent 
sequencing or PCR products was performed on ABI 3100 or ABI 3730 
Genetic analysers. Acrylamide gel electrophoresis and blotting was carried 
out using the XCell sure lock gel tank and blot module purchased from 
Invitrogen.
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2.3.9 Photography
Macroscopic pictures were recorded using a Nikon Coolpix 4500. 
Agarose gels were photographed using a Gel Doc 2000 UV transilluminator 
from Bio Rad and printed using the Mitsubishi P91 video processor with high- 
density thermal paper. Micrographs were prepared using a Zeiss 
AxioVision/AxioCam digital camera system.
2.4 General solutions
Commonly used solutions included 1xTAE (0.4M Tris-acetate, 10mM 
EDTA, pH 8.0), 1xTE (10mM Tris HCL, 1mM EDTA, pH 8.0),
1xSSC (3M NaCI, 0.3M fri-NaCitrate) and 1xTBS (0.15 NaCI, 0.005M Tris).
2.5 Methods
2.5.1 Animal husbandry
All procedures with animals were carried out in accordance with Home 
Office guidelines. Mice were housed in filter top cages and received filtered 
food and water. Cages were kept at an ambient temperature of 22°C and 
maintained on a 12 hour light :12 hour dark cycle (7:30 hours to 19:30 
hours). Mice were tagged using microchips and tail tips were cut from mice 
for genotyping using a local anaesthetic. Mice were killed by cervical 
dislocation.
2.5.2 Necropsy analysis
Necropsy analysis included macroscopic examination of the brain, 
heart, lungs, kidneys, liver, spleen and uterus (in females) in all animals. Half
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of each organ was fixed and processed into paraffin wax. The other half of 
the organ was snap frozen.
2.5.3 Histology
2.5.3.1 Tissue fixation and paraffin embedding
Fresh tissue was immersed into 10% formal saline and fixed overnight 
at 4°C. Fixed tissue was placed into the processor for a period of 1 V* hours in 
each of the following solutions; formaldehyde, 70% IMS, 90% IMS, 96% IMS, 
100% IMS x 3, chloroform x 3, paraffin wax and paraffin wax under vacuum. 
Tissues were embedded cut plane down and stored at room temperature. 
Paraffin sections were routinely sectioned at 4pm and floated onto poly-L- 
lysine treated glass slides. Sections were dried onto slides overnight at 45°C 
and stored at room temperature.
2.5.3.2 Freezing and sectioning tissue
Tissue was placed onto cork disks and covered with OCT embedding 
medium. Disks were dropped into liquid nitrogen-cooled isopentane until 
frozen, and stored in cryotubes at -70°C. Frozen sections were routinely 
sectioned at 10pm on a Bright cryostat and placed onto either PEN 
membrane covered or glass slides. Sections were air-dried at room 
temperature for 2 hours and stored at -20°C.
2.5.3.S Haematoxylin and eosin staining
Paraffin sections were stained with H&E by immersion for a period of 
~40 seconds in each of the following solutions; xylene x3, IMS x3, running
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water, instant heamotoxlyin x7, running water x3 ,1% acid alcohol, running 
water, Scotts tap water substitute, running water, 1% aqueous eosin (acified) 
x2, running water, IMS x3 and xylene x3. Sections were mounted with DPX.
2.5.4 Staining for p-galactosidase activity
Staining was carried out on frozen tissue sections. Slides were 
washed in water and sections were fixed for 10 minutes in 0.5% 
gluteraldehyde. Sections were stained overnight at 20°C using Xgal staining 
solution from the LacZ Reporter Assay Kit, washed in PBS/MgCfe solution, 
counterstained in eosin, dehydrated and mounted with DPX.
2.5.5 Laser capture microdissection
Laser micromanipulation offers microscopic high-resolution control of 
sample composition by selecting or rejecting tissue areas. For laser capture 
microdissection, frozen tissue was sectioned onto poly-L-lysine and UV 
treated (254nm) PEN membrane covered slides. Sections were washed in 
tap water and immersed in toluidine blue for 2 seconds. Following a further 
wash with water, sections were passed through 50%, 70% and 100% ethanol 
for 15 seconds and air dried overnight. A pulsed ultra-violet laser is 
interfaced into the microscope and focused through an objective. The laser 
cuts the tissue without the heating of adjacent material and results in a clear- 
cut gap between the desired sample area and the surrounding tissue. After 
microdissection, the isolated specimens are ejected out of the object plane 
and catapulted directly into the cap of a microfuge tube containing 1 pi of
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mineral oil positioned above the slide. DNA was extracted from there tissue 
samples using QIAamp DNA micro kits as described in section 2.5.12.4.
2.5.6 Immunohistochemistry
Paraffin sections were deparaffinised and rehydrated by passing 
through xylene x3, 100% ethanol x2, 70% ethanol, 50% ethanol and water. 
For antigen retrieval, sections were boiled in 10 mM citrate buffer (pH 6.0) for 
10 minutes. Endogenous peroxidase activity was blocked with 0.3% 
hydrogen peroxide for 30 minutes followed by 2x TBS washes for 5 minutes. 
Immunostaining of paraffin sections was performed in a humidity chamber 
using the rabbit VECTASTAIN ELITE ABC horseradish peroxidase kit. 
Sections were encircled with a wax ring and blocked in goat normal serum 
for 20 minutes. Primary antibodies were applied and incubated for 30 
minutes at room temperature or overnight at 4°C, followed by 2x 5 minute 
TBS washes. A Secondary antibody was applied and incubated for 30 
minutes followed by 2x 5 minute TBS washes. Avidin-biotin complex (ABC 
complex) was incubated for 30 minutes followed by 2x 5 minute TBS 
washes. Sections were developed using DAB, counterstained in Gills 
haematoxylin for 30 seconds, and blued in tap water. Sections were 
dehydrated through graded ethanols, cleared in xylene, mounted with DPX 
and air dried.
2.5.7 Protein extraction
Protein extraction from snap frozen and fresh tissues was performed 
using 500pl RIPA lysis buffer and homogenised on the fast prep system for
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30 seconds. The sample was left to settle on ice, spun at 13000 rpm for 1 
minute, and the supernatant collected and stored at -20°C.
2.5.8 Protein quantification
Proteins were quantified using the Bradford assay on the GeneQuant 
spectrophotometer.
2.5.9 SDS-PAGE
SDS-PAGE gels were cast at 5%, 8% or 10% depending upon the 
size of protein to be resolved and topped with a 4% stacking gel. Fifty 
micrograms of protein samples were solubilised by heating in Laemmli buffer 
(1ml 0.5M Tris/HCI pH6.8, 0.8ml glycerol, 1.6ml 10% SDS, 0.4ml P- 
mercaptoethanol, 0.2ml 0.05% bromophenol blue, 4ml distilled H2O) at 80°C 
for 15 minutes prior to loading on the gel. Electrophoresis was carried out in 
SDS-PAGE buffer (192mM glycine, 25mM Tris, 0.1% SDS) at 100V for 
approximately 2 hours.
2.5.10 Western blotting
Prior to transfer, the Immobilon-P (PVDF) membrane was wetted with 
methanol. The gel, Whatman paper and sponges were soaked in transfer 
buffer (192mM gycine, 25mM Tris, 20% methanol) for 15 minutes. The 
resolved proteins in the SDS-PAGE gel were blotted onto the membrane at 
30V for 1 hour in transfer buffer. The membrane was blocked with 5% Marvel 
(dried milk powder)/TBS-T (TBS and 0.001% Tween 20) for 30 minutes. 
Antibodies were diluted in 5% Marvel/TBS-T. The membrane was incubated
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with primary antibody for 1 hour, followed by 3 washes in TBS-T and a final 
TBS wash for 5 minutes each. The membrane was then incubated with 
secondary antibody and washed as described above. Protein bands were 
detected with chemiluminescence by incubating the membrane in the 
Visualizer EC reagents for 1 minute and exposing the film for various times 
to obtain the optimal image.
2.5.11 Protein loading controls
Equal loading of protein was confirmed by incubation of membranes 
with an anti-p actin antibody and Ponceau S staining.
2.5.12 Nucleic acid extraction
2.5.12.1 DNA extraction from tail tips
For the purpose of mouse genotyping, DNA was extracted from 3mm 
tail tips that had been immediately frozen after cutting. Tail tips were 
incubated overnight at 65°C with 500pl tail buffer (500mM Tris, 100mM 
EDTA, 100mM NaCI, 1% SDS, pH 8.0) and 20pl of proteinase K (20mg/ml). 
An extra 20pl of proteinase K was added and vortexed in the morning if the 
tail tip was not fully digested. Two hundred and fifty micro litres of 6M 
supersaturated NaCI was added to the lysate, the mixture vortexed, and 
centrifuged at 13000 rpm for 10 minutes. The supernatant was collected into 
a fresh eppendorf and 500pl of isopropanol added. The tube was manually 
inverted until a DNA precipitate could be seen. Eppendorfs were left 
overnight at -20°C to aid precipitation, when required. The DNA precipitate 
was then separated by centrifugation for 5 minutes at 13000 rpms. The
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supernatant was removed and the DNA pellet washed in 150pl of 70% 
ethanol. The pellet was air-dryed for 15 minutes to remove any remaining 
ethanol and re-suspended in 30-50pl of DNAase-free water overnight at 
35°C.
Samples were stored at -20°C.
2.5.12.2 DNA extraction from fresh and frozen tissue
DNA was extracted from fresh and frozen tissue using the QIAamp 
DNA mini kit according to the manufacturers instructions. Small pieces of up 
to 25mg of tissue were incubated overnight at 56°C with 180pl buffer ATL 
contents a trade secret (CTS) and 20pl of proteinase K. Two hundred micro 
litres of AL (CTS) was added to the lysate and incubated at 70°C for 10 
minutes. Two hundred micro litres of 100% ethanol was added and the 
solution was applied to the QIAamp silica gel based spin column and 
centrifuged at 13000 rpm for 1 minute. The column was transferred to a 
clean collection tube and 500pl of AW1 (CTS) wash buffer was added. The 
column was re-centrifuged at 13000 rpm for 1 minute. The elutant was 
discarded before a second wash was carried out using 500pl of AW2 (CTS). 
The column was re-centrifuged at 13000 rpm for 3 minutes followed by an 
extra 1 minute spin in a clean collection tube to remove any residual ethanol 
that may inhibit any downstream reactions. DNA was eluted in 200pl of 
DNAase free water by incubating for 1 minute at 25°C and centrifuging at 
13000 rpm for 1 minute. Samples were stored at -20°C.
2.5.12.3 DNA extraction from paraffin embedded tissue
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DNA was extracted from paraffin embedded tissue using the QIAamp 
DNA mini kit. Two or 3 sections of 4pm tissue were placed into an eppendorf 
tube. Tissue was incubated overnight at 65°C with 180pl buffer ATL (CTS) 
and 20pl of proteinase K. Two hundred micro litres of AL (CTS) was added to 
the lysate and incubated at 70°C for 10 minutes. Two hundred micro litres of 
100% ethanol were added and the solution was left at 25°C for at least 3 
hours to allow the wax set on the top of the sample. The solution was 
obtained by pipetteing through the wax, added to a QIAamp spin column and 
centrifuged at 13000 rpm for 1 minute. The column was then transferred to a 
clean collection tube and 500pl of AW1 (CTS) wash buffer was added. The 
column was re-centrifuged at 13000 rpm for 1 minute. The elutant was 
discarded before a second wash was carried out using 500pl of AW2. The 
column was re-centrifuged at 13000 rpm for 3 minutes followed by an extra 1 
minute spin in a clean collection tube to remove residual ethanol. DNA was 
eluted in ~100pl of DNAase free water by incubating for 1 minute at 25°C 
and centrifuging at 13000 rpm for 1 minute. Samples were stored at -20°C.
2.5.12.4 DNA extraction from laser microdissected tissue
DNA was extracted from laser captured tissue using the QIAamp DNA 
micro kit. Tissue was catapulted onto the lids of 0.6ml tubes. Forty micro 
litres of ATL (CTS) buffer and 10pl of proteinase K were carefully placed into 
the lid of the tube and the tubes were left inverted at room temperature for ~3 
hours. After the tissue was digested, 50pl of AL (CTS) buffer was added to 
the lysate and incubated at 70°C for 10 minutes. Fifty micro litres of 100% 
ethanol was added and the solution was applied to the QIAamp micro silica
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gel based spin column and centrifuged at 13000 rpm for 1 minute. The 
column was transferred to a clean collection tube and 500pl of AW1 (CTS) 
wash buffer was added. The column was re-centrifuged at 13000 rpm for 1 
minute. The elute was discarded before a second wash was carried out 
using 500pl of AW2 (CTS). The column was re-centrifuged at 13000 rpm for 
3 minutes followed by an extra 1 minute spin in a clean collection tube to 
remove residual ethanol. DNA was eluted in ~40pl of DNAase free water by 
incubating for 1 minute at room temperature and centrifuging at 13000 rpm 
for 1 minute. Samples were stored at -20°C.
2.5.13 Quantification of nucleic acid
The concentration of DNA in samples was determined by UV 
spectrophotometry at wavelengths of 260nm and 280nm. This allowed the 
amount of DNA to be quantified and the protein concentration to be 
established.
2.5.14 Restriction enzyme digestion
For DNA digestion, a total reaction volume of 40pl containing 4-5pg of 
DNA, an appropriate 10X reaction buffer, 1X BSA and 10U of restriction 
enzyme was used. The reaction was incubated at 37°C overnight. Digestion 
was assessed using agarose gel electrophoresis. An extra 20U of restriction 
enzyme was added and the sample re-incubated, if required.
2.5.15 DNA purification by Gene clean
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To prepare probes for Southern blotting, plasmid DNA was digested 
with appropriate restriction enzyme, run on a low melting point agarose gel 
and visualised under UV light. The correct band was excised, weighed and 
placed in a sterile tube. A volume of Nal equal to three times the gel slice 
weight was added. The tube was incubated for 5 minutes at 55°C and 5pl of 
glassmilk (CTS) was added and vortexed. DNA was allowed to bind to the 
silica matrix in the glassmilk by incubating on ice for 5 minutes with repeated 
vortexing. The matrix was centrifuged, the supernatant removed and the 
pellet washed 3x in 500pl of NEW wash solution containing a high 
concentration of NaCI (CTS). DNA was eluted from the silica matrix by 
incubating the pellet in 20pl of TE for 3 minutes at 55°C followed by 
centrifugation for 30 seconds and collection of the supernantant.
2.5.16 Southern blotting
For Southern blotting, digested DNA was run on a 0.7% agarose gel 
at 40V for 22 hours. The gel was then subjected to depurination (0.25M HCI) 
for 10 minutes, denaturation (0.5M NaOH, 1M NaCI) for 30 minutes and 
neutralisation (0.5M Tris, 3M NaCI, pH 7.4) for 40 minutes. Blotting was 
carried out using a Whatman paper wick dipped into 10x SSC and DNA was 
blotted onto the ZetaProbe membrane at room temerature for 16 hours. After 
blotting, the membrane was washed in 2x SSC and dried at 65°C for 45 
minutes. The probes were labelled using the MegaPrime DNA labelling 
system. Briefly, the probe and random primer oligomers were denatured at 
95°C for 10 minutes. The labelling buffer containing dATP, dGTP and dTTP 
nucleotides, Klenow polymerase enzyme and [a-32P] dCTP were added to
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make a 25|jl reaction volume, which was incubated at 37°C for 30 minutes. 
Unincorporated nucleotides were removed by ethanol precipitation followed 
by probe resuspension in 200pl of TE. The radioactivity of the probe was 
then determined. The radiolabelled probe was denatured at 100°C for 10 
minutes and added to pre-warmed (65°C) membrane in modified Church and 
Gilbert hybridisation buffer (7% SDS, 0.5M P04 [pH 7.2]), 10mM EDTA). 
Hybridisation was carried out for at least 16 hours. After hybridisation, the 
membrane was washed in 5x SSC and 0.1% SDS at 65°C for 30 minutes. 
The stringency of the washes were gradually increased until non-specific 
hybridisations were at a minimised. The membrane was then mounted on a 
plastic sheet, covered with cling film and placed in a cassette with X-ray film. 
The film was exposed at -70°C for 1 to 14 days depending on the strength of 
the signal obtained.
2.5.17 Primer design
Oligonucleotides were designed using Primer 3 (Rozen and Skaletsky 
2000). Where possible, the melting temperatures of the primer pairs were 
within 2°C of each other. Primers were between 18 and 23 nucleotides in 
length, lacked repetitive motifs and had little predicted dimerisation or 
secondary structure formation. Primers used in fluorescent analyses were 
modified by the addition of a 5' FAM fluorescent label.
2.5.18 Polymerase chain reaction (PCR)
Standard conditions for PCR included 25ng of template DNA, 0.25mM 
dNTPs, 12.5 pmoles of forward and reverse primers, 10x GeneAmp PCR
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buffer (100mM TrisHCI, pH8.3, 500mM KCI, 15nM MgCfe, 0.01% w/v gelatin) 
and 0.5Units of AmpliTaq Gold DNA polymerase in a total reaction volume of 
20pl. Reactions in tubes were scaled up to a 5 Op I total volume and overlaid 
with mineral oil. Cycling conditions were 94°C for 12 minutes, followed by 35 
cycles of 94°C for 1 minute, annealing temperature of 50°C to 60°C for 1 
minute, and 72°C for 1 minute. There was a final elongation step of 72°C for 
12 minutes.
2.5.19 Agarose gel electrophoresis
Agarose gels of 0.8 to 2.5% w/v concentration were prepared using 1x 
TAE buffer and 0.05pg/ml ethidium bromide. The higher the gel 
concentration, the smaller the pore sizes and that ensures, the better, the 
separation for small DNA fragments. NuSieve agarose was used at 3% w/v 
to separate very small (<200bp) DNA fragments. Two micro litres of loading 
dye (15% ficol, 10mM Tris pH 8, 1mM EDTA, 2% orange G) were added to 
each sample before loading and electrophoresis was performed in 1x TAE 
buffer at 100V. A 1kb DNA ladder was used to allow fragment sizing. DNA 
was visualised on a UV transluminator at a wavelength of 300nm and 
photographed using the Gel Doc 2000 system.
2.5.20 Capillary electrophoresis
One micro litre of fluorescenty-labelled PCR product was mixed with 
9pl of highly deionised formamide containing 40pM ROX GS500 size 
standard. The reaction was run on the 3100 Genetic Analyser and products 
were visualised and quantified using GeneScan software.
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2.5.21 PCR purification
Fifteen micro litres of PCR product was purified by the addition of 5U 
exonuclease I and 0.5U shrimp alkaline phosphatase. The sample was 
incubated at 37°C for 1 hour followed by denaturation at 80°C for 15 minutes.
2.5.22 Cycle sequencing
Sequencing reactions were performed using the BigDye Terminator 
Cycle Sequencing kit (Version 3.1). A total reaction volume of 10pl was used 
containing 0.8-3.0pl of DNA (~5ng), 0.25pmoles of primers, 0.75pl of 
Terminator ready reaction mix (labelled A, C, G and T dye terminators, 
dNTPs, AmpliTaq DNA polymerase FS, MgCfe and Tris-HCI buffer, pH 9.0) 
and 2pl BigDye terminator sequencing buffer. Cycle sequencing conditions 
were 96°C for 1 minute followed by 25 cycles of 96°C for 10 seconds, 50°C 
for 5 seconds and 60°C for 3:30 minutes. Purification of sequencing products 
was performed using Montage SEQg6 sequencing reaction clean up kits. 
Twenty micro litres of injection fluid was added to sequencing reactions and 
transferred into the micro well filter plate. The samples were drawn thought 
the plate using a vacuum pump (20 inches Hg) until the wells were empty. 
Two additional washes with injection fluid (25pl) were performed using the 
vacuum pump. Purified sequencing products were re-suspended in 25pl of 
injection fluid by shaking for 10 minutes. Samples were run on an ABI 3100 
Genetic Analyser.
2.6 Bioinformatic tools
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Genebank (http://www.ncbi.nih.gov/Genbank/) accession numbers for 
the genes analysed in this project are as follows:
Tsc1 (Mus musculus) NT_039206
Blm (Mus musculus) NT_039428
BLAST searches were carried out against DNA sequences from Genbank 
(http://www.ncbi.nlm.nih.gov/BLAST/). Open reading frames (ORF) were 
identified using the ORF finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html). 
mRNA sequences were aligned to a single genomic sequence using Spidey 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Ostell/Spidey/). Sequence data 
were viewed on Sequencher version 4.2. Microsatellite data were obtained 
from the Mouse Microsatellite Data Base of Japan (MMDBJ) 
(http://www.shigen.nig.ac.jp/mouse/mmdbj/top.jsp).
i
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Chapter 3: Characterising a mouse model of tuberous 
sclerosis 1 deficiency
3.1 Introduction
Two groups have generated mouse lines with constitutively 
inactivated Tsc1 (Kobayashi et al. 2001, Kwiatkowski et al. 2002) and Tsc2 
(Onda et al 1999, Kobayashi et al. 1999) alleles. These mice are 
predisposed to renal lesions; Tsc1+I~ mice develop renal lesions by fifteen to 
eighteen months, whereas Tsc2+I~ mice developed lesions by six months.
Here, we describe the development and characterisation of a further 
mouse model of tuberous sclerosis-1 deficiency, as a tool to determine the 
mechanisms by which hamartin deficiency leads to TSC-associated disease. 
This new model is more severely affected than the published Tsc1 murine 
models, and heterozygotes exhibit increased early post-natal mortality and 
metastatic renal cell carcinoma.
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3.2 Materials and methods
3.2.1 Targeted inactivation of the Tsc1 gene and generation of Tstf*1' 
mice
A replacement-type targeting vector was constructed in pUC19 using 
129/Ola cloned genomic DNA containing the Tsc1 gene (Cheadle et al. 
2000). This comprised a 1.3kb region spanning exon 5 and part of exon 6 of 
Tsc1 for the 5’ homology arm, and a 1.9kb region spanning exon 9 for the 3’ 
homology arm. A reporter/positive selection cassette, (TAG)3/IRES-/acz- 
polyA//oxP/MC1/?eo-polyA//oxP, was inserted between the homology arms. 
This cassette (a newer version of that previously described (Nehls et al. 
1996) modified to contain loxP sites) therefore disrupted exon 6 inserting 
TAG codons in all three reading frames at the junction and introduced a lacz 
reporter preceded by an internal ribosome entry site (IRES) and followed by 
an SV40 polyadenylation sequence. This allows expression of the reporter 
from the IRES but under control of the endogenous targeted gene’s 
promoter. The positive selection marker (MC1neo-polyA) contained in the 
cassette is independently expressed using its own enhancer/promoter and 
polyadenylation sequence. A negative selection cassette (MClf/c2), which 
consists of two copies of the HSV thymidine kinase gene independently 
expressed using its own enhancer/promoter and polyadenylation sequence 
(Smith et al. 1995), was appended to the end of the right homology arm. The 
vector was linearised at a unique Sa/I site. The knock-out construct was 
prepared by Jeremy Cheadle and Shelley Idziaszczyk.
Seventy five micrograms of linearised targeting construct were 
electroporated into 4.5x107E14 Tg2alV ES cells (from 129/Ola strain). Cells
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were selected on 160pg/ml G418 containing medium from one day after 
electroporation and then on G418 + Ganciclovir (GANC, 2.5pM) containing 
medium after a further four days, in order to enrich for targeted clones by 
positive-negative selection (Mansour etal. 1988). After 10 days, 700 G418 + 
GANC resistant colonies were picked into 96 well plates, and subsequently 
replica plated for freezing and DNA isolation. DNA was digested with EcoRI, 
and analysed by Southern blotting and hybridisation with external 5’ and 3’ 
flanking probes to identify correctly targeted clones. Gene Targeting was 
performed by Andrew Smith and Rosemary Bayne in The Gene Targeting 
Laboratory, Institute for Stem Cell Research, University of Edinburgh.
Tsrf*1' ES cell clones were injected into C57BL/6 blastocysts, 
transferred into pseudo-pregenant (CBA x C57BL/6) females and chimeric 
pups identified. Male chimeras were mated with inbred C57BL/6 females to 
generate F1 mice (50% 129ola/ 50% C57BL/6) carrying the targeted 
mutation, identified by coat colour and subsequent genotyping on tail 
biopsied DNA. Tsc1+I~ F1 mice were backcrossed (N£3) with inbred 
C57BL/6J Ola Hsd (C57BL/6), Balb/c Ola Hsd (Balb/c) and C3H HeN Hsd 
(C3H) mice (Harlan UK Limited). Blastocyst manipulation was performed by 
Andrew Smith and Rosemary Bayne in The Gene Targeting Laboratory, 
Institute for Stem Cell Research, University of Edinburgh.
3.2.2 Southern blotting and PCR genotyping
DNA was extracted from ES cells, yolk sacs, whole embryo paraffin 
sections or tail tips using QIAamp DNA mini kits (Qiagen) or NaCI/ 
isopropanol extraction methods (chapter 2). Southern blot analysis was
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performed as previously described (chapter 2 section 2.5.16). A ~0.7kb Psfl 
fragment cut from the vector pMCIneo-polyA, a ~0.8kb fragment containing 
exon 4 of Tsc1 and a ~0.6kb fragment containing exons 11 and 12 of Tsc1, 
were used as the neomycin probe, and 5’ and 3’ external flanking probes, 
respectively.
PCR genotyping of DNA from tail tips and embryo yolk sacs was 
performed by amplification of the wild type and mutant Tsc1 alleles using the 
following primers in a 35 cycle PCR reaction with AmpliTaq gold DNA 
polymerase (Applied Biosystems): wild type allele, 44F 5 -  
ATTCACCCGGAATTAGTGACTG-3’ & 45R 5’-
GCGTCCTCTTCTCCI I I IACAC-3’ (1730bp product), and, for the mutant
allele, either 16F 5-AGCGTTGGCTACCCGTGATATTG-3’ & 21R 5’-
GTGTTGATGGGGAACTCAAACTCT-3’ (2306bp product), or, sh2F 5 -
GCCGAATATCATGGTGGAAA-3’ & sh2R 5’-
ACGAAGGTGATCAGGGAATG-3’ (1100bp product). Products were
analysed on 1 % agarose gels. Some genotyping assistance was provided by
Shelley Idziaszczyk and Carol Guy.
An independent PCR of DNA extracted from paraffin embedded 
embryo sections was performed to validate the yolk sac genotypes. PCR 
was performed by amplification of the wild type and mutant alleles using the 
following primers in a 35 cycle PCR reaction: wild type allele, EXON 8F 5’- 
TGCCTGGAAGCCCAGGAAGGT-3’ & EXON 8R 5’- 
CTGCAGGGCCCATGGTGGTT-3’ (183bp product), and, mutant allele, IRES 
F 5-TAACGTTACTGGCCGAAG-3’ & IRES R 5’- 
GTCGCTACAGACGTTGTT-3’ (237bp product).
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3.2.3 RT-PCR analysis
RNA was extracted from tissues and embryos after snap freezing and 
grinding in liquid nitrogen using the RNAeasy kit (Qiagen). 50ng-1|ng RNA 
was used for first strand cDNA synthesis using oligo (dT)i5 and Superscript II 
RNase H' Transcriptase (Invitrogen Life Technologies). Second strand 
synthesis was carried out in 50pl reaction volumes using 1pl cDNA, 25pmol 
primers, 0.2mM dNTPs, 5pl reaction buffer and 2U AmpliTaq Gold DNA 
polymerase in 35 cycle PCR reactions. Four reactions were carried out: (i) 
K034 (exon 4 F) 5-ACGTGGGCCTATGCTTGTCAACA-3’ & K035 (exon 7 
R) 5,-AGCGCAGGAAGGAGACGAAGTTA-3\ (ii) K034 & IRES_R2 5 -  
TCCTTCAGCCCCTTGTTGAATAC-3’, (iii) LACZ_F 5 -  
AAACCCTGGCGTTACCCAACTTA-3, & LACZ_R 5’-  
ACCGTCGATATTCAGCCATGTTC-3’, and, (iv) K034 & K021 (exon 10 R) 
5-GT GTT GAT GGGGAACT C AAACT CT-3’. Products were analysed on 1% 
agarose gels, cloned into pGEM-T (Promega) and sequenced. RT-PCR 
analysis was performed by Lee Parry.
3.2.4 Animal care, necropsy and pathology
Animal care, necropsy and pathology was carried out as previously 
described (chapter 2). Tissues from 10, 15 and 20 Tsc1+I~ mice and wild type 
littermates on each background were analysed at 3-6, 9-12 and 15-18 
months, respectively. Half of each organ was fixed and processed into 
paraffin wax. The other half of the organ was snap frozen. To estimate the 
average number of microscopically visible kidney lesions per mouse, ten
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Tsc1+'~ mice were analysed per background at 3-6, 9-12 and 15-18 months - 
five representative sections ~200pm apart from each half kidney were 
stained with H&E and anti-gelsolin and inspected on an Olympus BX51 BF 
light microscope (lesions crossing more than one section were counted once 
and total numbers were doubled to generate a mean number per mouse). 
Animals that died before weaning were collected, genotyped and processed 
into paraffin wax, sectioned at 4pm and stained with H&E for microscopic 
analysis. Staining for p-galactosidase activity was carried out as described in 
chapter 2, section 2.5.4.
Embryos were removed at 9.5, 10.5, 11.5, 12.5 and 13.5 days post 
fertilisation (noon on the day on which the vaginal plug was formed was 
defined as embryonic day 0.5). Yolk sacs were removed for genotyping and 
whole embryos were processed into paraffin wax, sectioned at 4pm and 
stained with H&E for microscopic analysis.
3.2.5 Immunohistochemistry and immunoblotting
Immunostaining of paraffin sections was performed as described 
(chapter 2, section 2.5.6) using the rabbit VECTASTAIN ELITE ABC 
horseradish peroxidase kit (Vector Laboratories). Primary antibodies were 
incubated for 30 minutes at room temperature for anti-murine gelsolin (Onda 
et al. 1999) and overnight at 4°C for anti-Phospho-S6 Ribosomal protein 
(Ser240/244) and anti-Phospho-mTOR (Ser 2448) (Cell Signalling 
Technologies).
Immunoblotting was performed as previously described (chapter 2 
sections 2.5.7 to 2.5.11). Primary antibodies used included anti-mTOR, anti-
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phospho-mTOR (Ser 2448), or, anti-phospho-S6 ribosomal protein (Ser 
240/244) (Cell Signalling Technonlogies).
3.2.6 Somatic loss of heterozygosity analysis
Snap frozen tissue was sectioned at 10pm onto PEN (PALM) 
membrane covered slides, and stained with toluidine blue. Tumour and 
normal tissue were microdissected (PALM LCM) and DNA extracted using 
the QIAamp DNA micro kits (Qiagen). PCR of microdissected DNA was 
performed by simultaneous amplification of both the wild type (EXON 8F- 
5’FAM labelled & EXON 8R) and mutant (IRES F-5’FAM labelled &  IRES R) 
alleles in a 25 cycle PCR reaction. 2pl of PCR products were mixed with an 
ABI GS500 internal size standard and formamide loading buffer, and run on 
an ABI3100 genetic analyser. Results were analysed using Genescan v.3.7 
software. DNA extracted from 8 different normal tissue sections from  Tsc1H~ 
mice was used to normalise the assay (comparison of wild type:mutant allele 
peak heights). Loss of heterozygosity was defined as a wild typeimutant 
peak ratio of £2.0.
3.2.7 Statistical analysis
Comparisons of numbers of T stf*1' to Tsc1+,+ mice were calculated 
using the Chi-square test with 1d.f. Lesion counts per mouse were 
compared using the Kruskal-Wallis and Mann-Whitney confidence interval 
tests. Survival over 18 months was compared using Kaplan-Meier cumulative 
survival plots.
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3.3 Results
3.3.1 Generation of Tstf*1' mice
The murine T stf locus from the 129/Ola strain was previously cloned, 
sequenced and characterised (Cheadle et al. 2000). A replacement-type 
targeting vector for homologous recombination in mouse ES cells was 
constructed. This vector was designed to inactivate an endogenous Tsc1 
gene by deleting an internal region of the gene comprising the 3’ half of exon 
6 and all of exons 7 and 8, and substituting this with a p-galactosidase 
reporter/neomycin selection ((TAG)3/IRES/acz-polyA//oxP/MC1/?eo- 
polyAlloxP) cassette (Nehls etal. 1996) (Fig. 3.1a). Insertion of this cassette 
was predicted to truncate the Tsc1 coding sequence in exon 6 by introducing 
TAG stop codons in all three frames, and also create a bicistronic mRNA in 
which expression of the p-galactosidase coding sequence was brought under 
the control of T stf transcriptional regulatory sequences via an IRES. The 
linearised vector was electroporated into E14 Tg2alV ES cells and correctly 
targeted clones identified by Southern blot analysis of EcoRI digested DNA, 
using 5’ and 3’ probes external to, and flanking, the vector homology arms. 
Targeting efficiency was ~3.4%. Chimeric male mice generated from two 
independently derived targeted ES cell lines (I/F5 and I/G11) fathered 
offspring with the ES cell coat colour in test crosses with C57BL/6 females 
and germ line transmission of the targeted allele was confirmed in 50% of 
these by Southern blot analysis on tail DNA (Figs. 3.1b-c). Further 
confirmation of successful targeting was obtained by carrying out long 
distance PCR using a primer within the neomycin coding sequence and a
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Figure 3.1: (A) Schem atic illustration of the Tsc1 replacem ent targeting vector (upper panel), the  wild type Tsc1 
locus (middle panel) and the targeted  locus (lower panel). The vector w as comprised of cloned 129/Ola genomic 
DNA consisting of a 1 ,3kb region spanning exon 5 and part of exon 6 of Tsc1 for the 5’ homology arm and a 1 .9kb 
region spanning exon 9 of Tscl for the  3’ homology arm, flanking a (TAG)3/IRES-/acz-polyA//oxP/MC1neo- 
polyAlloxP reporter/ positive selection casse tte  in the sam e  transcriptional orientation. A negative selection casse tte  
MC1-fk2 consisting of two copies of the HSV thymidine kinase (tk) g ene  w as positioned at the outer end of the 3’ 
homology arm. The vector w as linearised at a unique Sa/I site in the plasmid backbone. The regions of homology in 
which cross-overs (denoted X) can occur between the linearised vector and the Tsc1 locus to result in a 
replacem ent event are indicated by the dashed  lines. The predicted targeted locus contains the reporter/positive 
selection cassette  inserted into exon 6 of Tsc1 and introduces stop codons (TAG)3 into all three reading fram es of 
the Tsc1 coding sequence. The targeting event also sim ultaneously deletes the 3’ part of exon 6 and all of exons 7 
and 8 of Tsc1. Exons are shown as num bered black rectangles, introns as a thick black line, flanking genomic 
regions as a thick dashed  line, plasmid vector seq u en ce  as a thin black line. The reporter/selection casse tte  is 
shown as a large light grey striped rectangle (IRES-/acz component) and a large filled light grey rectangle 
(MC1neo-polyA component), with dark grey triangles indicating loxP sites. The negative selection casse tte  is shown 
as a grey chequered rectangle. The positions of relevant EcoRI sites and the predicted sizes of EcoRI restriction 
fragments (thin dashed  lines with arrows) detected with the 5’ and 3’ probes (small black striped rectangles) before 
and after targeting, and the long d istance (LD) PCR products spanning the wild type locus and the 3’ recombination 
junction, are shown below the wild type and targeted loci. (B) Southern blot analysis of EcoRI digested DNA from 
wild type (wt) and Tscl*'- mice and Tscl-1- embryos, analysed with the 5’ probe. The 18.7 kb wild type fragm ent is 
present in only wild type and Tscl*'- mice, and the 16.7 kb targeted fragm ent is presen t in only Tscl*1- mice and 
Tscl-1- embryos, as expected. (C) Southern blot analysis of EcoRI d igested DNA from wild type (wt) and Tsc1*‘- 
mice and TscV- embryos, analysed with the 3’ probe. The 7.8 kb wild type fragm ent is p resent in only wild type and 
Tscl*'- mice, and the 4.4 kb targeted fragm ent is present in only Tscl*'- mice and Tscf-'- embryos, as expected. (D) 
Multiplex PCR of long distance PCR products generated from the wild type locus (using primers in exon 8 and 
intron 8 to amplify a 1.7 kb product) and from the targeted locus (using primers in the neomycin c asse tte  and exon 
10 to amplify a 2.3 kb product). The 1.7 kb wild type fragm ent is present in only wild type and Tscl*'- mice, and the 
2.3 kb targeted fragm ent is p resent in only Tscl*1- mice and TscT1- embryos.
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primer in exon 10 (outside the region of homologous recombination), and 
sequencing this 3’ recombination product (Fig. 3.1d).
A comprehensive molecular and phenotypic analysis of Tsc1+I' mice 
generated from both of these chimeras was initially carried out. However, 
since the derivatives from the two ES cell clones did not exhibit any obvious 
differences, only one line (derived from the I/F5 cells) was analysed further in 
the present study.
3.3.2 Functional consequence of the targeting event
RT-PCR expression analysis was performed using primers predicted 
to amplify both the wild type Tscl transcript (exons 4 to 7) and the mutant 
transcript (both exon 4 to IRES and internal to lacz) using RNA extracted 
from a range of tissues from Tsc1+I~ mice. Unexpectedly, products were only 
generated using the exon 4-7 primer set (specific to the wild type transcript). 
Consistent with a failure to detect lacz mRNA expression from the mutant 
allele, p-galactosidase activity in kidneys from Tscl*1' mice was not detected 
(Fig. 3.2) (although p-galactosidase activity in kidneys from Pkd1+/' mice that 
also carried a lacz expression construct was detected; Boulter et al. 2001).
RT-PCR was then performed with primers in exons 4 and 10, which lie 
outside the regions of homologous recombination, so that any aberrant 
expression products from the modified locus could be detected. A product 
corresponding to correctly spliced exon 4-10 transcripts was detected in RNA 
extracted from wild type and Tscl*1' mice, but not in RNA extracted from 
Tsc1',~ embryos. A strongly expressed truncated transcript was also detected 
in RNA extracted from Tscl*1' mice and was the only product detected in
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Figure 3.2: LacZ staining for p-galactosidase activity. (A) Renal tissue from Pkd1*/m mice 
carrying a lacZ-neomycin fusion gene with known p-galactosidase activity (Boulter et al. 
2001). Blue staining (arrows) indicates positive p-galactosidase activity (B) Tsc1+A renal 
tissue showing no p-galactosidase activity. Bars are 50pm.
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TscT1' embryos. This aberrant transcript was not present in RNA extracted 
from wild type mice. Cloning and sequencing of these products confirmed the 
presence of normal, correctly spliced Tscl transcripts in wild type and Tscl*1' 
mice, and revealed an unpredicted spliced transcript that lacked exons 6, 7 
and 8, and joined exons 5 and 9, in Tscl*1' mice and TscT1' embryos (Figs. 
3.3a-b). The aberrantly spliced transcript generated from the targeted allele 
causes a shift in the reading frame, leading to the introduction of a premature 
termination codon at the 8th codon of exon 9 of Tscl (Fig. 3.3c).
3.3.3 TscT1' mice die during embryonic development
Tscl*1' intercrosses (Tscl*1' x Tsc1*'~) were set up using F1 mice 
generated from the chimera test crosses (50% 129ola/ 50% C57BL/6). From 
eleven intercrosses, 138 progeny were obtained, 47 of which were Tscl*1*,
86 were Tscl*1' and 0 were TscT1' (5 mice failed to be genotyped). This ratio 
differs significantly from expected (P<0.0001) indicating that the Tscl mutant 
allele has a recessive, embryonic lethal phenotype. Tsc1*'~ mice were 
backcrossed (Tsc1+,~ x Tsc1*,+) onto a C57BL/6 background (N£4) and 15 
Tscl*1' intercrosses were set up for timed matings to study the embryonic 
development of TscT1' animals. TscT1' embryos died between embryonic day 
(E) 9.5 to E12.5 and no viable null embryos were observed at E13.5 (Table
3.1). TscT1' embryos were generally smaller and developmentally retarded 
as compared to wild type and heterozygous littermates (for example, mean 
size of TscT1', Tscl*'* and Tscl*1' embryos was 2.8, 4.3 and 3.8mm at 
E10.5, respectively). Two out of 12 (17%) null embryos displayed
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Figure 3.3: Functional consequence of homologous recombination with the knockout vector.
(A) RT-PCR analysis using primers in exons 4 and 10 of Tscl. Full length, normally spliced 
products of ~900 bp were detected only in RNA extracted from wild type and Tscl*1' mice. 
Truncated products were detected only in RNA extracted from Tscl*1' mice and Tscl 
embryos. Further faint bands that were not seen in wild type mice and TscT1' embryos were 
detected in RNA from Tscl*1' mice; these were shown to correspond to heteroduplex species 
formed between wild type and mutant RT-PCR products. (B) Sequence analysis of cloned RT- 
PCR products from T s c l mice and TscT1' embryos identified the presence of a mutant Tscl 
transcript lacking exons 6, 7 and 8 and fusing exons 5 and 9 as a consequence of an aberrant 
splicing event, thus excluding the coding sequence of the 5’ region of exon 6 and the IRES- 
lacz sequence in the mRNA. DNA sequences are indicated as in Figure 3.1 and RNA exon 
sequences are indicated by grey rectangles. (C) Mutant transcripts were predicted to cause a 
shift in the reading frame and introduce a premature termination codon at the 8th codon in exon 
9 of Tscl, and were thus considered to be inactivating.
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exencephaly (Fig. 3.4) and, at E12.5, 2 out of 2 null embryos had abnormal 
vacuolation of myocardial cells (Fig. 3.5). No liver hyperplasia was observed.
Table 3.1: Genotypes of embryos obtained from Tscl*1' intercrosses
Embryonic
day
No. of embryos 
genotyped
Tscl genotype 
+/+ +/- -/-
aNo. of
resorbed
embryos
9.5 18 7 8 2(1) 7
10.5 22 5 11(1) 3(2) 4
11.5 28 12(1) 12(1) 0(2) 3
12.5 19 6 11 2 8
13.5 18 8 10 0 10
Number in parentheses refers to resorbing embryos that could be genotyped. 
aNumber of resorption sites for which no material was available for genotyping.
3.3.4 Some Tscl*1' mice on a C57BL/6 background die post-natally
Tscl*1' mice were backcrossed (N£3) with inbred (wild type) C57BL/6 
mice. Genotyping showed that, out of the 253 offspring that survived until 
weaning, 103 were Tscl*1' and 142 were wild type (8 failed to be genotyped), 
which is significantly different from the expected 1:1 ratio (P= 0.014) (Table
3.2). This indicated ~27% excess mortality among Tscl*1' mice before 
weaning. To investigate the point at which these Tscl*1' mice died (in utero 
or post-natally), additional crosses between Tscl*1' mice at this backcross
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Figure 3.4: Macroscopic and microscopic examination of mouse embryos at 10.5 days 
post fertilisation. (A and B) A Tsc1+A mouse embryo displaying full neural tube closure 
and substantial organ differentiation. (C and D) Tsc1v- mouse embryos were smaller 
and developmentally retarded, as compared to heterozygous littermates. Some had 
neural exencephaly (arrows). Bars are 1mm.
D
*
88
Figure 3.5 Microscopic examination of embryo cardiac morphology at 12.5 days post 
fertilisation. (A) Tsc1+/+ embryo cardiac tissue displaying intact myocardial cell 
morphology. (B) Tsetsembryo cardiac tissue displaying abnormal vacuolation of the 
developing myocardial cells.
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generation and wild type C57BL/6 mice were set up and offspring genotyped 
at birth. Out of 184 new born pups, 95 were Tsc1+I~ and 88 were wild type (1 
mouse failed to be genotyped), thus excluding in utero mortality. Close 
examination of another cohort of mice revealed that a significant proportion 
of animals died soon after birth. The carcasses of 37 of these animals were 
collected and genotyped; 25 were Tsc1+I~ and 12 were wild type, which is 
significantly different from the expected 1:1 ratio (P= 0.033) (Table 3.2).
Table 3.2: Genotypes of offspring from Tscl*1' and Tscl*1* crosses (N>3 
C57BL/6)
aCohort of mice No. of animals bTsc1 genotype Failed to P
assayed +/- +/+ genotype
Analysed at birth 184 95 88 1 NS
Analysed at weaning 253 103 142 8 0.014
cDied between birth 37 25 12 - 0.033
and weaning
“Three independent cohorts of mice were analysed (one cohort was analysed at birth, 
one was analysed at weaning, and one was set up to collect and analyse animals that 
died between birth and weaning). bExpected a 1:1 ratio of Tsc1*,m:Tsc1*l+ offspring in 
each cohort, ^ho le  litters that died overnight on day 1 (normally due to maternal 
rejection) were excluded from this analysis; if included, 53 carcasses were collected, 
34 of which were Tscl*1' and 19 were Tscl*1* (P=0.04). NS -  not significant.
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Tsc1+I~ mice were backcrossed (N£3) onto two further genetic 
backgrounds (C3H and Baib/c). No evidence of increased post-natal 
mortality of Tscl*1' mice was observed on either of these backgrounds (144 
Tsc1+I~ and 138 Tscl*'* mice on the Balb/c background and 120 Tscl*1' and 
120 Tscl*1* mice on the C3H background survived until weaning), indicating 
that this phenotype was specific to the C57BL/6 background.
3.3.5 Survival of Tsc1*/m mice between weaning and 18 months
Survival of Tsc1+/~ mice backcrossed onto 3 different backgrounds was 
tracked from weaning until 18 months of age. Twenty-nine out of 106 (27%) 
Tsct+/- mice on a Balb/c background died prematurely, 5 out of 92 (5%) 
Tsc1+/' mice on a C3H background died prematurely, 8 out of 97 (8%) Tsc1*A 
mice on a C57BL6 background died prematurely (mean age of death= 10.1, 
10.3, and 12.9 months respectively). In contrast, Tsc1+/* mice from each 
background had low levels of premature death varying between 2% to 11%. 
Therefore, Tsc1+/~ mice on a Balb/c background had significantly more 
deaths between weaning and 18 months (P< 0.001) than Tsc1+/~ mice on a 
C3H or C57BL6 background (Fig. 3.6a), and significantly more deaths 
between weaning and 18 months (P= 0.038) than their Tsc1+/* littermate 
controls (Fig. 3.6b). Post mortem examination could not be performed on all 
animals due to autolysis or cannibalism by cage mates. Twenty four percent 
(7/29) of Tsc1+/~ mice on a Balb/c background that had died before 18 
months had heart abnormalities (Fig. 3.7a and b) that were classified as 
atrial thrombi by expert pathologist Charles H. Frith. Thrombosis of the heart 
artria commonly involved the left atrium which was enlarged and often
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Figure 3.6 Kaplan-Meier cumulative survival plots of Tscl mice from weaning to 18 
months. (A) Comparing survival rate of Tsc1+A mice on the 3 study backgrounds: 
Balb/c, C3H and C57BL6 from weaning to18 months. (B) Comparing survival rate of 
Tsct+A to 7scf+/+ mice on a Balb/c background from weaning to18 months.
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Figure 3.7 Macroscopic and microscopic examination of heart abnormalities in Tsc1+/- mice on a 
Balb/c background. (A and B) Macroscopic view of heart and lungs from Tsc*A mice on a Balb/c 
background that had died between weaning and 18 months, arrows indicating large atrial 
thrombosis on top of hearts (bars are 5mm). (C-F) Microscopic view of atrial thrombosis showing 
(C) hemosiderin pigment (bar is 50pm) (D) vascularisation (E) mineralisation (F) cartilaginous 
metaplasia (bars are 500pm).
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occluded by organising thrombi. The thrombi contained hemosiderin pigment 
(Fig. 3.7c) as a result of blood breakdown, areas of vascularisation (Fig.
3.7d) with vessel formation, areas of mineralisation (Fig. 3.7e), and areas of 
cartilaginous metaplasia (Fig. 3.7f). A retrospective analysis of the 12 Tsc1*/+ 
mice on a Balb/c background that had died between weaning and 18 
months, revealed 1 mouse with a similar atrial thrombosis.
Forty percent of Tsct+/- mice on a Balb/c background that had died 
between weaning and 18 months had macroscopic kidney lesions.
3.3.6 Renal pathology
The kidneys of mice at 3-6, 9-12 and 15-18 months were examined by 
macroscopic inspection and microscopic analysis of five sections ~200pm 
apart. On a C3H background, 44% (7/16) of Tsc1+I' mice developed 
macroscopically visible renal lesions by 3-6 months, increasing to 95% 
(37/39) by 15-18 months (Table 3.3). On the Balb/c and C57BL/6 
backgrounds, the phenotype was less dramatic with 13% (2/16) and 8% 
(1/13) of Tscl*1' mice developing macroscopically visible renal lesions by 3-6 
months, and 88% (35/40) and 67% (29/43) by 15-18 months (Table 3.3). 
Microscopically, all (10/10) Tscl*1' mice on a C3H background had renal 
lesions by 3-6 months (average of 10.2 lesions per mouse) compared to 90% 
(9/10) (6.2 lesions) and 60% (6/10) (2.0 lesions) on Balb/c and C57BL/6 
backgrounds, respectively. By 15-18 months, all mice had microscopically 
visible lesions regardless of background (with 29, 26.8 and 14.8 lesions per 
mouse on C3H, Balb/c and C57BL/6 backgrounds, respectively). None of the
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wild type littermates had macro- or microscopic kidney lesions by 15-18 
months.
Renal lesions varied from pure cysts through to solid anaplastic 
carcinomas and were classified as either cysts (simple cysts lined with one 
layer of epithelium), atypical cysts (cysts with single papillary projections into 
the lumen), branching cysts (cystadenomas with branching papillary 
projections), mixed cystic/solid carcinomas and solid carcinomas (examples 
shown in Figs. 3.8a-f). Solid carcinomas often displayed pleomorphic nuclei, 
which are characteristic of a malignant neoplasm (Fig. 3.8g). The majority of 
lesions expressed gelsolin (a proposed marker for Tsc-associated renal 
lesions, Onda etal. 1999), with staining intensities similar to distal tubules 
and collecting ducts; however, some did not (Fig. 3.8h). The distribution in 
the size of the lesions, with simple cysts tending to be smaller and more 
numerous than branching cysts, mixed cysts and solid carcinomas (Table 
3.4), suggests that some small cysts progressed to carcinomas. In addition, 
there was a preponderance of cysts in younger animals and a morphological 
continuity of lesions further supporting this progression (Fig 3.8b-f). By 15-18 
months, Tsc1+/~ mice on a C3H background had significantly more cystic 
lesions (simple, atypical and branching cysts) compared to mice on a 
C57BL/6 background (P= 0.013), and those on a Balb/c background had 
significantly more solid lesions (mixed cystic/solid lesions and solid 
carcinomas) compared to mice on C3H (P= 0.014) or C57BL/6 (P= 0.004) 
backgrounds.
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Figure 3.8: Macroscopic and microscopic analysis of renal lesions from TscV'- mice. (A) Kidneys from 
an 18 month old mouse showing macroscopic renal cystadenomas (indicated by an arrow). (B) 
Microscopic view of a cyst with a single layer of cuboidal lining cells. (C) Microscopic view of an 
atypical cyst with papillary growths into the centre of the cyst. (D) Microscopic view of a cystadenoma 
with branching papillae filling the centre of the cyst. (E) Mixed cystic solid lesion, complex 
cystadenoma with branching cystic region and kidney carcinoma that appears to have developed from 
the adjacent cyst. (F) Solid renal cell carcinoma. (G) Close up view of kidney carcinoma displaying 
pleomorphic nuclei. (H) Immunostaining with an anti-gelsolin antibody showed gelsolin expression 
(indicated by brown staining) in a papillary cystadenoma (arrow on left) and lack of expression in a 
solid carcinoma (arrow on right). Macroscopic bars are 1cm and microscopic bars are 200pm.
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Table 3.3: Frequency and size of macroscopic renal lesions (cystic and
solid) in Tscl*1' mice grouped according to background and age
Background Age
(months)
No. of 
animals
% with 
lesions
No. of lesions per mouse 
<2 mm 3-4 mm >5mm
C3H 3-6 16 44% 0.81 0 0
9-12 28 79% 2.68 0.04 0
15-18 39 95% 5.15 0.33 0.08
Balb/c 3-6 16 13% 0.19 0 0
9-12 37 81% 2.73 0.14 0.03
15-18 40 88% 4.70 0.98 0.68
C57BL/6 3-6 13 8% 0.08 0 0
9-12 35 37% 0.46 0.06 0
15-18 43 67% 1.56 0.21 0.14
No wild type littermates had macroscopic (or microscopic) kidney lesions.
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Table 3.4: Number and histological classification of microscopic renal
lesions in Tscl*1' mice grouped according to background and size
No. of microscopic lesions
Backgrou Size Simple Atypical Branching Mixed Solid
nd (mm) cyst cyst cyst cystic/solid RCC
C3H £0.49 103 44 14 0 3
0.5-0.99 13 6 21 1 1
1-1.99 7 3 30 7 4
S>2 0 0 2 0 0
Balb/c £0.49 78 12 7 0 3
0.5-0.99 19 9 21 4 7
1-1.99 4 0 18 8 10
>2 0 0 0 4 21a
C57BL/6 £0.49 56 15 2 1 3
0.5-0.99 8 2 3 1 2
1-1.99 3 3 4 1 2
>2 0 0 0 1 0
Total £0.49 237 71 23 1 9
0.5-0.99 40 17 45 6 10
1-1.99 14 6 52 16 16
2>2 0 0 2 5 21
Numbers based on the analysis of five sections (~200jim apart) from half kidneys of 
ten Tscl*1' mice at 3-6,9-12 and 15-18 months (30 mice in total for each strain). In 
general, severity of lesion increased with size (numbers in bold represent the highest 
number in each histological group), providing evidence for progression of cysts 
through cystadenomas (atypical/branching cysts) to solid carcinomas. aFour solid 
tumours had a sarcomatoid morphology.
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3.3.7 Tscl*1' mice develop renal cell carcinomas, resulting in grossly 
deformed kidneys
Eighty percent (16/20) of Tscl*1' mice on a Balb/c background 
exhibited solid renal cell carcinomas (RCC) by 15-18 months and in 41% 
(17/40), RCCs were £5mm, which resulted in grossly deformed kidneys of up 
to 2.5cm in size (Figs. 3.9a-c). One mouse displayed this distinctive 
phenotype as early as 11 months. Tscl*1' mice on C57BL/6 and C3H 
backgrounds rarely harboured RCCs £5mm at 15-18 months (7 and 3%, 
respectively, P<0.002). Four out of nine (44%) RCCs £5mm (analysed from 
different mice) had a sarcomatoid morphology consisting of spindle cells with 
nuclear anaplasia arranged in whorled patterns (Fig. 3.9d); three of these 
had metastasized to the lungs (the only lung tumours observed in this study) 
(Figs. 3.9e-f).
3.3.8 Extra-renal tumours
Microscopic liver hemangiomas were observed in 18% of 15-18 month 
Tscl*1' mice, regardless of background or sex; these lesions were not seen 
in wild type littermates. Histologically, hemangiomas consisted of abnormal 
vascular channels and a proliferation of smooth muscle cells (Figs. 3.10a 
and b). Liver hepatomas were seen at equal frequency (24%) in Tscl*1' and 
wild type littermates, suggesting that their pathogenesis is independent of 
Tscl mutation status. One Tscl*1' mouse (Balb/c background) had a splenic 
hemangioma and two (C3H background) had isolated uterine 
leiomyoma/leiomyosarcomas (Figs. 3.10c and d).
Figure 3.9: Renal cell carcinoma (RCC) in TscV'- mice on a Balb/c background resulting in 
grossly deformed kidneys and metastases in the lungs. (A, B) Paired kidneys from 18 month 
old TscV'- mice with RCC £5mm. (C) Section through a kidney displaying RCC. (D) 
Microscopic view of a sarcomatoid RCC with elongated sheets of spindle cells intermingled 
with more typical carcinomatous areas. (E) Macroscopic, and, (F) microscopic RCC  
metastases in the lungs (the metastatic nature of lesions was determined by the histological 
appearance of cells with renal tubular morphology in the lungs). Macroscopic bars are 1cm 
and microscopic bars are 200pm.
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Figure 3.10: Extra renal lesions in 7 sc f+/- mice. (A) Macroscopic view of liver hemangiomas 
(arrows) (B) Microscopic view of a liver hemangioma consisting of abnormal vascular channels 
and a proliferation of smooth muscle cells (C) Microscopic view of a splenic hemangioma with 
proliferation of smooth muscle cells neighbouring disorganised vascular channels (D) Microscopic 
view of a uterine leiomyoma/leiomyosarcomas. Macroscopic bars are 1cm and microscopic bars 
are 200fim
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3.3.9 Molecular and immunological analysis of lesions
DNA was extracted from LCM kidney, liver, uterine and lung (a kidney 
metastasis) lesions and analysed for loss of heterozygosity (LOH) at the 
Tscl locus using an IRES (mutant specific) and exon 8 (wild type specific) 
quantitative PCR assay. Loss of the Tscl wild-type allele was observed in 
5/12 renal lesions, 2/5 hepatic hemangiomas, 1/2 uterine lesions and 1/1 
lung lesion (a kidney metastasis) (Fig. 3.11a). We investigated the 
expression levels of mTOR, phosphorylated (p)-mTOR and p-S6 ribosomal 
protein (p-S6) in the renal lesions. Western blot analysis showed that 
although levels of mTOR were the same in normal kidney and adjacent solid 
tumours, levels of p-mTOR and p-S6 were increased substantially in all 
lesions examined (Fig. 3.11b). Immunohistochemical analysis also showed 
increased expression of p-mTOR and p-S6 in renal cystadenomas as 
compared to adjacent normal tissue (Figs. 3.11c and d).
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Figure 3.11: Molecular and immunological analysis of renal lesions in Tsc1+/- mice on a Balb/c 
background. (A) Detection of LOH in a microdissected renal tumour. Loss of the wild type Tscl 
allele in the tumour, but not in adjacent normal tissue, is indicated by an arrow (W T -  wild type 
allele, Mut - mutant allele). The red trace is an ABI GS500 internal size standard. (B) Western 
blot analysis showing relative expression levels of mTOR, phosphorylated m TOR (P-m TOR) 
and phosphorylated S6 ribosomal protein (P-S6) in tumour (a cystadenoma) (T) and normal 
(N) kidney tissue. (C,D) Immunostaining of a papillary cystadenoma using (C) an anti- 
Phospho-mTOR antibody, and, (D) an anti-Phospho-S6 ribosomal protein antibody.
Expression of Phospho-mTOR and Phospho-S6 around the periphery of the cyst is indicated 
by brown staining. Microscopic bars are 200nm.
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3.4 Discussion
3.4.1 Generation of Tsc1*/m mice
Mice bearing a targeted disruption of Tscl were generated by deleting 
part of exon 6 through to exon 8 with the concurrent insertion of a 
reporter/selection cassette. This targeted modification should have 
expressed a bicistronic RNA transcript containing Tscl and IRES-/acz 
sequences that was terminated at the polyadenylation site in the cassette, 
with the Tscl open reading frame truncated by a stop codon introduced at 
the beginning of the cassette sequence. However, we found that TscT1' 
embryos only expressed Tscl transcripts generated as a consequence of an 
aberrant splicing event fusing exons 5 and 9, therefore excluding exon 6 and 
the IRES-/acz sequence. The exon 5-9 fusion alters the Tscl reading frame, 
which is then predicted to prematurely terminate at a TGA codon in exon 9. 
Therefore, any protein produced from this allele would lack all of the known 
functional and interacting domains of hamartin (reviewed in Cheadle et al. 
2000b). The results suggest that in the targeted allele, the exon 9 splice 
acceptor is utilised in preference to that of exon 6 and therefore a transcript 
containing the IRES-/acz sequence is not produced efficiently. This explains 
the failure to detect p-galactosidase activity in kidneys from Tsc1+I~ mice.
3.4.2 Tsc1*/m mice are a valid model of hamartin deficiency
The targeted mouse strain was confirmed to be a valid model for 
tuberous sclerosis-1 deficiency, by several criteria: (i) Tsc1~'~ embryos die in 
utero at a similar stage to other murine models of Tscl-deficiency 
(Kobayashi etal. 2001, Kwiatkowski etal. 2002). (ii) Somatic mutation
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analysis of DNA extracted from microdissected renal and extra renal lesions 
showed loss of the wild type Tscl allele, (iii) Western blot analysis and 
immunostaining showed increased levels of phosphorylated mTOR and 
phosphorylated S6 ribosomal protein in kidney lesions (in agreement with the 
findings of Kwiatkowski et al. 2002).
3.4.3 Some Tscl*1' mice on a C57BL/6 background die post-natally
Approximately 27% of Tsc1+I~ mice on a C57BL/6 background were 
found to die before weaning and this mortality appeared to occur in the post­
natal period, primarily 1-2 days after birth. At birth, the trans-placental 
nutrient supply is suddenly interrupted and neonates face severe starvation 
until a supply can be restored through milk nutrients. It has been shown that 
neonates adapt to these adverse circumstances by immediately inducing 
autophagy in a number of tissues (Kuma et al. 2004). Autophagy is the 
primary means for the degradation of cytoplamic constituents within 
lysosomes. The materials in vesicles are degraded and recycled to general 
nutrient stores to maintain essential cellular functions under starvation 
conditions (Inoki et al. 2005). Interestingly, it has recently been shown that 
autophagy is under mTOR control (Kamada et al. 2004). In normal growth 
situations, mTOR inhibits autophagy and stimulates cell proliferation. Under 
cellular stress mTOR becomes inactive, allowing the cell to induce 
autophagy, thus releasing valuable nutrients for cell survival. Therefore, 
some neonatal Tsc1+/~ mice may be unable to effectively inhibit mTOR, 
leading to inability to stimulate autophagy at this critical period of starvation.
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Further studies are necessary to determine if lack of autophagy is the critical 
factor in the death of these Tsc1+/~ neonates.
3.4.4 Survival analysis
Survival analysis demonstrated that some Tsct+/_ mice on a Balb/c 
background died prematurely between weaning and 18 months when 
compared to both Tsc1+/+ littermate controls (P< 0.038) and Tsc1+/~ mice on 
a C3H or C57BL6 background (P< 0.001). Upon post mortem examination, 
24% of Tsc1+/' mice on a Balb/c background and 8% of Tsc1+/+ mice on a 
Balb/c background that had died prematurely between weaning and 18 
months were shown to have atrial thrombi. Atrial thrombosis has been 
reported as a strain associated disease in female Balb/c mice and Balb/c 
crosses (Ayers and Jones 1978, Frith etal. 1983). In addition, factors such 
as sex, age, diet and pregnancy may have some role in the development of 
thrombi in the atria (Carlton and Engelhardt 1991). Interestingly 40% of 
Tsc1+/- mice on a Balb/c background that had died prematurly also had 
macroscopic kidney lesions. Characteristic symptoms of RCC in humans 
include secretion of vasoactive substances (e.g. renin) that may cause 
arterial hypertension, and release of erythropoietin that causes polycythemia 
(increased production of red blood cells). The potential extra physiological 
stress from renal lesions in the Tsc1+/~ mice on a Balb/c background may 
have contributed to the increased number of thrombosis-related events.
3.4.5 Renal phenotype in Tsc1*/m mice
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The Tsc1+I' mice described herein have a more severe renal 
phenotype as compared to the published models (Kobayashi et al. 2001, 
Kwiatkowski et al. 2002). By 3-6 months, 44% of the Tsc1+I~ mice on a C3H 
background developed macroscopically visible renal lesions and 100% had 
microscopic lesions. In contrast, Kobayashi et al. (2001) failed to identify any 
macroscopic renal lesions in their Tsc1+I~ mice by 9-12 months. Furthermore, 
80% of the 15-18 month mice on a Balb/c background showed progression 
to RCC, which is considerably higher than described by Kwiatkowski et al. 
(2002) (up to 31% depending on the background), and in 41%, RCCs were 
>5mm which resulted in grossly deformed kidneys. Some of these 
carcinomas had a sarcomatoid morphology of spindle cells in whorled 
patterns and, unlike other Tsc1+I~ mice, metastasized to the lungs. Further 
molecular and cellular studies are necessary to determine whether the 
phenotypic differences between the Tsc1+I~ strain described herein and the 
published strains are due to the precise nature of the targeted modifications 
and/or to the presence or absence of modifiers in the various genetic 
backgrounds in which the mutated gene was studied. The Tsc1+/~ mice 
produced by Kwiatkowski et al. (2002) had a targeting modification close to 
the 3’ end of Tsc1. However, Immunoblot analysis indicated that no hamartin 
was produced from the mutant allele. The Tsc1+/~ mice produced by 
Kobayashi et al. (2001) bear a similar targeting modification to the mice 
described herein. Therefore the phenotypic differences are likely to be due to 
the different genetic backgrounds rather than the nature of this targeting 
event. It should be noted that the Tsc1+I' mice analysed here were 
extensively backcrossed so that any random genetic changes introduced
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during ES cell culture are likely to have been segregated from the targeted 
allele (Kumar et al. 2004). By contrast, the Tsc1+I~ mice studied by 
Koybayashi etal. (2001) and Kwiatkowski etal. (2002) were F1s of mixed 
genetic backgrounds.
The distribution in the size of lesions (Table 3.4) and the 
morphological continuity between cystic, mixed, benign and malignant solid 
lesions (Fig.3.8) provides evidence for sequential progression from simple 
cyst through to solid lesions and metastasis. This progression may result 
from an accumulation of somatic mutations in key target genes involved in 
tumourigenesis. A model that already exemplifies this progressive pathway 
from benign lesion to carcinoma is colorectal cancer (CRC). The model has 
indicated that CRCs arise initially from biallelic inactivation of APC. However, 
Mutations in at least 4 or 5 different genes are then required for the formation 
of a malignant tumour (Fearon and Vogelstein 1990). Therefore the Tsc1+I~ 
mice renal lesions may provide a powerful model to examine renal tumour 
progression.
108
Chapter 4: Induction of renal tumourigenesis with increased 
somatic deletions in Tsc1*/m mice
4.1 Introduction
4.1.1 Bloom's syndrome
Bloom's syndrome (BS) is a rare recessively inherited genetic disorder 
first described in 1954 (Bloom 1954). Only ~220 cases have been confirmed 
since 1975, of which many affected individuals are of Ashkenazi Jewish 
origin (BlmAsh) (Hickson 2003). Patients are predisposed to cancer, 
particularly leukaemias, from an early age. The BS gene, BLM, encodes the 
BLM RecQ helicase homolog protein, which plays an important role in the 
maintenance of genomic stability in somatic cells.
4.1.2 BS manifestations
BS patients have a variable spectrum of manifestations that include 
growth retardation, microcephaly, immune deficiency and a characteristic 
high pitch voice. Skin abnormalities include hyper- and hypo-pigmented 
spots, and sun-sensitive telangiectatic erythema (German 1993). BS patients 
have an increased neoplastic risk: out of 150 patients on the Bloom's 
syndrome registry from 1933-1991, there were 118 instances of cancer 
recorded (mean age 24.4 years), of which 86 were malignant (German 
1993). The cancers were characterised by multiplicity and diversity in site 
and type. BS cells show an elevated frequency of several types of 
chromosomal aberrations that include breaks, quadriradials and 
translocations. However, the hallmark feature of BS is an ~10-fold elevation
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in the frequency of sister-chromatid exchanges (SCEs) (German 1993, 
Cheok et al. 2005). SCE arise from crossing-over of chromatid arms during 
homologous recombination, a ubiquitous process that exists to repair DNA 
double stranded breaks and replication forks (Wu and Hickson 2003). SCEs 
by themselves are non-mutagenic and therefore unlikely to be harmful. 
However, this may not hold true for aberrant recombination events such as 
unequal SCE that occur between homologous chromosomes or repetitive 
sequences at ectopic sites (Fig. 4.1). The resultant somatic 
deletions/duplications may contribute to the genomic instability seen in BLM 
cancer cells (Mankouri and Hickson 2004).
4.1.3 BLM gene
BLM is located on human chromosome 15q26.1 (German etal. 1994). 
It encodes a 1417 amino acid protein that belongs to a family of proteins 
called the RecQ helicases. The RecQ family is highly conserved in evolution 
from bacteria to humans. The centrally-located helicase domain that contains 
seven characteristic sequence motifs is particularly well conserved (Cheok et 
al. 2005). The family contains two other proteins that are defective in human 
disorders associated with cancer predisposition; WRN is defective in 
Werner's syndrome and RECQ4 is defective in Rothmund-Thomson 
syndrome (Rassool et al. 2003). Helicases are enzymes that separate the 
complementary strands of nucleic acid duplexes using the energy derived 
from ATP hydrolysis (Hickson 2003). The RecQ helicases are one family of 
these proteins that have the ability to recognise and unwind a wide variety of 
different DNA structures. The BLM gene product forms part of a muti-enzyme
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Figure 4.1: Schematic representation of theoretically possible genetic consequences of equal and 
unequal sister-chromatid exchange (SCE). Two homologous chromosomes are drawn with 3 
lower regions denoted 1-3. In chromosomes A and B (left) SCE occurs between regions 1 and 2, 
and at mitosis, each daughter cell receives an identical chromosome. In chromosome C and D 
unequal SCE occurs between 1 and 2 (Chrm C) as well as 2 and 3 (Chrm D), and at mitosis, 
genetically different chromosomes will be transmitted to each daughter cell with either a 
segmental chromosome deletion or duplication (adapted from German 1993). Such 
rearrangements could be detected by dosage analysis.
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complex that appears to play roles both in the disruption of alternative DNA 
structures and in the resolution of DNA intermediates that arise during 
homologous recombination reactions (Cheok et al. 2005).
4.1.4 BLM Mouse models
Several independent groups have developed mouse models with 
defects in the murine Blm gene (Chester et al. 1998, Luo et al. 2000, Goss et 
al. 2002). In the Blmtm1Ches model, disruption of the Bloom's allele was 
achieved by the introduction of a neomycin selection marker into exon 8 of 
the murine Bloom's gene following homologous recombination (Chester et al. 
1998). Homozygous mutants were embryonically lethal and heterozygous 
mice were phenotypically indistinguishable from wild types until at least one 
year of age. The Blmtm3Brd (Blrrf13) mouse model was generated by an 
integration event that caused three copies of the vector (LoxP-PGKneo) to 
be introduced into the Blm locus. Using Cre mediated recombination, the 
vector sequences and neomycin gene were then removed from the locus, 
generating an allele with a duplication of exon 4. This lead to a frameshift in 
the reading frame that truncated the Blm protein (Luo et al. 2000). In contrast 
to Blmtm1Ches homozygous mice, Blnf'3/m3 mice are viable and are prone to a 
wide variety of cancers that arise after one year. When crossed with mice 
carrying an Ape mutation (Apcm'n), Blrrf13 deficiency increased the number of 
intestinal tumours formed (Luo et al. 2000). Luo et al. (2000) confirmed that 
the major mechanism of LOH leading to the loss of the Ape wild type allele in 
the ApcF,n Blm-deficient mice was mediated by mitotic recombination (Luo et 
al. 2000). The Blrrf13 allele has now been shown to be a hypomorph, which
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produces sufficient Blm protein to rescue the embryonic lethality seen in the 
Blmtm1Ches homozygous mice. Quantification of the Blm protein suggests that 
each Blrrf13 allele produces 12.5% of wild type levels (McDaniel et al. 2003). 
A third bloom deficient mouse (BlmCm) was developed to mimic human 
Blrrf8h. Gene targeting was used to replace exons 10, 11 and 12 of the Blm 
allele with a hypoxantine phosphoribsyltransferase (Hprt) cassette (Goss et 
al. 2002). Homozygous mutants were embryonically lethal. Heterozygous 
mice developed lymphoma earlier than wild types in response to challenge 
with murine leukemia virus and they developed twice the number of intestinal 
tumours when crossed with mice carrying an Ape mutation. This data 
suggest that haploinsufficiency for Blm is associated with tumour 
predisposition (Goss et al. 2002).
4.1.5 Modulation of the somatic mutation spectra
Normally, a diverse range of mechanisms including nonsense, 
frameshift and deletion mutations and epigenetic silencing, are implicated in 
the somatic inactivation of the wild type allele of TSGs. This diversity of 
somatic alterations makes genetic mapping of loci involved in tumour 
progression problematic. Mutant mouse models can be used as powerful 
tools to modulate the type of somatic mutations found in TSGs. Modulation of 
the somatic mutation spectra has been achieved in Msh2-, Msh6- and Msh3- 
deficient mouse models that were crossed with Apc1638N or Ap(f"n mice 
(Smits et al. 2000, Kuraguchi et al. 2001). Intestinal lesions of the Apc- 
mutant mice usually show inactivation of the wild-type Ape allele by complete 
loss of chromosome 18. However, complete loss of a chromosome does not
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allow any differentiation in specific sequences. Therefore somatic mutation 
site cannot be analysed within the Ape gene (Smits et al. 2000). By crossing 
onto the Msh-deficient backgrounds LOH is reduced and somatic point 
mutations are increased (Smits et al. 2000, Kuraguchi et al. 2001), allowing 
the mapping of mutant alleles. Therefore, investigators have been able to 
look for the interdependence of 2 hits on the Ape gene. Such an 
interdependence has been shown in humans with FAP and sporadic 
colorectal tumours where mutation combination results in different growth 
advantages ( Lamlum et al. 1999, Albuquerque et al. 2002, Cheadle et al. 
2002, Sieber et al. 2006).
4.1.6 Aims
The study reported here investigated whether Blrrfl3/m3 mice could be 
used to induce tumourigenesis in extra-colonic tissue by crossing with Tsc1+/' 
mice that are predisposed to renal cystadenomas and carcinomas (Chapter 
3). We hypothesized that by crossing our Tsc1+/' mice onto a B/m-deficient 
background we would modulate the somatic mutation spectra observed at 
the Tsc1 locus by increasing the frequency of large somatic deletions. If so 
this would provide a convenient means of directly mapping other genes 
involved in Tsc-associated tumourigenesis.
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4.2 Methods
4.2.1 Animal care, genotyping, necropsy and pathology
Tsc1+I~ mice on a Balbc background (N£3) (chapter 3) were crossed 
with Blrrf1*™3 mice on a C57BL6 background (Luo et al. 2000) and Tsc1+I~ 
Blm+/m3 offspring were intercrossed to generate mice for subsequent 
analyses. DNA was extracted from mouse tail tips using the Qiagen QIAamp 
DNA mini kits and genotyping was performed as previously described (Luo et 
al. 2000, chapter 3). Necropsy analysis included macroscopic examination of 
the brain, heart, lungs, kidneys, liver, spleen and uterus in 20 Tsc1+I~ Blm+/m3 
and 20 Tsc1+I~ Blrrf1*™3 mice at 3-6 and 9-12 months. Half of each organ was 
fixed and processed into paraffin wax, sectioned at 4pm and stained with 
H&E for microscopic inspection (tissues from 10 mice per genotype were 
analysed microscopically at 3-6 and 9-12 months). Estimations of the 
average number of kidney lesions per mouse were determined as previously 
described (chapter 3). The other half of the organs were snap frozen in liquid 
nitrogen-cooled isopentane for LCM.
4.2.2 Immunohistochemistry
Immunohistochemistry using anti-phospho-S6 ribosomal protein 
(Ser240/244) (Cell Signalling Technologies) was performed as previously 
described (chapter 2 section 2.5.6).
4.2.3 Somatic mutation analysis
Snap frozen tissue was sectioned at 10pm onto PEN (PALM) 
membrane covered slides, and stained with toluidine blue, cystadenoma
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(CA), RCC and normal tissue was microdissected (PALM LCM) and DNA 
extracted using the QIAamp DNA micro kits (Qiagen). LOH at the Tsc1 locus 
was assayed as previously described (Chapter 3) using wild type:mutant 
peak ratios of <0.67 or £1.3 as indicative of LOH (Zhou et al. 2004). To 
search for intragenic somatic Tsc1 mutations, the entire Tsc1 ORF was 
amplified as 25 fragments and sequenced directly (Table 4.1). LOH at the 
Blm locus was assayed by amplifying and directly sequencing the region 
encompassing the variant 4109-152 G>A, located in intron 18 of the Blm 
gene, using the primers rs8248591/2F 5-ACAGTTCTGAGAGGGGCTCA-3’ 
and rs8248591/2R 5’-CCTAGCTTTCCACAGGCACT-3’. LOH of the Blm WT 
allele was determined by visual inspection of the 4109-152 G>A variant on 
the sequencing chromatograms by two independent investigators.
4.2.4 Simple sequence length polymorphism (SSLP) markers flanking 
Tsc1
Six highly polymorphic SSLP markers flanking Tsc1 (D2MH484, 
D2Mit451, D2MH63, D2Mit37, D2Mit433 and D2MH431, Table 4.2) were 
analysed in 18 and 14 tumours with LOH of the Tsc1 WT allele from Tsc1+I' 
B!rrfn3/m3 and Tsc1+/~ Blm+/+ mice, respectively. Amplification of DNA from 
tumours was performed as previously described (chapter 3) using a 25 cycle 
PCR reaction. 2pl of PCR products were mixed with an ABI GS500 internal 
size standard and formamide loading buffer, and run on an ABI3100 genetic 
analyser. Results were analysed using Genescan v.3.7 software and LOH 
determined as previously described (Zhou et al. 2004).
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Table 4.1: Primer sequences, product sizes and amplification 
temperatures used to screen for mutations in the Tsc1 ORF
Primer
name/exon
Primer sequence 
(5-3’)
Product 
size (bp)
Annealing 
temp. (°C)
mTsc1ex3F GCTT GTTTT CCT GCAGGTTT 395 54
mTsc1ex3R T CCAGGCTAATTT GGAAT GC
mTsc1ex4F GACAGCCACT GAGGGAAAAG 242 54
mTsc1ex4R ACTAT GGAT GAGCT GCTGTGG
mTsc1ex5F AGGAAGACTT GAGGCCTT GG 350 54
mTsc1ex5R GAGACCCACAT GGT CGAAAG
mTsc1ex6F TTT CAGT GCTGTCCCT CAAAT 350 54
mTsc1ex6R CTT CCTT CCCGCATACACAT
mTsc1ex7F AGAGCTT CCGAGAGAAAGC A 427 54
mTsc1ex7R G ACT CGG ACT CAG AAAGACG A
mTsc1ex8F TGCTGCATTCCT I ITTGTTG 362 54
mTsc1ex8R TTCCAGGCACAGGCAGTAG
mTsc1ex9F T GCCACT GAGCTAGCCT CTT 373 54
mTsc1ex9R CAGTTACGCTT GAAGGACAGAA
mTsc1ex10F AGCCAACGGI I I IAAGCAGA 266 54
mTsc1ex10R GAGGT GAAGGCAT GCT GAGT
mTsc1ex11F GCAACTT GT CT CGCGGTAA 465 54
mTsc1ex11R CCAAGCAAT CAAGT CCACCT
mTsc1ex12F CTGAGGCTGATCTGGATTCTG 388 54
mTsc1ex12R CCT GGT CT GTACCGT GACCT
mTsc1ex13F CT CT GCGACACAGAACAT GC 340 54
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mTsc1ex13R T CT C AGGCCGAAAT GT CT CT
mTsc1ex14F TGGT CCCAACTTT CT CT GCT 366
mTsc1ex14R TT GGCATT CCTTT CCCTGTA
mTsc1ex15aF ACGAACGTT CCCT GTAGT GC 406
mTsc1ex15aR AAGGGCT GGGAGT GAGGATA
mTsc1ex15bF CT CCCATAGACCCACCCT CT 434
mTsc1ex15bR CTGCCTTGGGTATAGGTGGA
mTsc1ex16F CGGCAGGAGACT CT CAAAAC 211
mTsc1ex16R AAGCCAAAGAAGT CCCTT CC
mTsc1ex17F CCTT CCAAGACCCCAAGAAT 398
mTsc1ex17R CCAT GCACAT CT GTT CCT CA
mTsc1ex18F T GT GCTAAT GT GCAGTTT GGA 484
mTsc1ex18R TTCTGTCCTCGGATCCATTC
mTsc1ex19F GGAT C AGGT CTTT GGGAAGG 440
mTsc1ex19R ACT CGAACCAACGT CT CCAG
mTsc1ex20F T GGACT CAGT GGGAAT GGTT 392
mTsc1ex20R CAT GTAGCCT GGACCT CTGC
mTsc1ex21F GCCAGG AAGT CCTCCT CACT 404
mTsc1ex21R GCCT CATACCT GCT CTCTGC
mTsc1ex22F TT CT GGCCAAGAAAGACCAC 414
mTsc1ex22R GGCAGACT GAGTACAGCCAAC
mTsc1ex23aF GTTT CAGGCAGGCACATACA 447
mTsc1ex23aR CCAGGAAGCI I I IGGAACTG
mTsc1ex23bF AGCAGCAT CCCCACCACT 384
mTsc1ex23bR CT GCT CAGACCCT GGAAACA
54
54
54
54
54
54
54
56
56
54
54
54
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4.2.5 Statistical analysis
Comparisons of numbers of mice were performed using the Chi- 
square test. Lesion counts per mouse were compared using the Mann- 
Whitney confidence interval tests and frequencies of LOH were compared 
using Fisher’s exact test.
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Table 4.2: Primer sequences, chromosomal positions, product sizes 
and amplification temperatures used to analyse SSLP markers flanking 
Tsc1
Primer Primer sequence cM Size Temp.
name/exon (5'-3*) (bp) (°C)
D2Mit484F AGGAGT GGTAAGCAT GGT GG 57.8 112 54
D2Mit484R T GCT GCAGGGAGGTAACAG
D2Mit451F CATTAGATAGACT GGGCAAGGG 75.6 116 54
D2Mit451R T CCT CCCT CCAAACCCT C
D2Mit63F GCAGTCTACCAGGAGCAACC 56.69 209 54
D2Mit63R TGGAT GTAGGCAT GT GCCT
D2Mit37F T GT GCAAGCCAGAAAAGTT G 46.66 141 54
D2Mit37R GAAGGGGATT GTAAATT GGTACC
D2Mit433F CTGTCTATCCTCATATTAGGAAATGG 33.18 173 54
D2Mit433R AACTT'I I AAAGACCAI T 1 1ATAGCCTT
D2Mit431F AAATAGT CT GTT CT GACT CCAGGG 23.12 98 54
D2Mit431R GCCAGGCAGTGGTAAAAAGA
D2Mit484F AGGAGT GGTAAGCAT GGTGG 57.8 112 54
D2Mit484R TGCTGCAGGGAGGTAACAG
Primer sequences were obtained from the Mouse Microsatellite Data Base of Japan 
(MMDBJ) (http://www.shigen.nig.ac.jp/mouse/mmdbj/top.jsp).
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4.3 Results
4.3.1 B/m-deficiency has no effect on Tsd*1' mortality
Tsc1+I~ Blm+/m3 mice were intercrossed. Genotyping showed that out of 
the 360 offspring that survived until weaning, 204 were Tsc1+I~ and 134 were 
wild type (22 failed to be genotyped). Indicating that all T s c f' and ~24% of 
Tsc1+I~ mice died before weaning (F^0.016). Genotyping of the Blm allele in 
Tsc1+I~ animals showed no deviation from the expected 1:2:1 ratio (42 Blm+/+, 
90 Blm+/m3, 52 B lrrf*1"3 mice (20 failed to be genotyped)).
4.3.2 Renal tumour analysis in Tsd*1' mice on a B/m-deficient 
background
The kidneys of mice at 3-6 months were examined by macroscopic 
inspection and microscopic analysis of five sections ~200pm apart. A 
significant increase in renal tumours in Tsd*1' mice on a B/m-deficient 
background was observed; 70% (14/20) of Tsd*1' B lrrf*1"3 mice developed 
macroscopically visible renal lesions (average 4.2 lesions per mouse), 
compared to only 15% (3/20) of T sd +I~ Blm*/m3 mice (average 0.2 lesions per 
mouse, ^0.0003) (Table 4.3, Fig. 4.2). At a microscopic level, Tsd*1' 
Blrrf*""3 mice had an average of 23.2 lesions per mouse compared to 5.4 for 
Tsc1+I- Blm+/m3 mice (P=0.0203). Renal lesions from Tsd*1'B lr r f * m3 mice 
stained positively with anti-phospho-S6 ribosomal protein (Ser 240/244) (Fig. 
4.2).
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Figure 4.2: Renal cystadenomas in Tsc1+I- mice on a B/m-deficient background. (A) An 
example of a kidney from a Tsc1+I- Blrnm3/m3 mouse at 3-6 months showing significantly 
more macroscopically visible lesions compared to (B) a kidney from a Tsc1+I- Blm+/m3 
mouse. (C,D) Microscopic view of cystadenomas from TscV'- Blrnm3/m3 mice stained with 
H&E (C) and immunostained with an anti-phospho-S6 ribosomal protein (p-S6) antibody 
(D) (region shown in D is a magnified view of the region boxed in C). Lesions on a B/m- 
deficient background showed increased expression of p-S6 (indicated by brown staining) 
suggesting that these lesions develop through the normal pathway of Tsc-associated 
tumourigenesis. Scale bars are 5mm (in A, B and C) and 1mm (in D).
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Table 4.3: Frequency of renal lesions in 3-6 month old Tsc1*lm mice on
Blm*/m3 and Blnf'3/m3 backgrounds
Type of Blm genotype of Total no. of Mean no. of P
analysis Tsd*1' mice tumours tumours per mouse
Macroscopic +/m3 4 0.2
m3/m3 84 4.2
0.0003
Microscopic +/m3 27 5.4
m3/m3 116 23.2
0.0203
Numbers based on the analysis of 20 Tsc1*,m mice on Blm*/m3 background and 20 on a 
Blrnm3/mS background for macroscopic inspection and 10 Tsd*1' mice in each category 
for microscopic inspection.
4.3.3 Somatic mutation analysis of Tsc1 and mechanism of LOH
DNA was extracted from LCM kidney lesions and analysed for LOH 
at the Tsc1 locus using an IRES (mutant specific) and exon 8 (wild type 
specific) quantitative PCR assay, as previously described (Chapter 3). We 
observed significantly increased levels of somatic LOH of the Tsd  WT allele 
in renal lesions from Tsd*1' Bl(rfn3/m3 mice (53/61, 87%) as compared to 
renal lesions from Tsd*1' Blm+/* mice (61/118, 52%) (P<0.0001) (Fig. 4.3).
To determine the mechanism of increased somatic LOH in these lesions, we 
analysed the extent of the LOH events using 6 SSLP markers on mouse 
chromosome 2, on which Tsd  resides. Two out of 18 tumours showing loss
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Figure 4.3: LOH analysis of renal lesions from Tsd*1' mice on B/m-proficient (Blm+/+), 
haploinsufficient (Blm*/m3 ) and deficient (Blrnm3/m3) backgrounds. (A) Example of LOH in 
a microdissected renal tumour. Loss of the wild type Tsd  allele in the tumour (lower 
panel), but not in adjacent normal tissue (upper panel), is indicated by an arrow (WT -  
wild type allele, Mut - mutant allele). The unshaded trace is an ABI GS500 internal size 
standard. (B) Graph showing the percentage of lesions with LOH versus those without 
LOH, from Tsd*'- Blm+/+, Tsd*'- Blm*/m3 and Tsd*1' Blmm3/m3 mice. P values reflect 
differences in the frequency of LOH in Tsd*'- Blm*/m3 and Tsd*'- Blrnm3/m3 mice as 
compared to Tsd*'- Blm+/* mice.
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of the Tsd  WT allele from T sd*'' Blrrfn3/m3 mice remained heterozygous at 
the marker D2MH431 located ~5cM upstream of Tsd  (Fig. 4.4), whereas no 
tumours with loss of the Tsd  WT allele from T sd +/~ Blm*/+ mice retained 
heterozygosity at any of the markers tested. Intragenic somatic Tsd  
mutations were sought in DNA from the eight tumours from Tsd*1' Blrrfn3/m3 
mice that retained the Tsd  WT allele, by direct sequence analysis of the 
entire Tsd  ORF. High quality sequencing for £89% of the Tsd  ORF was 
generated for each tumour and identified a single intragenic somatic 
mutation, characterised as a 2bp deletion in exon 22 (Tsd  del 2872-2873) 
(Fig. 4.5).
4.3.4 Tsc1*lm Blm*/m3 mice do not show increased tumour burden?
We did not observe significantly more renal lesions in Tsd*1' Blrn*/m3 
mice at 3-6 months when compared to Tsd*1' Blm+/* mice that had 
previously been backcrossed (N>3) onto two different backgrounds (Balb/c 
and C57BL6) (chapter 3). However, we did observe significantly increased 
levels of somatic LOH of the Tsd  WT allele in renal lesions from Tsd*1' 
Blm*/m3 mice (23/32, 71%) as compared to T sd +/~ Blm+/* mice (61/118, 
52%)(P^0.03). To determine whether tumours from Tsd*1' Blm*/m3 mice had 
lost the 8/mWT allele, we analysed of polymorphism 4109-152 G>A which 
lies within intron 18 of the Blm gene. Nineteen out of 20 (95%) renal lesions 
from Tsd+/~ Blm*/m3 mice that had lost the Tsd  WT allele and were 
informative for this marker, retained the BlmWT allele, indicating that the 
increased somatic LOH at the Tsd  locus in these mice was mediated by 
Blm haploinsufficiency.
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Figure 4.4: Analysis of the extent of LOH on mouse chromosome 2 in Tsc1+'- Blrnm3/m3 
mice advanced lesions. Lesions had known LOH at Tsc1 and were heterozygous at 
the SSLP marker D2Mit431. Loss of the wild type D2Mit431 allele in tumour 1, is 
indicated by an arrow (middle panel), but is not in adjacent normal tissue (upper 
panel). Tumour 2 (lower panel) has no LOH of the wild type D2Mit431 allele. This 
result indicates the lesion retained heterzygosity of the chromosomal region 
immediately surrounding the LOH at the Tsd  locus, suggesting that the LOH of Tsd 
was mediated by mitotic recombination. Stutter peaks can be observed which occur 
during amplification of microsatellite loci (they are thought to be caused by polymerase 
slippage during elongation).
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Figure 4.5: An example of an intragenic frame shift mutation in a microdissected CA 
from a Tsc1+/-Blm-^ mouse. A 2 base pair deletion in exon 22 ( Tsc1 del 2872-2873) 
in the tumour (lower panel), but not in adjacent normal tissue (upper panel), is 
indicated by an arrow.
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4.3.5 The nature of the second hit does not influence the spectrum and 
distribution of Tsc-associated lesions
To study whether the increased frequency of LOH at Tsd  in the Blm- 
deficient animals influenced the spectrum and distribution of their tumours 
Tsd*1' Blm*/m3 and Tsd*1' Blrrfn3/m3 mice at 9-12 months were examined and 
compared with Tsd*1' Blm*'* mice. Renal tumours were more frequent in 
Tsd*1' Blrrfn3/m3 mice compared to Tsd*1' Blm*/m3 mice (P=0.0027), and 
consistent with the increased tumour induction at 3-6 months, Tsd*1' 
Biu/nvm3 a hjghep proportion of more severe renal tumours (with a
solid to cystic tumour ratio of 1:5) compared to Tsd*1' Blm*/m3 mice (ratio of 
1:11.5), with a single renal lesion metastasizing to the lungs.
The spectrum and distribution of extra-renal tumours in Tsd*1' mice 
on Blm*/m3 or Blrnm3/m3 backgrounds was not significantly different to Tsd*1' 
mice on a Blm*/+ background -  only an isolated liver hemangioma was 
observed in a single Tsd*1' Blrrfn3/m3 mouse and no other lesions were seen 
after macro and microscopic examination of the brain, heart, lungs, spleen 
and uterus.
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4.4 Discussion
4.4.1 Exploiting the power of the B/m-deficient model
N-ethyl-N-nitrosourea (ENU) has been used in whole animal 
mutagenesis systems to discover novel alleles for studying human disease in 
mice (Hrabe de Angelis and Balling 1998). However, despite rewarding 
results these screens are costly and time consuming (Chen et al. 2000). 
Homozygous mutations in cultured ES cells provide both a source of cells 
that can generate mice for in vivo studies and an in vitro model for 
understanding disease. Therefore producing a system that creates a genome 
wide library of homozygous mutant ES cells will prove invaluable. Recently, 
several investigators have exploited the high rate of mitotic recombination in 
Blm-deficient ES cells to allow these powerful recessive genetic screens to 
be carried out (Guo et al. 2004, Yusa et al. 2004). Guo et al. (2004) and 
Yusa et al. (2004) used ES cells with the Blm allele under conditional control 
of tetracycline (Blmtet). Consequently transient inactivation of the Blm protein 
can be produced using doxycycline, minimising changes to the ES cell 
phenotype. Transient loss of Blm caused an 18-27-fold increase in the rate of 
bi-allelic mutations (Guo et al. 2004, Yusa et al. 2004), and allowed the 
identification of the novel MMR gene Dnmtl (Guo et al. 2004).
The high rate of mitotic recombination induced by Blm deficiency has 
also been used in vivo. Luo et al. (2000) crossed Apc/nm mice with mice on a 
Blm deficient background. ApcTin/+ Blrrf1* "13 mice developed an average of 
80 more polyps (larger than 1mm) than Apcf1^ * B lrrf * + mice. In this study 
we have also exploited the high rate of mitotic recombination in Blm-deficient 
mice. We investigate whether Blrrf1*"13 mice could induce tumourigenesis in
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extra-colonic tissue by crossing with Tsc1+/~ mice that are predisposed to 
renal cystadenomas and carcinomas. We show that Tsc1+I~ mice on a Blm- 
deficient background have a significantly increased number of renal lesions. 
In addition, we show that renal lesions from Tsd*1' Blrrfn3/m3 mice stained 
positively with anti-phospho-S6 ribosomal protein (Fig. 4.2). Together with 
the investigations by Luo et al. (2000), this study shows the value of the Blm- 
deficient mice in inducing lesions in cancer prone models of disease. 
Furthermore, Tsc1+/~ Blrrfl3/m3 lesions seem to develop through the normal 
pathway of Tsc-associated tumourigenesis.
4.4.2 Increased levels of somatic LOH mediated by mitotic 
recombination
It has been hypothesised that the underlying mechanism leading to 
cancer predisposition in Bloom's syndrome is an increase in LOH resultant 
from uneven SCEs (Mankouri and Hickson 2004). Luo et al. (2000) 
hypothesised that elevated recombination processes in the intestine of 
Ap(flin/* Blmfn3/m3 mice leads to an increase in LOH, therefore elevating the 
incidence in tumours. However, because intestinal lesions of the Ape-mutant 
mice normally show inactivation of the wild-type Ape allele by complete loss 
of chromosome 18 (Smits et al. 2000) studying changes in LOH was not 
possible. In our study we were able to show significantly increased levels of 
somatic LOH of the Tsc1 wild type allele in renal lesions from Tsc1*''
Blrrfn3/m3 mice (87%) as compared to renal lesions from Tsc1+I' Blm+/* mice 
(52%) (P<0.0001). We have therefore provided evidence for the first time 
that increased LOH is the major mechanism of somatic mutagenesis in Blm-
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deficient mice. Furthermore, analysis of the extent of the LOH events using 6 
SSLP markers on mouse chromosome 2 suggested that the LOH on a Blm- 
deficient background was mediated by mitotic recombination, in agreement 
with Luo et al. (2000).
Intragenic mutation analysis of the Tsc1 ORF in eight tumours from 
Tsd*1' B lrrf3/m3 mice that retained the Tsd  wild type allele, identified a 
single intragenic somatic mutation. Therefore, 11% of advanced tumours 
from Tsd*1' B lrrf3/1113 mice have no detected LOH or coding region 
variations. Since these animals are on a background with increased LOH, 
these Tsd- mutation negative lesions may have large deletions elsewhere in 
the genome. Deletions may be affecting the promoter region of the Tsd  
gene or genes that regulate the expression of the Tsd  transcript. Further 
studies are necessary to verify these deletions
4.4.3 Blm haploinsufficiency
Goss et al. (2002) showed that mice heterozygous for a targeted null 
mutation of Blm developed lymphoma earlier than wild-type littermates when 
challenged with murine leukemia virus and developed twice the number of 
intestinal tumours when crossed with Apc*/M,n mice. Furthermore, Gruber et 
al. (2002) demonstrated that carriers of a BLM mutation have more than a 
twofold-increased risk for colorectal cancer. However, we did not observe 
significantly more renal lesions in Tsd*1' Blm*/m3 mice at 3-6 months when 
compared to Tsd*'~ Blm*/+t although, we did observe significantly increased 
levels of somatic LOH of the Tsd  wild type allele in renal lesions from Tsd*1' 
Blm*/m3 mice (P= 0.03). McDaniel et al. (2003) recently showed that the B lrrf3
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allele is in fact hypomorphic and expresses a low level of normal Blm protein. 
This may explain the failure to find significantly increased tumour burden in 
Tsc1+I' Blm+/m3 mice. However, our results indicate that the previously 
reported tumour predisposition associated with Blm haploinsufficiency (Goss 
etal. 2002, Gruber etal. 2002) may be mediated by increased somatic LOH.
4.4.4 The nature of the 2nd hit does not affect the spectrum and 
distribution of extra-renal lesions in Tscl*1' mice
To date, investigators have induced renal lesions in Tsc1+I~ mice 
(Kobayashi etal. 2001) using ENU, which causes a high frequency of 
somatic point mutations on the Tsc1 wild type allele. These animals do not 
appear to develop any unusual extra-renal tumours. We sought lesions in 
Tsc1+I~ mice on Blm+/m3 or Blmm3/mS background to investigate if nature of the 
2nd hit (large deletions) influences the spectrum and distribution of extra renal 
lesions. Tsc1+/' mice on the Blm+/m3 or Blrnm3/m3 backgrounds did not appear 
to develop any unusual extra-renal tumours. Lesions have also been induced 
in Apdn,n mice by loss of the MMR genes Msh3, Msh6 and Msh2 (Smits et al. 
2000, Kuraguchi et al. 2001). Apd""1 mice are prone to intestinal lesions that 
normally occur because of large deletion events inactivating the Ape wild 
type allele. Loss of the MMR genes in ApcF10 mice increased the frequency 
of somatic point mutations on the wild type Ape allele (Smits et al. 2000, 
Kuraguchi et al. 2001). Consistent with our studies, there was no reported 
unusual extra-colonic tumours as a result of different 2nd hits in the Ape 
mutant mice. Together, these data indicate that the nature of the 2nd hit does
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not affect the spectrum and distribution of lesions in either of the TSG- 
deficient mouse models.
4.4.5 Conclusion
This study confirms the utility the BlnrTym3 mouse for inducing LOH by 
mitotic recombination. It also confirms utility of the Blrrfn3/m3 mouse for 
inducing tumourigenesis in cancer prone mouse models in agreement with 
Luo et al. (2000). The high levels of LOH in the resultant tumours (and 
consequently low level of intragenic mutations) will help facilitate the 
mapping of TSG loci that may play a role in tumour progression.
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Chapter 5: Tscf-haploinsufficiency is sufficient for renal cyst 
formation in Tsc1*/m mice
5.1 Introduction
Several studies have identified somatic mutations in the wild type 
TSC1 or TSC2 alleles (so called ‘2nd hits’) in TSC-associated renal 
angiomyolipomas (Niida et al. 2001), in accordance with Knudson’s ‘two-hit’ 
hypothesis of tumourigenesis (Knudson 1971). However, somatic mutations 
appear to be very uncommon in the majority of TSC-associated brain lesions 
(Niida et al. 2001), although physiologically inappropriate phosphorylation 
tuberin may act as a 2nd hit in some of these (Han et al. 2004).
In studies using the Eker rat, somatic LOH at the Tsc2 locus was 
found in only 21% (4/19) of single altered renal tubules (Kubo et al. 1995), 
raising the possibility that although 2-hits are present in some early lesions, 
haploinsufficiency for Tsc2 may be sufficient for their initiation. Here, we 
investigated the role of Tsc1 haploinsufficiency in Tsc-associated renal 
tumourigenesis by examining cysts, cystadenomas (CAs) and RCCs from 
Tsc1+/'ar\6 Tsc1+/~ Blmv~ (Bloom-deficient) mice using a combination of 
complementary mutation screening strategies and IHC.
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5.2 Materials and methods
5.2.1 Animal care, genotyping, necropsy and pathology
All procedures with animals were carried out in accordance with Home 
Office guidelines. Kidneys were collected from Tsc1+I~ and Tsc1+I~ B lm mice 
as previously described (chapter 3, chapter 4). Half of each kidney was snap 
frozen in liquid nitrogen-cooled isopentane for LCM and the other half was 
processed into paraffin wax and sectioned at 4pm for H&E or IHC.
5.2.2 Somatic mutation analysis
DNA was extracted from renal lesions after LCM from kidneys of 55 
Tsc1+,~ and 31 Tsc1+I~ Blmv' mice. LOH at the Tsc1 locus was assayed by 
simultaneous amplification of both the wild type and mutant alleles in a 25 
cycle PCR reaction, as previously described (chapter 3), using 3ng of DNA 
(multiple sections of the same lesion were sometimes required to provide 
sufficient yields of DNA). LOH was defined as a change in wild type:mutant 
peak ratios of <0.67 or £1.3 (chapter 4). To search for intragenic somatic 
Tsc1 mutations, the entire Tsc1 ORF was amplified as 23 fragments (Table 
4.1) and sequenced directly. The Wales Gene Park assisted with sequencing 
and somatic mutation detection.
5.2.3 Immunohistochemistry
IHC using anti-mTOR, anti-phospho-mTOR (Ser 2448), anti-S6 
ribosomal protein and anti-phospho-S6 ribosomal protein (Ser240/244) (Cell 
Signalling Technologies) was performed as previously described (chapter 3). 
Renal lesions were identified after H&E staining and adjacent sections were
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stained with antibodies to p-mTOR or p-S6 (kidneys from 36 Tsc1+/~ and 30 
Tsc1+I' Blm'1' mice were used for the p-mTOR analyses and 44 Tsc1+I' mice 
were used for the p-S6 analyses). Staining intensities were ranked blind by 
two independent investigators as little/absent or strong (there was 70.4% and 
81.2% concordance in staining estimates for p-mTOR and p-S6, 
respectively). Cleo Bonnet assisted with some paraffin sectioning and p-S6 
IHC.
5.2.4 Determination of cyst and cell size
Total cyst area was measured using Motic image plus 2.0 software in 
17 p-S6 positively stained cysts and 9 p-S6 negatively stained cysts. Cell 
areas were estimated by measuring the height and width of 20 adjacent cells 
within 12 p-S6 positively stained cysts, 9 p-S6 negatively stained cysts, 6 
CAs and 6 RCCs (positively stained for p-S6), and 20 normal tubule cells 
selected at random within the same kidneys.
5.2.5 Determining the sensitivity of the LOH assay for detecting the 
level of mutant alleles
LCM of cysts is technically challenging due to their small size and 
proximity to normal renal cells. Therefore, DNA extracted from cysts may 
have relatively high levels of contaminating wild type alleles. Theoretically, 
the LOH assay would be able to detect LOH of the wild type allele down to 
12.5% tumour tissue if LOH is defined as a change in wildtype: mutant peak 
ratios of £1.3. However in practice tissue is heterogeneous. To determine the 
lowest level of mutant alleles that could be detected by the LOH assay, RCC
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tissue with known LOH was excised and mixed with different amounts of 
normal renal tissue. DNA extracted from these mixed samples was assayed 
as previously described. Mutant to wild type allele proportions were 
estimated to vary between 25% to 97% (n=60). As expected, increasing the 
amount of wild type allele decreased the LOH ratio for the samples (Fig. 5.1). 
This data indicated LOH could be detected with 95% confidence when the 
proportion of mutant alleles was as low as 25%.
5.2.6 Statistics
Comparisons between numbers of somatic mutations was performed 
using Fisher’s Exact test. Comparisons between staining grades were 
performed using the Mann-Whitney confidence interval test. Determinations 
of cyst and cell sizes were compared using the ANOVA followed by a Tukey 
test.
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Figure 5.1: Determining the sensitivity of the LOH assay to detect low levels of mutant 
allele. Plot of LOH ratios obtained from DNA extracted from RCC tissue (with known LOH) 
mixed with differing amounts of normal renal tissue (n=60). DNA extracted from 8 different 
normal tissue sections from Tsc1+/- mice was used to normalise the assay (comparison of 
wild type:mutant allele peak heights). Red curved line indicates theoretical values 
expected. LOH was defined as a change in wild type:mutant peak ratios >1.3 (green line).
138
5.3 Results
5.3.1 Somatic Tsc1 mutations are not abundant in renal cysts from 
Tsc1*/m mice
DNA was extracted from 19 renal cysts, 49 renal CAs and 65 RCCs 
from Tsc1+I~ mice after LCM. We sought somatic Tsc1 mutations in DNA from 
these lesions by LOH analyses and by direct sequencing the entire Tsc1 
ORF. In total, we identified 97/133 (72.9%) of anticipated somatic Tsc1 
mutations, which included 70 LOH events and 27 intragenic mutations. 
Interestingly, in 68.4% (13/19) of cysts we did not identify somatic Tsc1 
mutations, as compared to only 20.4% (10/49) of CAs and 20.0% (13/65) of 
RCCs (Table 5.1, Figs. 5.2 and 5.3). Although it is likely that we missed 
some somatic mutations lying outside of the ORF and would not have 
detected inactivation of alleles by epigenetic silencing, we observed 
significantly fewer 2nd hits in cysts as compared to CAs (^0.0003) and 
RCCs (P=0.0001).
5.3.2 The mTOR pathway is activated in only a proportion of renal 
cysts
We investigated whether the low level of somatic Tsc1 mutations in 
cysts correlated with low levels of mTOR activation. We assessed the 
expression levels of phosphorylated (activated) (p-)mTOR in 45 renal cysts, 
51 renal CAs and 27 RCCs from Tsc1+/' mice by IHC. In total, 94/123 
(76.4%) lesions showed strong staining for p-mTOR. However, 53.3%
(24/45) of cysts showed little or no p-mTOR staining, compared to only 3.9% 
(2/51) of CAs and 11.1 % (3/27) of RCCs, the majority (>88.9%) of which
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Figure 5.2: (A and B) Examples of somatic LOH identified in cysts from Tsa1+/' mice. Loss 
of the wild type Tsc1 allele in the cyst (lower panel), but not in adjacent normal tissue 
(upper panel), is indicated by an arrow (W T -  wild type allele, Mut - mutant allele).
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Figure 5.3: Examples of somatic intragenic mutations identified in cysts from Tsc1+/- 
mice. (A) An example of an intragenic nonsense mutation (S163X) in a renal cyst. The C 
to A substitution at nucleic acid position 488 was identified in the cyst (lower panel), but 
not in the adjacent normal tissue (upper panel) (indicated by an arrow). (B) An example 
of an intragenic 58 base pair deletion in exon 17 was identified in the cyst (lower panel), 
but not in the adjacent normal tissue (upper panel) (indicated by an arrow).
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showed strong staining (Table 5.2, Fig. 5.4). We also assessed the 
expression levels of phosphorylated S6 (p-S6) in 54 renal cysts, 60 renal 
CAs and 38 RCCs. One hundred and twenty-five out of 152 (82.2%) lesions 
showed strong staining for p-S6. However, 37.0% (20/54) of cysts showed 
little or no p-S6 staining, compared to only 5.0% (3/60) of CAs and 10.5% 
(4/38) of RCCs, the majority (>89.5%) of which showed strong staining 
(Table 5.3, Fig. 5.4). Therefore, significantly fewer cysts appear to have p- 
mTOR and p-S6 activation compared to CAs and RCCs (P<0.00001).
Table 5.1: Somatic Tsc1 mutations in renal lesions from Tsc1*/m mice
Type of no. of mutation +ve mutatiori -ve
lesion lesions LOH intragenic % no. %
cyst 19 4 2 31.6 13 68.4
CA 49 25 14 79.6 10 20.4
RCC 65 41 11 80.0 13 20.0
Total 133 70 27 72.9 36 27.1
5.3.3 Detailed analysis of renal cysts
We determined the pattern of p-S6 activation throughout individual 
renal cysts from Tsc1+I~ mice by staining consecutive serial sections. 
Seventeen out of 26 (65%) cysts studied in this way showed consistently
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Figure 5.4: IHC of renal lesions from Tsc1+A mice using an anti-p-mTOR (A-C) and anti-p- 
S6 (D-F) antibodies. (A) A RCC (top right hand corner) shows intense (brown) staining 
with p-mTOR (boxed region enlarged in B), whereas a cyst (lower left hand corner) shows 
little or no staining (boxed region enlarged in C). (D) Some cysts (right hand side) showed 
staining with p-S6 (boxed region enlarged in E), whereas others (left hand side) showed 
little or no staining (boxed region enlarged in F). Control staining using S6 and mTOR  
antibodies showed consistent staining throughout the kidney and all lesions studied (data 
not shown). N.B. cysts that did not stain for either p-mTOR or p-S6 were rarely adjacent to 
RCCs (that might have contributed to their formation). Scale bars are 200pm.
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strong p-S6 staining and the remaining 9 (35%) showed consistently little or 
no staining, in every serial section (Fig. 5.5). Three of the cysts with little or 
no p-S6 staining had some sections in which single cells displayed strong 
positivity (e.g. in Fig. 5.5D); however, this pattern was also seen in some 
normal tubular epithelial cells.
Table 5.2: p-mTOR analysis o f renal lesions from Tsc1*/m mice
Type of no. of lesions % with little or no % with strong staining’
lesion staining*
cyst 45 53.3 (24) 46.7 (21)
CA 51 3.9 (2) 96.1 (49)
RCC 27 11.1 (3) 88.9 (24)
Total 123 23.6 (29) 76.4 (94)
numbers of lesions are shown in parentheses
Table 5.3: p-S6 analysis o f renal lesions from Tsc1*/m mice
Type of no. of lesions % with little or no % with strong staining*
lesion staining*
cyst 54 37.0 (20) 63.0 (34)
CA 60 5.0 (3) 95.0 (57)
RCC 38 10.5(4) 89.5 (34)
Total 152 17.8 (27) 82.2 (125)
numbers of lesions are shown in parentheses
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Figure 5.5: IHC of consecutive serial sections of renal cysts from Tsc1+/- mice using a 
p-S6 antibody. Examples of serial sections through cysts that consistently either 
stained (A and B), or, that did not stain strongly (C and D). Note: other lesions 
present in other parts of sections shown in C and D stained for p-S6 (data not 
shown), confirming that the antibody worked successfully. Scale bars are 100pm.
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5.3.4 Size and morphology of p-S6 stained and unstained cysts
We found no significant difference in the size of cysts that stained for 
p-S6 (average size of 21441pm2, range 3177-151578pm2) and those that did 
not (average 10615pm2, range 3264-25661 pm2), nor did we find any gross 
morphological differences. In terms of cells that lined the cysts, p-S6 stained 
cells were of a similar size to unstained cells (100.4pm2 vs. 106.8pm2), and 
of a similar size to adjacent normal tubular epithelial cells (98.9pm2). 
Furthermore, cells lining both p-S6 stained and unstained cysts had similar 
morphologies. In contrast, cells from CAs and RCCs were significantly larger 
than cells from cysts or adjacent normal tubular epithelial cells (172.7pm2 
and 188.3pm2, respectively, P0.001).
5.3.5 Analysis of renal lesions from Tsc1*/m Blm1' mice
We have crossed our Tsc1+/~ mice onto a B/m-deficient background 
(Luo et al. 2000), which increases the frequency of somatic LOH of the Tsc1 
wild type allele (chapter 4), thereby facilitating the detection of 2nd hits. As 
observed in Tsc1+/~ mice, cysts from Tsc1+/~ Blm'1' mice were smaller and 
more numerous than CAs and RCCs, supporting the model of tumour 
progression. We sought somatic LOH events and intragenic mutations at the 
Tsc1 locus in DNA extracted from 23 renal cysts, 38 renal CAs and 24 RCCs 
after LCM from Tsc1+/~ Blm'A mice. In total, we identified 82.4% (70/85) of 
somatic Tsc1 mutations, which included 69 LOH events and 1 intragenic 
mutation. However, in 34.8% (8/23) of cysts we did not identify any somatic 
Tsc1 mutations, as compared to only 13.2% (5/38) of CAs and 8.3% (2/24) of
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RCCs (Table 5.4); therefore, in agreement with our studies on Tsc1+I' mice, 
somatic Tsc1 mutations were significantly less frequent in cysts as compared 
to CAs (P=0.048) and RCCs (P= 0.03) on a Tsc1+/~ Blnri/~ background. We 
also assessed the expression levels of p-mTOR in 23 renal cysts, 42 renal 
CAs and 9 RCCs from Tsc1+/~ Blm^' mice by IHC, and, consistent with our 
previous findings, we observed that significantly fewer cysts had activation of 
the mTOR pathway as compared to the more advanced lesions (P= 0.02).
Table 5.4: Somatic Tsc1 mutations in renal lesions from Tsc1*/m Blnf/m 
mice
Type of 
lesion
no. of 
lesions
mutation +ve mutation -ve
LOH intragenic % no. %
cyst 23 15 0 65.2 8 34.8
CA 38 32 1 86.8 5 13.2
RCC 24 22 0 91.7 2 8.3
Total 85 69 1 82.4 15 17.6
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5.4 Discussion
5.4.1 Sensitivity of the LOH assay and methodological drawbacks
LCM of cysts is technically challenging and DNA extracted from cysts 
may therefore have a relatively high level of contaminating wild type alleles. 
However, we show that our assay could detect LOH in samples with as low 
as 25% mutant alleles with 95% confidence. Furthermore, we have found 
many examples of cysts with high levels of mutant alleles (Figs. 5.2 and 5.3), 
confirming mutations in cysts could be easily located.
Unfortunately, in this study there were a number of reasons why we 
were unable to undertake both mutation analysis and IHC on the same cysts. 
Firstly, the small size of cysts makes LCM and extraction of sufficient 
amounts of DNA difficult. Secondly, p-S6 staining did not work on frozen 
tissue. Thirdly, DNA extracted from paraffin embedded tissue was not 
reliable in LOH assays. Finally, immunohistochemical staining of paraffin and 
frozen tissue hinders DNA extraction. Therefore, paraffin embedded p-S6 
stained cysts could not be used for DNA extraction and frozen cysts could 
not be stained for p-S6.
5.4.2 7scf-haploinsufficiency in a proportion of renal cysts
A wide range of mutational mechanisms may cause somatic 
inactivation of the wild-type allele of tumour suppressor genes.
Consequently, reports of tumour haploinsufficiency at tumour suppressor loci 
may sometimes be incorrect and simply reflect an inability to find second 
mutations. We have utilised two complimentary approaches to demonstrate 
Tsc1-haploinsufficiency in a proportion of renal cysts from Tsc1+I~ mice.
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Firstly, we have shown by staining for p-mTOR and p-S6, that there is little or 
no activation of the mTOR pathway in ~37-53% of cysts. Secondly, we have 
crossed Tsc1+/‘ mice onto a B/m-deficient background which dramatically 
increases the frequency of somatic LOH of the wild type Tsc1 allele, making 
the identification of 2nd hits straightforward (chapter 4); on this background 
~34.8% of cysts appeared to be haploinsufficient for Tsc1. Interestingly, 2nd 
hits at Tsc1 and activation of the mTOR pathway were found in the vast 
majority of more advanced renal tumours suggesting that although these are 
important steps in Tsc-associated renal tumourigenesis, they may not be key 
initiating events in this process.
5.4.3 Haploinsufficiency in tuberous sclerosis
Other studies have also suggested that haploinsufficiency for TSC1 or 
TSC2 has both biochemical and phenotypic consequences. Microscopically 
normal renal tubular epithelial cells from TSC mutation carriers have 
significant differences in gene expression profiles compared to similar cells 
from controls. TSC renal epithelial cells showed increased expression of 
transcripts for several factors involved in protein synthesis including 
eukaryotic translation initiation factor 3 and upregulation of several ribosomal 
protein genes (S6, S25, L6, L21) (Stoyanova et al. 2004). These data 
suggest that heterozygous TSC renal epithelial cells may have compromised 
inhibition of mTOR signalling. In addition, heterozygous TSC renal epithelia 
had altered HIF signalling, shown by increased expression of the HIF1a 
subunit, hypoxia-inducible protein 2 and hypoxia induced gene 1 (Stoyanova 
et al. 2004).
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Work on rodent models of Tsc has also suggested an effect of Tsc1 or 
Tsc2 associated haploinsufficiency. Heterozygous loss of one Tsc2 allele 
has been shown to affect the cognitive abilities of young Eker rats that rarely 
harbour brain lesions. These animals exhibit enhanced responses to 
chemically-induced kindling by repeated injection of pentylenetetrazole 
(Waltereit et al. 2006). Furthermore, in grossly normal Tsc1+,~ and Tsc2+I~ 
mouse brains, Uhlmann et al. (2002) noted a 1.5-fold increase in the 
numbers of astrocytes in the hippocampus. Compound Tsc1+/~Tsc2+/~ 
animals displayed a 2-fold increase in astrocyte number in the hippocampus, 
suggesting that heterozygosity for both Tsc proteins can further promote 
dysregulation in astrocyte number (Uhlmann et al. 2002). In vitro, mouse 
Tsc1 haploinsufficient neurons also have increased soma size, decreased 
spine density and increased spine length and head width (Tavazoie et al. 
2005). This abnormal neuronal morphology became more pronounced after 
loss of the 2nd Tsc1 allele suggesting that the Tsc pathway is sensitive to 
gene dosage (Tavazoie et al. 2005). Further studies are therefore warranted 
to determine the effects of TSC1 and TSC2 haploinsufficiency and to define 
the key event(s) in tumour initiation.
5.4.4 Implications for Rapamycin treatment
It has recently been suggested that rapamycin, an mTOR inhibitor, 
may be an effective drug in treating patients with TSC and other mTOR 
activation syndromes. Studies have shown that rapamycin treatment of Eker 
rats resulted in a significant decrease in the size of the 7sc2-related renal 
tumours, accompanied by down-regulation of p-S6 activity (Kenerson et al.
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2005). However, rapamycin had no effect on the number of microscopic 
precursor lesions, suggesting a rapamycin-insensitive pathway during Tsc2- 
associated tumour initiation (Kenerson et al. 2005). Our data may also 
indicate an mTOR independent pathway during Tsc1-associated tumour 
initiation. Therefore, although rapamycin may help control TSC-associated 
tumour development, it may not prevent tumour initiation.
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Chapter 6: General Discussion
6.1 Targeted mouse strain confirmed to be a valid model for 
tuberous sclerosis-1 deficiency
In this study, mice bearing a targeted disruption of Tsc1 were 
generated by deleting part of exon 6 through to exon 8 with the concurrent 
insertion of a reporter/selection cassette. The targeting event produced an 
aberrantly spliced transcript that caused a shift in the reading frame, leading 
to the introduction of a premature termination codon at the 8th codon of exon 
9 of Tsc1. Therefore, the targeted mouse strain was confirmed to be a valid 
model for tuberous sclerosis-1 deficiency.
6.2 Tsc1*/m mice exhibit a more severe renal phenotype than existing 
models
Our new murine model of hamartin deficiency exhibits a more severe 
renal phenotype than existing models of Tsc (Kobayashi et al. 2001, 
Kwiatkowski et al. 2002): 80% of mice on a Balb/c background exhibited 
solid RCCs by 15 to 18 months and in 41%, RCCs were £5mm, resulting in 
grossly deformed kidneys. Some of these carcinomas had a sarcomatoid 
morphology of spindle cells in whorled patterns and, unlike other Tsc1*'~ 
mice, metastasised to the lungs.
The incidence of spontaneous RCC in laboratory strains of mice and 
rats is very low (<5%) (Kleymenova et al. 2004). Therefore rodent models 
have been produced to model human familial kidney tumour syndromes. 
Unfortunately many of these models do not display a kidney lesion
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phenotype. Vhf'~ mice do not develop spontaneous or chemically induced 
kidney lesions (Kleymenova et al. 2004). Mice targeted for a mutation in Wt1 
(Wilms’s tumour) appear normal and show no tumour development until 10 
months of age (Kreidberg et al. 1993). Mice targeted for a mutation in MET 
that causes hereditary papillary renal carcinoma, do not display a renal 
lesion phenotype (Liang et al. 1996). Some models do however display a 
renal lesion phenotype. Rankin et al. (2006) have recently produced a 
conditional mouse model of Vhl. Conditional VhTA mice develop renal cysts 
in 18% of animals when more than 12 months of age, however, they do not 
develop RCCs. A germline mutation in the Birt Hogg Dube (BHD) gene in a 
colony of rats (Named the ‘Nihon’ rat; Okimoto et al. 2004) causes altered 
renal tubules as early as 3 weeks of age that progress through adenoma to 
RCC (Kouchi et al. 2006). However, none of these models of kidney lesions 
display metastasis. Therefore, our Tsc1+/~ mice will provide a valuable model 
for studying progression of RCC to metastasis.
6.3 Tsc rodent models have a different renal phenotype to humans
It is interesting to note that all the Tsc1+/~ and Tsc2+/' rodent models 
have a different renal phenotype to humans. In man, angiomyolipomas are 
the most common renal lesion while in Tsc rodent models cysts, CA and 
RCC are predominant. Although the occurrence of RCC in humans with TSC 
is unusual, an association is recognised (Henske 2004). The RCCs are 
typically discovered at a young age and the proportion of sarcomatoid 
features in TSC renal carcinomas (50%) is far greater than in sporadic RCC 
(1 -2  %) (Bjomsson etal. 1996, Gomez etal. 1999). The Tsrf*1' mice RCCs
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with a sarcomatoid morphology studied here may therefore prove an 
invaluable model to study this facet of the human disease.
The absence of major brain lesions in our and other mouse models of 
Tsc is surprising considering the brain pathology seen in human patients with 
TSC. Thus a mutation of the same gene can cause phenotypic variation 
between species. The differences may reflect longevity differences or simply 
smaller size or cell number. However, it is also possible that the progenitor 
cells which give rise to human brain lesions have different mechanisms of 
tuberin/hamartin regulated growth and differentiation compared to mouse 
brain precursor cells (Cheadle et al. 2000a).
6.4 Haploinsufficiency in Tsc-associated tumourigenesis
To examine haploinsufficiency in Tsc-associated renal lesions, cysts, 
CAs and RCCs were analysed using a combination of complementary 
mutation screening strategies and IHC (chapter 5). Interestingly, in 68% of 
cysts from Tsc1+/~ animals we did not identify somatic Tsc1 mutations 
implicating haploinsufficiency in there formation. In parallel studies with 
Tsc1+/' mice on a B/m-deficient background (where the frequency of somatic 
LOH of the wild type Tsc1 allele is dramatically increased, making the 
identification of 2nd hits straightforward (chapter 4)) 35% of cysts were 
haploinsufficient for Tsc1. In addition to haploinsufficiency causing cyst 
formation these data also suggest that in ~33% of Tsc1+/~ mouse cysts there 
was possible undetected silencing of the Tsc1 wild type allele. Therefore, 
here we have implicated the possibility that epigenetic or other undetected 
silencing events of the Tsc1 wild type allele can occur in a proportion of renal
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cysts. Immunohistochemical staining of cysts from a Tsc1+/~ background 
indicated that -37-53% of cysts showed little or no p-S6 and p-mTOR 
staining. This result is in agreement with molecular analysis of Tsc1+/~ Blmy‘ 
cysts and thus indicates -35% of cysts are haploinsufficient for Tsc1. 
Therefore indicating that mTOR activation is not necessarily an important 
step in Tsc-associated renal tumour initiation.
6.5 Haploinsufficiency in other hamartoma syndromes
Recent work on the TSC signal transduction pathway has led to the 
discovery of links between components of this pathway and genes mutated 
in other hamartoma syndromes (Fig. 6.1). In the recent review, Inoki et al. 
(2005) classified hamartoma syndromes based on molecular pathogenesis. 
They proposed two categories; hamartoma syndromes with an established 
molecular link to the dysregulation of mTOR; including LKB1, PTEN, TSC1 
and TSC2. The second category consisted of hamartoma syndromes that 
have been implicated with the dysregulation of mTOR or possess clinical 
similarities to those syndromes in the first category. This category included 
PRKAR1A, NF1, VHL, FLCN, APC, SMAD4 and BMPR1A genes (Inoki etal.
2005). There is increasing evidence that loss of one allele for the respective 
gene in these disorders may be necessary for tumour initiation.
6.5.1 Peutz-Jeghers syndrome
Peutz-Jeghers syndrome (PJS) is a dominantly inherited hamartoma 
syndrome characterised by the development of gastrointestinal 
hamartomatous polyps (affecting the small bowl, stomach and colon) as well
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Figure 6.1: Classification of hamartoma syndromes based on molecular pathogenesis 
(adapted from Inoki et al. 2005). Hamartoma syndromes with an established molecular 
link to the dysregulation of mTOR pathway include PTEN hamartoma syndromes 
(PTHs), Peutz-Jeghers syndrome (PJS) and Tuberous sclerosis (TSC1/TSC2). 
Hamartoma syndromes that have been implicated with the dysregulation of mTOR 
include Juvenile polyposis (JP) and Carney complex (CNC).
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as mucocutaneous pigmentation of the lips, buccal mucosa and digits (Peutz 
1921, Jeghers et al. 1949). PJS patients show a high risk of developing 
gastrointestinal and non-gastrointestinal cancers at relatively young ages 
(Giardiello et al. 1987, Boardman etal. 1998, Giardiello etal. 2000).
Germline mutations in the LKB1/STK11 gene have been shown to be the 
cause of the majority of PJS cases (Hemminki et al. 1998, Jenne et al.
1998). The LKB1 tumour suppressor gene encodes a protein kinase that 
phosphorylates and activates, upon ATP depletion, the AMP-activated 
protein kinase (AMPK). AMPK is a central sensor of cellular ATP levels and 
key regulator of cellular energy consumption. Loss of LKB1 results in down 
regulation of the TSC complex thus stimulating mTOR activity (Shaw et al. 
2004, reviewed in Kwiatkowski and Manning 2005, Hardie 2005). Several 
studies have shown the vast majority of lesions in PJS patients show loss of 
the wild type LKB1 allele (Hemminki et al. 1998, Gruber et al. 1998, Resta et 
al. 1998, Wang et al. 1999, Miyaki et al. 2000, Entius et al. 2001). Gruber et 
al. (1998) identified LOH of the LKB1 wild type allele in 70% of tumours. 
However, others have suggested that biallelic inactivation of LKB1 may be 
more rare. Resta et al. (1998) and Entius et al. (2001) found LOH of the 
LKB1 wild type allele in only 19% and 38% of tumours from PJS patients 
respectively implicating a role for haploinsufficiency.
Several murine models of Lkb1 deficiency have been produced 
(Ylikorkala et al. 2001, Bardeesy et al. 2002, Jishage at al. 2002, Miyoshi et 
al. 2002). Lkb1+/~ mice are predisposed to gastrointestinal polyps, which 
histologically have a striking similarity to human PJS polyps (Miyoshi et al. 
2002, Rossi et al. 2002). Miyoshi et al. (2002), Rossi et al. (2002) and
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Jishage at al. (2002) have all shown, using a variety of techniques, that loss 
of only one copy of the Lkb1 allele is necessary to produce gastrointestinal 
polyps in Lkb1+/~ mice.
6.5.2 PTEN hamartoma syndromes
Cowden's disease (CD) is an autosomal dominant disorder 
characterised by multiple hamartomas including trichilemmomas and 
mucocutaneous papillomatous papules, as well as a high risk of breast and 
thyroid cancers (Eng 2000). Bannayan-Riley-Ruvalcaba syndrome (BRRS) is 
a rare autosomal dominant congenital disorder characterised by 
macrocephaly, lipomatosis, hemangiomatosis and speckled penis (Gorlin et 
al. 1992). Proteus syndrome (PS) is a complex disorder characterised by 
hamartomatous overgrowth of multiple tissues including connective tissue 
naevi, epidermal naevi and limbs (Biesecker at al. 1999, Zhou et al. 2001). 
Lhermitte-Duclos disease (LDD), or dysplastic gangliocytoma of the 
cerebellum is characterised by hamartomatous overgrowth of hypertrophic 
ganglion cells, resulting in circumscribed enlargement of the cerebellar folia 
(Nowak and Trost 2002, Zhou et al. 2003). CD, BRRS, PS, Proteus like 
syndromes (PLS) and LDD, show remarkable clinical overlap (Merks et al. 
2003). Although it is controversial whether each disease is a clinically distinct 
entity, they have been grouped together as PTEN hamartoma syndromes 
(PTHs) because all are caused by germline mutations in PTEN (Marsh et al. 
1999, Eng 2003, Inoki et al. 2005).
PTEN encodes a dual-specificity phosphatase that lies upstream of 
Akt. It reduces intracellular levels of PI3K lipid products thereby inhibiting Akt
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activation. Thus in cells lacking PTEN, Akt is constitutively active, and there 
is a corresponding increase in TSC2 phosphorylation and downstream 
mTOR signalling (Manning et al. 2005). Somatic mutations of PTEN have 
been identified in a large fraction of prostate, brain, breast, endometrial, skin 
and kidney lesions, consequently placing it among the most commonly 
mutated genes in human cancer (Li et al. 1997, Steck et al. 1997, Risinger 
1997, Di Cristofano et al. 1998). However, complete loss of PTEN function in 
early stage tumours occurs only in endometrial and ovarian cancer (Trotman 
et al. 2003). The vast majority of cancers only show biallelic PTEN 
inactivation as a late event in cancer progression (Byun et al. 2003, Trotman 
et al. 2003). There has been a number of reports that haploinsufficiency of 
PTEN is sufficient for tumour initiation. Li et al. (2003a) showed that PTEN 
haploinsufficiency results in altered gene expression in subventricular zone 
precursor cells. Furthermore, CD primary sporadic breast cancers and 
merkel cell carcinomas have been shown not to have biallelic PTEN 
mutations (Marsh et al. 1999, Van Gele et al. 2001).
Three different groups have produced Ren knockout mice (Di 
Cristofano et al. 1998, Suzuki et al. 1998, Podsypanina et al. 1999). The 
phenotype of the mice vary. However, features of CS and BRRS have been 
described. Analysis of hyperplastic-dysplastic changes of the colon mucosa 
and polyps in the lower gastrointestinal tract in Pten+/~ mice has shown that 
loss of the normal Ren allele does not occur (Di Cristofano et al. 1998). 
Furthermore, Ren+/~ mice crossed with Tsc2+/~ mice exhibit Ren type lesions 
in compound heterozygous animals that are more severe but still retain 
heterozygosity at both alleles (Ma et al. 2005, Manning et al. 2005).
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6.5.3 Juvenile polyposis
Juvenile polyposis syndrome (JP) is an autosomal dominant disorder, 
characterised by development of 50-200 hamartomatous polyps distributed 
throughout the colon (McColl et al. 1964, Chow and Macrae 2005). The 
cause of some cases of JP has been shown to be germline mutations in 
SMAD4 (DPC4) (Howe et al. 1998). SMAD4 encodes a cytoplasmic mediator 
involved in the Transforming growth factors p (TGFp) signal transduction 
pathway (Chow and Macrae 2005). Interestingly, molecular and functional 
association between TGFp signalling and TSC2 have been described. 
SMAD4 interacts with its binding partner SMAD3 which interacts with AKT 
and TSC2 (Birchenall-Roberts et al. 2004). Biallelic somatic SMAD4 
mutations have been identified to a varying degree in JP patients. Wooford- 
Richens et al. (2000) noted 65% of lesions had LOH of the SMAD4 wild type 
allele using microsatellite markers near to the SMAD4 locus. Furthermore, 
SMAD4 has been shown to be inactivated specifically during late stages of 
human colorectal cancer (Takagi et al. 1996, Thiagalingam et al. 1996, 
Koyama et al. 1999, Miyaki et al. 1999). However, Howe et al. (1998) noted 
only 9% of gastrointestinal polyps showed LOH of the wild type allele. 
Therefore it has been suggested that haploid loss of SMAD4 can initiate 
hamartoma formation, and diploid loss is may be required for advancement 
of tumourigenesis. Several independent investigators have addressed this 
hypothesis using Smad4 deficient mouse models (Xu et al. 2000, Alberici et 
al. 2005). In general, mice heterozygous for the Smad4 allele are 
predisposed to the development of multiple polyps in the upper
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gastrointestinal tract (Sirard et al. 1998, Takaku et al. 1999, Xu et al. 2000, 
Alberici et al. 2005). Xu et al. (2000) and Alberici et al. (2005) have 
demonstrated that early gastrointestinal lesions from Smad4+/~ mice often do 
not display LOH of the Smad4 wild type allele, thus supporting a 
haploinsufficient mechanism of in tumour initiation.
6.5.4 Carney complex
Carney complex (CNC) is an autosomal dominant disorder 
characterised by myxomas, spotty skin pigmentation and abnormal 
endocrine activity (Carney 1985). Germline mutations in the PRKARIA gene 
have been shown to be the cause of approximately 50% of cases (Kirschner 
at al. 2000a). PRKAR1A encodes the regulatory subunit l-a (Rla) of the 
cAMP-dependant kinase (PKA) holoenzyme (Tasken et al. 1997). PKA has 
been shown to target components of the ERK-MAPK signalling system. 
Specifically, mutated PRKAR1A leads to reversal of PKA-mediated inhibition 
of MAPK signalling (Robinson-White et al. 2003, Robinson-White et al.
2006). TSC2 has been shown to be a phosphorylation target of ERK 
signalling and this phosphorylation results in the suppression of its tumour 
suppressor functions (Ma et al. 2005). LOH of the PRKAR1A wild type allele 
has been found in a variety of tumours from patients with CNC (Kirschner at 
al. 2000b, Stergiopoulos and Stratakis 2003). However, analysis of cardiac 
and eyelid myxomas and primary pigmented nodular adrenocortical tumours 
from patients with CNC showed no somatic mutations of the PRKAR1A wild 
type allele (Casey et al. 2000, Groussin et al. 2002, Bertherat et al. 2003, 
Tsilou et al. 2004).
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Prkarla+/~ mice have been produced to address the question of 
haploinsufficiency in lesion formation (Amieux et al. 2002, Griffin et al. 2004). 
The Prkarla+/~ mice develop features reminiscent of CNC. Splenic 
hemangiosarcomas and soft tissue sarcomas did not display LOH of the 
Prkarl a wild type allele or altered PKA activity and they retained expression 
of wild type Rla protein (Veugelers et al. 2004). Again, haploinsufficiency is 
therefore implicated in tumour initiation.
6.5.5 Somatic inactivation of the wild type allele is an important factor 
in the later stages of tumourigenesis
In addition to the haploinsufficiency seen in early lesions of 
hamartoma syndromes, a common theme observed is that more advanced 
lesions display biallelic inactivation of their corresponding TSG allele. 
Analysis of advanced hepatocellular carcinomas in Lkb1+/' mice has revealed 
biallelic inactivation of the Lkb1 gene (Nakau et al. 2002). Xu et al. (2000) 
demonstrated in Smad4+/~ mice, that only 20% of gastrointestinal lesions less 
than 0.4mm and 63% of lesions more than 0.4mm displayed LOH of the 
Smad4 allele. In agreement, Alberici et al. (2005) showed that LOH of the 
Smad4 allele was detected in 40% of lesions from Smad4+/~ mice up to 15 
months, which increased to 64% in tumours from mice over 18 months. In 
humans, Entius et al. (2001) found LOH of the LKB1 wild type allele in only 
38% of polyps from PJS patients but in contrast, LOH of the LKB1 wild type 
allele was found in 100% carcinomas. Furthermore, homozygous inactivation 
of PTEN is generally associated with only advanced cancer and metastasis 
(Di Cristofano and Pandolfi 2000, Trotman et al. 2003).
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Here, we have identified somatic Tsc1 mutations and mTOR 
activation in more than 80% of CAs and RCCs from Tsc1+/~ mice. Therefore, 
2nd hits at the Tsc1 locus are found in the vast majority of more advanced 
tumours. This suggests that although haploinsufficiency may be an important 
step in the initiation of Tsc-associated renal tumourigenesis, biallelic 
inactivation of Tsc1 is an important factor in the latter stages. Together, 
these results suggest a possible common mechanism of tumour initiation in 
hamartoma syndromes, whereby 1-hit initiates tumourigenesis, while a 
second hit promotes the progression to more advanced lesions.
6.6 Blrrfn3/m3 mice and mapping loci involved in tumour progression
Microarray-based comparative genomic hybridization (aCGH) 
provides a means to quantitatively measure DNA copy-number aberrations 
and to map them directly onto genomic sequence (Snijders et al. 2001). 
Briefly, aCGH involves co-hybridisation of both labelled tumour DNA (with 
Cy3 green) and normal genomic DNA (with Cy5 red) to an array made up of 
oligos probes or clones. A laser scanner reads spot intensities on the 
hybridised array. The relative intensities of Cy3:Cy5 for each spot and thus 
the ratios of normal to tumour DNA can be computed and plotted for visual 
analysis (Fig. 6.2). While aCGH is not useful for detection of small intragenic 
mutations, is extremely well suited to high-throughput, whole genome 
detection of chromosomal gains and losses at high resolution (Weber 2002). 
Normally, a diverse range of mutations and epigenetic silencing, are 
implicated in the somatic inactivation of the wild type allele of TSGs. This 
diversity of somatic alterations makes genetic mapping of loci involved in
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Figure 6.2: The process of array based comparative genomic hybridisation (aCGH). Firstly, 
both labelled tumour DNA (with Cy3 green) and normal genomic DNA (with Cy5 red) are co­
hybridised to an array. A laser scanner reads spot intensities on the hybridised array. The 
relative intensities of Cy3:Cy5 for each spot and thus the ratios of normal to tumour DNA can 
be computed (red for deletion, green for amplification) and plotted for visual analysis (red 
arrows deleted areas of chromosomes, green duplicated areas of chromosome).
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tumour progression problematic. In this study, Blnrin3/m3 mice were crossed 
with cancer prone Tsc1+/~ mice to induce renal tumourigenesis. The high 
levels of LOH in the resultant tumours (and consequently low level of 
intragenic mutations) may provide an oppertunity for application of aCGH in 
the mapping of loci that may play a role in tumour progression. Preliminary 
data from whole genome aCGH analysis of DNA extracted from Tsc1+/~ Blm'A 
mouse RCCs demonstrates the increased sensitivity to detect somatic 
mutations when compared to Tsc1+/~ Blm+/+ mouse RCCs (Fig. 6.3). Using 
Tsc1+/~ Blmv' mice DNA can be extracted from tumours from each stage of 
progression, from simple cyst through to RCCs with a sarcomatoid 
morphology and metastasis. This approach will therefore facilitate 
identification of genes implicated in Tsc-associated renal tumour 
progression.
6.7 The future for mouse models
With the completion of the genome sequence of humans and mice 
(International Human Genome Sequencing Consortium 2001, Venter et al. 
2001, Mouse Genome Sequencing Consortium 2002), attention is now 
focused on functional annotation of these genomes. The mouse offers 
particular advantages for the study of disease for a number of reasons; 
genetically determined diseases of humans can often be recapitulated in the 
mouse since 99% of mouse genes have human homologs and these can be 
easily manipulated with the use of targeted mutagenesis and ES cell 
technologies. However, to date published knockouts exist for only about 10%
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Figure 6.3: Preliminary data for whole genome aCGH analysis of DNA extracted from (A) a Tsc1+I* mouse RCC, and (B) a Tsc1+/- B ln r mouse RCC. DNA 
from the Tsc1+I- mouse RCC shows increased copy number of only chromosome 5, whereas DNA from the Tsc1*A B lm mouse RCC shows increased copy 
number of chromosomes 5, 15 and Y, and loss of chromosome 12 (arrows), therefore demonstrating the increased sensitivity to detect somatic mutations by 
aCGH analysis on a B/m-deficient background.
of mouse genes (The Comprehensive Knockout Mouse Project Consortium 
2004). Large-scale mouse mutagenesis programs are currently being 
initiated (The Comprehensive Knockout Mouse Project Consortium 2004, 
The European Mouse Mutagenesis Consortium 2004) using gene targeting, 
gene trapping and RNA interference methods. The aim is to phenotype large 
numbers of mouse mutants with standardised screens and place these 
resources into the public domain (The Eumorphia Consortium 2005). These 
genome-wide knockout mouse projects could provide targeting and trapping 
constructs and vectors, ES cell lines, live mice, frozen embryos or sperm, 
tissue samples and phenotypic data (The Comprehensive Knockout Mouse 
Project Consortium 2004) and will help to relies the potential of the genome 
projects and their translation to benefit human health.
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